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Hepatic fibrosis and cirrhosis cause strong human suffering and necessitate a monetary
burden worldwide. Therefore, there is an urgent need for the development of therapies.
Pre-clinical animal models are indispensable in the drug discovery and development
of new anti-fibrotic compounds and are immensely valuable for understanding and
proofing the mode of their proposed action. In fibrosis research, inbreed mice and rats
are by far the most used species for testing drug efficacy. During the last decades,
several hundred or even a thousand different drugs that reproducibly evolve beneficial
effects on liver health in respective disease models were identified. However, there
are only a few compounds (e.g., GR-MD-02, GM-CT-01) that were translated from
bench to bedside. In contrast, the large number of drugs successfully tested in animal
studies is repeatedly tested over and over engender findings with similar or identical
outcome. This circumstance undermines the 3R (Replacement, Refinement, Reduction)
principle of Russell and Burch that was introduced to minimize the suffering of laboratory
animals. This ethical framework, however, represents the basis of the new animal
welfare regulations in the member states of the European Union. Consequently, the legal
authorities in the different countries are halted to foreclose testing of drugs in animals
that were successfully tested before. This review provides a synopsis on anti-fibrotic
compounds that were tested in classical rodent models. Their mode of action, potential
sources and the observed beneficial effects on liver health are discussed. This review
attempts to provide a reference compilation for all those involved in the testing of drugs
or in the design of new clinical trials targeting hepatic fibrosis.
Keywords: hepatic fibrosis, 3R principle, therapy, animal experimentation, collagen, α-smooth muscle actin,
clinical trials, translational medicine
INTRODUCTION
The last statistical report on the number of animals used for experimentation and other scientific
purposes in the member states of the European Union was published in 2011 (EU Parliament,
2013). It contains data collected in 26 member states in 2011 and in France in 2010. In summary,
this report shows that about 11.5 million animals were used for experimental and other scientific
purposes in the EU, of which mice (60.9%) and rats (13.9%) were by far the most used species (EU
Parliament, 2013). Over 46% of these animals were used for biological studies of a fundamental
nature and 8.75% in the area of toxicology and other safety evaluations. These are particular the two
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FIGURE 1 | Rodent models in experimental liver fibrosis. (A) The application of hepatotoxins or parasites, bile duct surgery, or the feeding of specialized diets is
widely applied to induce liver damage and hepatic fibrogenesis in mice and rats. In addition, genetically engineered mice models that develop spontaneous hepatic
fibrosis are further alternatives. (B) In these models, a time-dependent progress of liver damage occurs in which inflammation, fibrosis, and cirrhosis time-dependently
follow each other.
research areas in which novel test drug candidates for future
human trials are pre-clinical screened for their safety and efficacy.
In hepatology research, there is a mandatory need for novel anti-
fibrotic therapies and many different in vivo and in vitro rodent
models were introduced during the last decades (Figure 1). Mice
and rats are relatively inexpensive and can be bred in large
quantities, their inbred character helps to establish reproducible
results, and their anatomy, genetics and biology is similar to
humans. Most importantly, the pathogenesis of experimental
hepatic disease in rodents closely resembles the disease progress
in humans (Friedman, 2008). In this process, hepatic stellate cells
(HSC) and portal fibroblasts are major collagen-producing cells.
Abbreviations: ACE, angiotensin-converting enzyme; α-SMA, α-smooth
muscle actin; CAS, Chemical Abstracts Service; CCl4, carbon tetrachloride;
CTGF, connective tissue growth factor; DHA, docosahexaenoic acid; DMN,
dimethylnitrosamine; ECM, extracellular matrix; EGCG, Epigallocatechin-
3-gallate; EGF, epidermal growth factor; EPA, eicosapentaenoic acid; FGF,
fibroblast growth factor; FZHY, Fuzheng Huayu; GSH, reduced glutathione;
HAT, histone acetyl transferases; HCC, hepatocellular carcinoma; HDAC,
Histone deacetylase(s); HGF, hepatocyte growth factor; HMG-CoA, hydroxy-
3.methly-glutaryl-CoA; HSC, hepatic stellate cell(s); IFN, interferon; IGF,
insulin-like growth factor; IL(s), interleukin(s); LOXL2, Lysyl oxidase-like-2;
MCD, methionine-choline-deficient; MMP, metalloproteinase(s); NAC, N-
acetyl-L-cysteine; NASH, non-alcoholic steatohepatitis; NOX, NADPH oxidases;
Nrf2, nuclear factor erythroid-2-related factor 2; PDGF, platelet-derived growth
factor; ROS; reactive oxygen species; RTK, receptor tyrosine kinases; SAC, S-
allylcysteine; SAM, S-adenosyl-L-methionine; SNAC, S-Nitroso-N-acetylcysteine;
SPARC, secreted protein acidic and rich in cysteine; TAA, thioacetamide; TGF-β,
transforming growth factor-β; TNF-α, tumor necrosis factor-α; VEGF, vascular
endothelial growth factor; XN, xanthohumol.
The proliferative activity is triggered by numerous pro-fibrogenic
chemokines and cytokines that in liver are produced by residental
cells or infiltrating blood cells (Gressner andWeiskirchen, 2006).
This complex network of cellular interactions and the great
diversity of different mediators offer a wealth of potential drug
targets for targeting disease progression.
Using pre-clinical rodent models, many hundred (or
thousands) pharmacological active ingredients with presumed
fibropreventive, fibrostatic, or fibrolytic spectrum were
discovered (Figure 2). However, the translation of these
encouraging findings to humans and the initiation of human
trials is perennially hampered by many factors. Consequently,
there are no effective treatments for hepatic fibrosis to date.
Instead, many of the identified substances are tested in regular
intervals in other cell systems or animal models confirming
previous reports. Although the authors of these confirmatory
studies will compile some nice publications, the novelty of these
studies is rather low. In addition, all these studies are expensive,
cause needless pain, and suffering to animals and subvert the
ethical framework for conducting scientific experiments with
animals that was first proposed by Russell and Burch (1959).
These guidelines encourage the replacement, reduction and
refinement of animals used for scientific purposes and testing.
Currently largely ignored, this so called 3R principle is the basis
of the new animal welfare rules that have been implemented in
themember states of the EU by the EUDirective 2010/63 and had
turned into law at the beginning of year 2013 (EU Parliament,
2010). Nevertheless, in future this regulation predicts that new
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FIGURE 2 | Potential anti-inflammatory and anti-fibrotic drug targets and treatments. Based on the complexity of hepatic fibrosis, there are numerous
possibilities for therapeutic intervention.
animal studies initiated with the aim to test drugs that were
already tested before will not be approved in the Member states
of the EU. Moreover, applying for a new animal study will
require a concise review on what is done so far and what was not
tested yet.
In the present review, a comprehensive synopsis on
experimentally tested anti-fibrotic compounds is given. The
chemical structure, potential sources, mode of action, molecular
target and their experimental pharmacological activity in hepatic
fibrogenesis of each drug is discussed.
ANTIOXIDANTS/RADICAL SCAVENGERS
Reactive oxygen species (ROS) formation is one key driver of
hepatic inflammation and fibrosis. Under normal physiological
conditions, oxygen-containing reactive molecules control key
physiological activities such as cell growth, proliferation,
migration, differentiation, and apoptosis (Manea et al., 2015).
However, elevated intracellular ROS concentrations induce
damage to cell structures (DNA, RNA, protein, lipids, and
cofactors), oxidative stress and inflammation. In the liver, ROS
induce apoptosis and necrosis of hepatocytes, stimulate the
production of profibrogenic mediators by Kupffer cells and
recruitment of circulating inflammatory cells, and leads to direct
activation of HSC (Sánchez-Valle et al., 2012). Accumulating
evidence suggest that beside multiple other mechanisms, the
upregulation of different NADPH oxidases (NOX) subtypes in
liver fibrogenesis is majorly the cause for increased intracellular
ROS concentrations (Crosas-Molist and Fabregat, 2015; Manea
et al., 2015). This assumption was recently confirmed in NOX1-
or NOX4-deficient mice (Lan et al., 2015). When these mice were
treated with carbon tetrachloride (CCl4) to induce liver fibrosis,
they showed reduced hepatic inflammation than wild type mice.
Moreover, culture-activated HSC derived from these mice had
overall reduced expression of pro-fibrogenic genes and the
dual NOX1/4 inhibitor GKT137831 suppressed ROS production
and expression of inflammation-associated genes (Lan et al.,
2015). Intracellular ROS formation also affects the activity of
pro-fibrogenic genes and vice versa. Of particular interest in
hepatic fibrogenesis is the interrelation of ROS and transforming
growth factor-β (TGF-β). In cultured HSC, TGF-β increases the
production of H2O2 (De Bleser et al., 1999), which in turn
induces the expression of α1(I) procollagen mRNA (García-
Trevijano et al., 1999). Consequently, catalase, an enzymatic
scavenger of H2O2, abrogated TGF-β-mediated type I collagen
gene expression (García-Trevijano et al., 1999). Numerous agents
available prevent or even interfere with ROS formation, or
alternatively eliminate or scavenge elevated intracellular ROS
traces. Based on their chemical composition, they can be divided
into sulfur-containing and non-sulfur containing antioxidants.
In the following, some examples of both groups and their
beneficial effects in hepatic fibrosis are summarized.
Glutathione, N-acetyl-L-cysteine,
S-Nitroso-N-acetylcysteine,
S-adenosyl-L-methionine, S-allylcysteine
There are a large number of sulfur-containing antioxidants
with beneficial effects on hepatic inflammation and fibrosis
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(Supplementary Figure 1). Glutathione (GSH) is an essential
nutrient that is synthesized in the body from amino acids L-
cysteine, L-glutamic acid, and glycine. It exists in both reduced
from (GSH) or in a dimer oxidized (GSSG) form. In the
reduced form, the sulfhydryl group of the cysteine residue is
able to donate a reducing equivalent and serve as a proton, give
rise to its activity as an antioxidant. GSH and its structurally
related compounds N-acetyl-L-cysteine (NAC), S-Nitroso-N-
acetylcysteine (SNAC), S-adenosyl-L-methionine (SAM) and S-
allylcysteine (SAC) have been used in clinics for the treatment
of fibrotic diseases. NAC, SNAC, SAM, and SAC either serve
as direct GSH precursors, nitric oxide (NO) donors, or serve
as methyl group donors required for methylation of nucleic
acids, phospholipids, histones, biogenic amines, and proteins.
In addition, NAC dose-dependently blocked TGF-β signaling
in fibrogenic cells by monomerization of the biological active
TGF-β dimer (Meurer et al., 2005). NAC attenuated hepatic
oxidative stress and prevented increases in cytochrome P450 2E1
apoprotein, TNF-α expression, and induction of auto-antibodies
associated with lipid peroxidation in a dietary polyunsaturated
fat model of non-alcoholic steatohepatitis (NASH) in rats
(Baumgardner et al., 2008). Likewise, NAC prevented cirrhosis
by reducing oxidative stress and TGF-β expression (Galicia-
Moreno et al., 2009). The oral SNAC administration resulted in
a reduction in collagen α1, increased matrix metalloproteinase
(MMP)-13 activity, and a significant suppression of TIMP-2 and
TGF-β1 (Mazo et al., 2013). It further induced de-differentiation
of the immortalizedmurine hepatic stellate cell line GRX (Stefano
et al., 2011). SAM is a modulator of cellular apoptosis, suppressor
of tumor necrosis factor (TNF)-α and inducer of interleukin (IL)-
10 expression (Pfalzer et al., 2014). It further inhibits cellular
proliferation, adhesion, migration and invasion of human HSC
in vitro (Zhang et al., 2014). The efficacy of SAC was proven
in a porcine serum-induced hepatic fibrosis model in rats in
which this compound attenuated hepatic fibrosis and suppressed
α-smooth muscle actin (α-SMA) expression (Shinkawa et al.,
2009).
Bucillamine
This substance is a cysteine derivative that contains two
donatable thiol groups thereby acting as a potent sulfhydryl
donor rendering a potent antioxidant activity. It is particular
efficacious in acute settings characterized by inflammation and
oxidative stress (Horwitz, 2003). It further sequesters iron (II)
and copper (II) that are both involved in oxidative stress-induced
damage (Mazor et al., 2006). Bucillamine also inhibits neutrophil
activation during hepatic injury and modulates the Bax/Bcl-2
ratio without affecting the tissue GSH levels (Junnarkar et al.,
2010).
Lipoic Acid
Lipoic acid (or better α-lipoic acid) contains two sulfur atoms
that are connected by a redox-sensitive disulfide bond. It
functions as a cofactor for some enzyme systems involved in
acyl group transfer. Independent studies have shown that α-
lipoic acid and its reduced form dihydrolipoic acid inhibit liver
fibrosis in rats chronically treated with thioacetamide (TAA),
most likely by preventing ROS generation and ROS-mediated
signaling in HSC (Foo et al., 2011). In addition, lipoic acid
prevented the development of BDL-induced hepatic fibrosis
and effectively attenuated TGF-β-stimulated PAI-1 expression
through inhibition of the TGF-β-associated mediators Smad3,
AP1, and SP1 (Min et al., 2010). Similarly, this substance
prevented fibrosis development, inflammation and cellular
apoptosis in rats that were subjected to a high fat diet (Kaya-
Dagistanli et al., 2013).
Taurine
This compound is a derivative of cysteine that is a major
constituent of bile and has many biological activities in bile
acid conjugation, membrane stabilization and calcium signaling.
It further acts as a direct antioxidant and protects against
the toxicity of different metals. Taurine administration in
drinking water prevented the activity of lipid hydroperoxides,
improved mitochondrial enzyme activities, and regulated iron
and calcium levels in experimental rat liver fibrosis that was
induced by simultaneous application of ethanol and iron (Devi
and Anuradha, 2010). In the samemodel system, taurine lowered
the levels of IL-6, TNF-α and peroxidation products, as well
as the expression of α-SMA, desmin, and TGF-β1 and further
improved the antioxidant status (Devi et al., 2010). Other studies
showed that this β-amino acid is neither a classical scavenger nor
a regulator of the anti-oxidative defenses but more likely serves as
a regulator of mitochondrial protein synthesis (Jong et al., 2012).
α-tocopherol and Trolox
The non-sulfur-containing lipid-soluble benopyranol α-
tocopherol (vitamin E) and its water-soluble analog Trolox
are effective peroxyl radical scavengers and absorber of oxygen
radicals (Figure 3). Moreover, these substances were found to
act as non-competitive inhibitors of cyclooxygenase, suppressor
of vascular endothelial growth factor (VEGF) and TGF-β gene
transcription (Abdelazim et al., 2015). The importance of the
antioxidant capacity of vitamin E in preventing fibrosis was
proven in animals studies (Zhang et al., 1996) and clinically
confirmed (Harrison et al., 2003).
Ascorbic Acid
This soluble essential nutrient (vitamin C; Figure 3) is an
essential cofactor in enzymatic reactions, involved in many
biochemical activities, and as a electron donor acting as a direct
free radical scavenger (Padayatty et al., 2003). Vitamin C alone or
in synergy with other agents decreases lipid peroxidation directly
or indirectly by regenerating vitamin E (Adikwu and Deo, 2013).
In line with this assumption, the pre-treatment with vitamin C
prior exposure to TAA is sufficient to prevent hepatic cirrhosis
in rats (Al-Attar, 2011). However, ascorbic acid also induced
pro-fibrotic effects in hepatic fibrogenesis in mice that lacked
regucalcin (SMP30), a gene that is critically involved in hepatic
Ca2+ homeostasis (Park et al., 2010).
Melatonin
This substance, also known as N-acetyl-5-methoxytryptamine
(Figure 3), is a free-radical scavenger and antioxidant that
Frontiers in Pharmacology | www.frontiersin.org 4 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
FIGURE 3 | Non-sulfur-containing antioxidants with therapeutic potential in hepatic fibrosis. α-tocopherol (CAS 59-02-9), trolox (CAS 53188-07-1), ascorbic
acid (CAS 50-81-7), melatonin (CAS 73-31-4), rosmarinic acid (CAS 20283-92-5), and caffeic acid (CAS 331-39-5) were successfully applied in many experimental
models of hepatic fibrosis. Major sources of ascorbic acid are citrus fruits, while caffeic acid can be found in high concentrations in coffee beans. Rosmarinic acid is
ingredient of culinary herbs such as oregano, thyme, and rosemary.
protects against nuclear and mitochondrial DNA damage and
interacts with the immune system. It has also the capacity to
form complexes with different metals. In dimethylnitrosamine
(DMN)-induced liver fibrosis in rats, melatonin functions as
a potent fibrosuppressant and antioxidant by preventing the
decrease of GSH and superoxide dismutase levels (Tahan et al.,
2004). This substance has recently renewed interest because it
is an effective drug that inhibits autophagy, necroptosis, and
endoplasmic reticulum stress in CCl4-induced hepatic fibrosis
in mice (San-Miguel et al., 2015, p. 38; Choi et al., 2015). In
the same model, it attenuated liver injury and inhibited the
expression of collagens types I and III, TGF-β, PDGF, connective
tissue growth factor (CTGF), amphiregulin, and activation of
Smad3, while theMMP-9 activity decreased and the expression of
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nuclear factor erythroid-2-related factor 2 (Nrf2), representing is
a central regulator of anti-oxidative response, increased (Crespo
et al., 2015).
Caffeic Acid, Rosmarinic Acid
The natural phenol caffeic acid (Figure 3) is present in modest
concentration in coffee. However, it is unrelated to caffeine
and is composed of a phenol ring carrying an unsaturated
carboxylic acid side chain. Like its ester, rosmarinic acid,
caffeic acid has a high rate constant to react with hydroxyl
radicals (Bors et al., 2004). Rosmarinic acid (Figure 3) inhibited
proliferation and induced apoptosis in HSC-T6, partly due to the
inhibition of phosphorylation in STAT3 (Zhang et al., 2011b).
The intraperitoneal application of phenethyl ester of caffeic acid
was recently shown to evolve hepatoprotective effects and to
suppress HSC activation by inhibiting oxidative stress in rats that
were injected subcutanly with CCl4, feed with high fat forage, and
administered with alcohol orally (Li et al., 2015b).
Genistein, Luteolin, Quercitin, Apigenin,
Naringenin, and Other Polyphenolic
Compounds
Genistein is a naturally occurring phytoestrogic isoflavone that
is present in high concentration in soy and many other plants.
Similar to many other polyphenolic substances (Figure 4), this
compound acts as a direct antioxidant. It reduces damaging
effects of free radicals, prevents the release of cytochrome c
from mitochondria and has further the ability to modulate the
activity of the nuclear receptor Peroxisome proliferator-activated
receptor (PPAR)-γ and the estrogen receptor (Dang et al.,
2003; Borrás et al., 2010) . Dietary supplementation of genistein
down regulated the augmented gene expression associated with
hepatic inflammation and fibrosis in a methionine-choline-
deficient (MCD) diet in leptin receptor deficient db/dbmice (Yoo
et al., 2015). Likewise, genistein ameliorated developing liver
injury and fibrosis that was induced by repeatedly intragastric
administration of alcohol (Huang et al., 2013). Luteolin is a
flavone that is found in high concentrations in leaves of the
yellow myrobalan (Terminalia chebula), avocado, celery, olive
oil, chamomile, peppermint and many aromatic plants. It was
supposed that this compound and some of its derivatives act as
dopamine transporter activators (Zhang et al., 2010). Although
the precise activity is not fully understand, this drug increased the
expression of MMP-9 and Metallothionein thereby promoting
extracellular matrix (ECM) degradation in established hepatic
fibrosis that was induced by administration of CCl4 (Domitrovic´
et al., 2009). More recently, it was demonstrated that luteolin
inhibited DEN-initiated alcohol-promoted hepatic inflammation
by stimulating hepatic sirtuin 1 activity that is a master regulator
in hepatic lipid metabolism (Rafacho et al., 2015). Other reports
have suggested that luteolin prevents progression of liver fibrosis
through a multitude of different mechanisms that include
inhibition of fibrosis-related genes in HSC, induction of HSC
apoptosis and cell arrest, and inhibition of cytokine signaling
pathways (TGF-β and PDGF; Li et al., 2015a). Quercitin is a
pentahydroxyl flavonoid occurring for example in onions, apples,
broccoli and green beans. In CCl4-treated rats, this substance
prevented oxidative stress, lipid peroxidation and increased
levels of GSH, SOD, catalase, GPx, and GST levels (Amália
et al., 2007). Similarly, quercitin decreased ALT, AST, GGT and
LDH levels and increased expression of albumin in a high fat
diet model in rats (Surapaneni and Jainu, 2014). This drug
was also effective in a MCD diet model in mice in which it
attenuated pro-fibrotic and pro-inflammatory gene expression
(Marcolin et al., 2012). Strong antioxidant activity, anti-apoptotic
and hepatoprotective effects were also reported for the flavone
apigenin that occurs in garden parsley (Petroselinum crispum),
celery (Apium graveolens), and different chamomiles. The efficacy
of this drug was proven in different toxic liver injury models
(Tsalkidou et al., 2014; Wang et al., 2014). Naringenin occurs in
high concentrations in grapefruit and other citrus fruits in form
of conjugated glucosides such as naringenin-7-rhamnoglucoside
or naringenin-7-glucoside. The oral administration of naringenin
prevented DMN-induced hepatic fibrosis in rats (Lee et al.,
2004a). A subsequent study in vitro study performed in HSC-
T6 cells showed that naringenin dose-dependently exerts its
anti-fibrogenic activity by down-regulation of Smad3 protein
expression and activation (Liu et al., 2006). Furthermore, this
substance reduced the plasma fat and the hepatic expression
of pro-inflammatory mediators such as TNF-α, IL-6, IL-1β,
iNOS, MMP-2, and MMP-9 in rats that were fed with a high
cholesterol diet (Chtourou et al., 2015). Likewise, there are many
other natural plant-derived polyphenolic compounds with anti-
oxidative activity including acids (3,4-OH-benzoic, gallic, O-,
and P- coumaric, syringic, vanillic), alcohols (tyrosol and OH-
tyrosol), theobromine, rutin, catechine, and apigenin. All these
substances are in the pipeline of researchers and are worth to be
tested in experimental models of hepatic fibrogenesis.
Nicotinic Acid, Nicotinamide, and
Nicotinamide Adenine Dinucleotide
(Phosphates)
Nicotinic acid (niacin) and its amide (vitamin B3) serve as the
most fundamental nicotinamide adenine dinucleotide precursors
(Supplementary Figure 2). They are critical cofactors in a wide
variety of intracellular oxidation-reduction reactions and serve
as antioxidants. Nicotinamide adenine dinucleotides consist of
either oxidized or reduced unphosphorylated (NAD+ or NADH)
and phosphorylated (NADP+ and NADPH) forms. These
compounds are indispensable for a multitude of dehydrogenase
enzymes, act as mitochondrial electron carriers and electron
donors for GSH, thioredoxin, and NADPH oxidases (i.e., the
NOX enzymes). They further act as ADP donors in ribosylation
reactions, substrates for NAD+-dependent enzymes (e.g., PARPs
and Sirtuins), and redox regulators that modify ion channel
function (Nakamura et al., 2012). Since the cellular concentration
of oxidized and reduced forms of these intracellular ROS
modulators is itself influenced by countless factors (e.g., total
ROS concentration, enzymatic activities of ROS producers
and scavengers), this axis offers a plenitude of possibilities to
modulate the intracellular ROS concentration. In TAA-induced
hepatic fibrogenesis, the co-administration of nicotinic acid
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FIGURE 4 | Polyphenol substances as therapeutics in hepatic fibrosis. Genistein (CAS 446-72-0), luteolin (CAS 491-70-3), quercitin (CAS 117-39-5), apigenin
(CAS 520-36-5), and naringenin (CAS 480-41-1) share a similar polyphenolic structure with ability to scavenge free radicals. Fruits or vegetables in which these
substances occur are depicted besides the formulas.
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prevented fibrosis by its antioxidant properties and reduction
of TGF-β expression (Arauz et al., 2015). As mentioned above,
NOXs play crucial roles in hepatic fibrogenesis and HSC express
a non-phagocytic form of NOX, which plays a critical role
in activating fibrosis-associated pathways (Bataller et al., 2003;
De Minicis et al., 2010). The deficiency of NOX1 and NOX4
in CCl4-treated mice reduced liver injury, inflammation, and
activation of stellate cell thereby attenuating fibrosis (Lan et al.,
2015). The importance of NOX1 and NOX4 in HSC was
further underpinned by the fact that the dual NOX1/4 inhibitor
GKT137831 (Supplementary Figure 2) not only suppressed ROS
production but also prevented HSC activation by inhibition
of inflammation- and proliferation-associated signaling (Lan
et al., 2015). Likewise, the application of the coumarin derivative
decursin that blocks the expression and activity of NOX1, NOX2,
and NOX4 reduced the quantities of ROS and fibrogenesis in
a CCl4-induced liver injury model in mice (Choi et al., 2014).
Another possibility to reduce the hepatic ROS content and
fibrogenesis is the overexpression of the ubiquitously expressed
thioredoxin. This protein acts as an antioxidant by facilitating the
reduction of other proteins by cysteine thiol-disulfide exchange.
In line with this attributed, thioredoxin transgenic mice were
protected against TAA-induced hepatic fibrogenesis and HSC
isolated from these mice were less proliferative than those
isolated from wild type littermates (Okuyama et al., 2005).
HMG-COA REDUCTASE INHIBITORS
The central and rate-controlling enzyme in the synthesis of
cholesterol is the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-
CoA) reductase that NADH- or NADPH-dependently forms
mevalonate from HMG-CoA. There are a large number of
drugs, i.e., the statins, which inhibit the activity of this enzyme.
A growing number of statins such as lovastatin, atorvastatin,
simvastatin, pravastatin, fluvastatin, pitavastatin, rosuvastatin,
and others (Supplementary Figure 3) and combinations thereof
are on the market. They should prevent cardiovascular disease in
liver-diseased patients (Argo et al., 2008). Atorvastatin attenuated
ongoing and established hepatic fibrogenesis in BDL rats by
inhibiting HSC activation or turnover suggesting that this statin
has both protective and therapeutic potential (Trebicka et al.,
2010). In accordance with its therapeutic potential, it was shown
that atorvastatin decreased cytokine and collagen production
in myofibroblasts (MFB) in vitro and initiated apoptosis (Klein
et al., 2012). Anti-proliferative activity in cultured primary
HSC was also demonstrated for lovastatin and simvastatin that
both inhibited proliferation and collagen expression (Rombouts
et al., 2003). Rosuvastatin successfully improved hepatic steatosis
in a high-fat and high-cholesterol diet-induced NASH model
in rats and further improved hepatic fibrosis via improved
peroxisomal β-oxidation (Okada et al., 2013). Simvastatin
administered intragastrically in a model of high fat diet in
rats significantly reduced expression of inducible nitric oxide
(iNOS) synthase, α-SMA, TGF-β1, and collagen, while inducing
the expression of endothelial nitric oxide (eNOS) synthesis that
evolves protective function in the cardiovascular system (Wang
et al., 2013). However, there are an increasing number of reports
that somewhat questioning the beneficial effects of statins in
therapy of hepatic disease. In a BDL model performed in rats,
the administration of rosuvastatin in early stages of cholestasis
decreased α-SMA expression and inhibited NF-κB activation but
also increased hepatocytolysis, oxidative stress formation, and
hepatic inflammation and sustained increased levels of TGF-β1
(Olteanu et al., 2012). Likewise, in the TAA model in rats both
atorvastatin and rosuvastatin failed to inhibit liver cirrhosis or
oxidative stress formation and had no effect of HSC proliferation
(Shirin et al., 2013).
HEPATOPROTECTIVE SUBSTANCES
AFFECTING FAT METABOLISM
Excessive alcohol consumption, high caloric intake, or several
metabolic disorders predispose for fatty liver in which
triglycerides accumulate in liver cells. This process termed
steatosis is accompanied by inflammation that on long term
ends in fibrosis. Therefore, substances that prevent intracellular
fat uptake or increase the turnover and metabolization of
triglycerides have anti-inflammatory and anti-fibrotic impact.
L-carnitine
Carnitine (Figure 5) is found in highest concentrations in red
meat and is structurally a quaternary ammonium compound
with essential function in long-chain fatty acid transport. It acts
as a fatty acid carrier across the mitochondrial membrane. The
protective effects of carnitine were demonstrated experimentally
in CCl4-treated rats in which this substance reduced expression
of TNF-α, platelet-derived growth factor (PDGF)-BB and IL-
6 (Demiroren et al., 2014). Other animal studies have shown
that the dietary supplementation with L-carnitine protects
mitochondria and influences the outcome of chemically induced
hepatitis and subsequent hepatocellular carcinoma (HCC), as
well as NASH-related HCC (Chang et al., 2005; Ishikawa et al.,
2014).
Polyenylphosphatidylcholine (PPC)
This highly purified mixture of different phospholipids is marked
as “Essentiale” with indications in acute and chronic hepatitis,
fatty degeneration, toxic liver damage and dyslipoproteinemia.
This preparation should evolve several hepatoprotective activities
such as recovery of hepatocytes, improvement of lipid and
glycogen metabolism, correction of mitochondrial failure and
activation of RNA synthesis. Its main phosphatidylcholine
species dilinoleoylphosphatidylcholine is highly effective in
blocking TGF-β1-induced collagen and TIMP-1 expression in rat
HSC, while Palmitoyl-linoleoylphosphatidylcholine, the second
most abundant component in PPC had no effect on expression of
these pro-fibrogenic genes (Cao et al., 2002).
HEPATOPROTECTIVE SUBSTANCES
AFFECTING SUGAR METABOLISM
Elevated fasting glucose is a risk factor for non-alcoholic fatty
liver disease that is associated with NASH, fibrosis, and cirrhosis.
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FIGURE 5 | The hepatoprotective agent L-carnitine. This quaternary ammonium compound (CAS 541-15-1) is enriched in meats of mutton, lamb and other
mammals. It has essential function in long-chain fatty acid transport, prevent mitochondria dysfunction, and reduces expression of TNF-α, PDGF, and IL-6.
Insulin resistance and diabetes contribute to the progression
from NASH to fibrosis through the development of a pro-
fibrotic environment in the liver (Chiang et al., 2011). Therefore,
drugs with insulin-sensitizing or anti-hyperglycaemic activity are
one option that protects for hepatic inflammation and fibrosis.
Several drugs are available that either has one or both of these
activities.
Pioglitazone (Actos) and Rosiglitazone
(Avandia)
Based on its insulin-sensitizing and anti-hyperglycaemic activity,
this drug is clinical used for the treatment of adult-onset diabetes.
Chemically, it belongs to the large group of thiazolidinediones
also known as glitazones (Supplementary Figure 4) that activate
the nuclear PPAR receptors. In experimental hepatic steatosis
and fibrosis in rats induced by feeding of a choline-deficient
L-amino-acid-defined diet, pioglitazone reduced the expression
of TIMP-1, TIMP-2, and prevented the activation of HSC
(Kawaguchi et al., 2004). These experimental findings were
also confirmed in a rat model of high fat-induced steatosis in
which pioglitazone reduced excess hepatic fatty degeneration
and fibrosis, serum levels of transaminases, triglycerides, free
fatty acids, glucose, insulin, and expression of hepatic collagen
I and α-SMA (Zhang et al., 2012b). In humans, a detailed
meta-analysis of pioglitazone activity in 137 patients that suffered
from NASH showed that patients taken this drug had significant
lower grade of fibrosis, lower body weight fat and improvement
of ballooning degeneration, lobular inflammation, and steatosis
than the placebo group that contained 134 individuals (Boettcher
et al., 2012). However, in some rat models the therapeutic anti-
fibrotic efficacy of this thiazolidinedione was limited. It failed to
interrupt progression of BDL-induced fibrosis suggesting that the
etiology leading to fibrosis, the duration of the underlying liver
disease, and/or the severity of fibrosis at the time of initiation
of piaglitazone treatment significantly influence the therapeutic
potential this drug (Leclercq et al., 2006). Rosiglitazone, another
thiazolidinedione, showed highly beneficial effects in prevention
and ameliorating nutritional fibrosing steatohepatitis in rodents
(Nan et al., 2009). In contrast this drug on long-term id associated
with increased expression of pro-inflammatory genes in humans
that however has no effects on collagen I or TGF-β expression
(Lemoine et al., 2014). In summary, all these findings indicate
that not all glitazones might be entirely suitable for treatment of
NASH or uniformly useful in other kind of hepatic injuries.
INHIBITORS OF CYTOKINE SIGNALING
Cytokines are produced by a broad range of cells. They
and act in an autocrine or paracrine manner by binding to
specific cell-surface receptors thereby initiating intracellular
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signaling cascades commonly resulting in modulation of gene
transcription. Over the last decades, there has been increasing
knowledge on the involvement of different cytokines and their
pathways in the pathogenesis of hepatic fibrosis (Figure 6).
Some cytokines that seems to be extremely important for
initiation and progression of hepatic fibrosis represent good
drug targets that were comprehensively explored during the last
decades.
TGF-β
Transforming growth factor (TGF-β) and its intracellular
signaling mediators, the Smad proteins, is the key cytokine axis
driving collagen gene transcription. Most obvious the important
role of TGF-β in collagen synthesis was shown in mice that
carried a fusion gene consisting of modified porcine TGF-β1
cDNA directed under regulatory control of the mouse albumin
gene promoter. Respective mice developed hepatic fibrosis and
apoptotic death of hepatocytes (Sanderson et al., 1995). Vice
versa, the suppression of TGF-β expression in ongoing hepatic
fibrosis in rats effectively attenuated hepatic fibrogenesis (Arias
et al., 2003). Similar results were obtained with soluble TGF-
β receptors that sequester biological active TGF-β, dominant-
negative TGF-β receptors, dominant negative Smad proteins,
or in experiments in which inhibitory Smad7 was expressed
(Gressner et al., 2002). Nowadays, novel small inhibitors (such
as SB-431542, GW788388, SKI2162, EW-7197, SM16) that
specifically target the TGF-β type I receptor (ALK5) that mainly
drives the fibrogenic responses in HSC are experimentally
tested in mice and rats (de Gouville et al., 2005; Gellibert
et al., 2006; Park et al., 2015a,b). In addition, the adenoviral
FIGURE 6 | The cytokine signaling wheel in hepatic fibrogenesis. Hepatic inflammation and fibrosis is the consequence of multiple cytokine activities that
have multiple biological functions. Representative cytokines involved in disease process are TGF-βs, PDGFs, TNF-α, EGFs, FGF, IGFs, IFNs, NGFs, ILs, VEGFs,
and the HGF/c-met axis. The images were prepared with Ribbons vers. 3.0 using the structure coordinates deposited in the RCSB Protein Data Base under
accession no. 1KLC (human TGF-β1), 1TNF (human TNF-α), 1JL9 (human EGF-1), 1EVT (human FGF1), 1IMX (human IGF-1), 1AU1 (human IFN-β), 4EAX (mouse
NGF), 1IL6 (human IL-6), 1SHY (human β-chain of HGF in complex with the sema domain of the c-met receptor), and 1PDG (human PDGF-BB), respectively. The
bars represent each 10 A.
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overexpression of BMP-7 that physiologically opposes TGF-β
activities was beneficial in experimental models (Kinoshita et al.,
2007).
PDGF
The five members of the PDGF family of cytokines, PDGF-AA,
PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD, mediate their
signals via two types of receptor tyrosine kinases (PDGFRα,
PDGFRβ) that can form pure or mixed dimers. In general,
PDGFs are potent mitogens that drive cell proliferation and
differentiation. Their involvement in the pathogenesis of hepatic
fibrosis was proven in transgenic mice that expressed PDGF-
B under control of the hepatocyte specific albumin promoter
(Czochra et al., 2006). This study further revealed that the PDGF-
B-induced process of fibrogenesis does not require upregulation
of TGF-β suggesting that PDGF-B alone is able to initiate
hepatic fibrosis by TGF-β-independent mechanisms. Likewise,
the overexpression of PDGF-C is already sufficient to induce
hepatic fibrosis in mice, irrespectively if this cytokine is expressed
transient or stable (Campbell et al., 2005). Conversely, the
lack of PDGF-C in mice is not suitable to prevent hepatic
fibrosis suggesting that antagonizing strategies for PDGF-C
are not effective to treat liver fibrosis (Martin et al., 2013).
During inflammatory liver insult, the expression of different
ligands and receptors of the PDGF network is differentially
regulated (Borkham-Kamphorst et al., 2008). Most of the
experimental studies suggest that the targeting of PDGF-B,
PDGF-D, and PDGFRβ should be more effective in treatment
of hepatic fibrosis, while the ligands that are more connected
to the PDGFRα signaling branch are more relevant in tumor
angiogenesis and maintenance of the tumor microenvironment
that is necessary for progression to hepatocellular carcinoma
(Oseini and Roberts, 2009). In this regard, it is worth to mention
that PDGF-B and PDGF-D show the same fibrotic activities
in HSC and portal MFB (Borkham-Kamphorst et al., 2015a).
In line with these findings, the overexpression of a dominant-
negative soluble PDGFRβ blocked HSC proliferation and hepatic
fibrogenesis in rats (Borkham-Kamphorst et al., 2004). Today are
also varieties of small components available that (more or less)
specifically target the PDGFR kinase activity. Some in vitro and
in vivo studies have reported beneficial effects of the quinoxaline-
type tyrphostin AG-1295 in hepatic fibrosis.
TNF-α
Tumor necrosis factor-α (TNF-α) is the prototype of the
TNF family that consists of 19 different proteins sharing a
homotrimeric or heterotrimeric structure. TNF-α is mainly
secreted bymacrophages and binds with different affinities to two
receptors (TNF-R1, TNF-R2), that initiate several intracellular
cascades leading to activation of NF-κB. This pathway triggers
cellular activation, differentiation, cytokine production and
cellular apoptosis. The activation of TNF-α-associated pathways
is causatively linked to liver injury and hepatic inflammation.
This connection is particularly demonstrable after Concanavalin
A injection that induces acute hepatitis (Heymann et al.,
2015). There is an infinite number of studies that unanimously
demonstrated that the blockade of TNF-α is suitable to
attenuate the inflammatory response. Monoclonal antibodies
(e.g., infliximab, adalimumab, certolizumab pegol, golimumab)
and circulating receptor fusion proteins (e.g., etanercept) that
block TNF signaling are already applied in humans. Although
these drugs are beneficial to reduce hepatic inflammation
in many disease models, some of these compounds cause
different forms of hepatic injury indicated by elevation of serum
aminotransferases, induction of auto-antibodies, cholestasis, and
reactivation of hepatitis viruses (Efe, 2013).
NGF
Nerve growth factor (NGF) binds to different receptors
(p75NTR, TrkA) and leads to activation of several pathways
(e.g., AKT/PKB, MAPK, NF-κB). During fibrotic liver injury,
hepatocytes express NGF that dose-dependently leads to increase
in HSC apoptosis (Oakley et al., 2003), while proNGF protects
MFB from apoptosis (Kendall et al., 2009). These findings suggest
that the NGF axis might be of particular interest for therapeutic
targeting of HSC apoptosis. It will be interesting to follow how
NGF, proNGF, monoclonal antibodies against NGF, non-peptidic
NGF agonists and other drug systems that target the NGF route
will modulate experimental hepatic fibrosis.
VEGF
As the term vascular endothelial growth factor (VEGF) already
suggest, the five members of this cytokine family (VEGF-
A, VEGF-B, VEGF-C, VEGF-D, and PIGF) are important for
vascular development and angiogenesis. They bind to tyrosine
kinase receptors (VEGFRs) that trigger multiple downstream
signals. It is generally assumed that VEGF-A is implicated in
hepatic fibrosis. This growth factor is induced in cells upon
oxygen tension. It modulates the density of microvessels and is
involved in the production of portal hypertension (Corpechot
et al., 2002). However, studies that are more recent have shown
that VEGF is not only a promoter of hepatic fibrosis but is
vice versa also required for hepatic tissue repair and fibrosis
resolution (Yang et al., 2014c). Therefore, modulation of VEGF
or VEGFR activity might provide some drug targets for therapy
of hepatic fibrosis. There are several (pan-specific) tyrosine
kinase inhibitors (e.g., PTK787/ZK22258, sunitinib, sorafenib,
ramucinumab, vatalanib, brivanib) on the market that were
already successfully tested in experimental rodent models.
ILs
Over 40 different cytokines form the group of ILs. Together
with their different types of receptors, they possess a pleiotropic
activity in the innate and adaptive immune response and in all
kinds of inflammatory responses. Beside their linkage to hepatic
inflammation, several studies showed that some ILs (e.g., IL-22)
have hepatoprotective and anti-fibrotic effects. Therefore, several
clinical studies actually examine their effects in liver disease. The
high number of ILs and their receptors as well as the availability
of IL agonists or antagonists offers infinite therapeutic modalities.
Since ILs may evolve pro- or anti-inflammatory activities (as
well as both activities), it is most likely that strategies targeting
one particular IL or a specific IL receptor will be beneficial
only in selected disease subsets. A comprehensive summary of
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experimental studies in mice targeting different ILs is given
elsewhere (Hammerich and Tacke, 2014).
Fibroblast Growth Factors
The 22 members of the fibroblast growth factors (FGFs) family
bind to five distinct receptors (FGFR1-4, FGFRL1). Signaling
of these cytokines is mediated through several downstream
pathways including the Ras-Raf-mitogen-associated protein
kinase and phosphoinositol-3 kinase-AKT cascades. The FGF
family is involved in the initiation of fibrosis and progression
of hepatic fibrosis to cirrhosis (Cheng et al., 2011). Mice that
lacked FGFR4 were more prone to hepatic fibrosis, while mice
that lacked FGF1 and FGF2 showed decreased liver fibrosis
in the CCl4 model (Yu et al., 2002, 2003) These unexpected
and somewhat contradictory findings suggest that FGF signaling
offers some potential therapeutic clues for prevention or
treatment of hepatic fibrosis.
HGF
Hepatocyte growth factor (HGF) or scatter factor binds to
the c-Met receptor that possesses tyrosine kinase activity. This
cytokine has pleiotropic effects on liver cells and influences
cell proliferation, apoptosis, differentiation, motility, invasion
and angiogenesis. In experimental liver disease, HGF attenuated
liver fibrosis (Xia et al., 2006). Mechanistically, it was supposed
that HGF suppresses pro-fibrogenic signaling via induction of
galectin-7 that can bind to phosphorylated Smad2/3 thereby
preventing its transcriptional regulator function (Inagaki et al.,
2008). The pleiotropic activities of this cytokine combined
with the availability of novel inhibitory peptides, therapeutic
antibodies, truncated antagonistic peptides (e.g., HGF/NK1), and
small molecule inhibitors (e.g., INC280, Tivantinib) that target c-
Met will open new avenues for anti-fibrotic treatment strategies.
EGF
The epidermal growth factor (EGF) induces on its receptor
(EGFR) tyrosine kinase activity. This cytokine has recently
attracted much interest because EGFR inhibition by erlotinib
was shown to attenuate liver fibrosis and development of HCC
in DEN-treated mice and BDL rats (Fuchs et al., 2014). EGF
and FGF2 synergistically suppressed expression of α-SMA and
reversed human activated primary HSC into a transitional
state demonstrating that this cytokine counteracts profibrogenic
signaling (El Taghdouini et al., 2015).
IFN
The type I (IFN-α, IFN-β, IFN-ω, IFN-τ, IFN-κ, IFN-λ, IFN-
ς) and type II (IFN-γ) interferons (IFN), and their receptors
(IFNR) transduce signals via the classical JAK-STAT pathway and
mediate antiviral and growth-inhibitory effects. Their important
immunomodulatory activity alone (for example of pegylated
IFN-γ) or in combination with other antiviral drugs is already
clinical exploited in treatment of hepatitis virus associated liver
disease since many years (EASL, 2015).
IGF
The two insulin-like growth factors (IGF-1, IGF-2), their six
binding proteins (IGFBP-1 to IGFBP-6) and their two receptors
(IGF1R, IGF2R) form a complex network, i.e., the “IGF axis.”
This axis is critically associated with the development of liver
disease. In accordance with this assumption, the treatment with
recombinant human IGF-1 attenuated and reversed the fibrotic
degeneration of hepatic tissue (Bonefeld and Møller, 2011).
Although the importance of the IGF axis is somewhat fallen into
oblivion during the last years, there are reasonable arguments
that still make IGF and its signaling pathways attractive for
therapeutic interventions.
INHIBITORS OF CHEMOKINE SIGNALING
Chemokines are a large family of chemotactic and
immunomodulatory molecules that act through 19 known
G-protein coupled receptors. Based on their chemical structure
and the spacing of common four conserved cysteine residues,
the different chemokines are grouped into four groups, i.e., CXC,
CC, CX3C, and XC. Most chemokines act as chemoattractant
that become released by different cell types. They modulate
the biological attributes of immune cells and some chemokines
promote hepatic fibrosis. A summary of chemokines and
receptors relevant in the pathogenesis of hepatic disease was
recently published (Marra and Tacke, 2014). A wealth of studies
suggested that the different chemokine-receptor axes offer a
large variety of therapeutic options. Neutralizing antibodies
to a specific chemokine or its receptor, inactive chemokines
blocking receptor docking sites, small molecule receptor
antagonists, intracellular signaling blockers, or direct blockade
of chemokine synthesis by siRNA or aptamers are currently
under investigation. Several clinical trials are on the way testing
the efficacy of chemokine antagonism in patients with chronic
liver inflammation and fibrosis (Marra and Tacke, 2014). In
particular, several 50–120 kDa polysaccharides (e.g., GR-MD-02,
GM-CT-01) are promising drugs (Supplementary Figure 5).
These compounds target galectin-3 that regulates TGF-β driven
HSC activation and inflammation-associated chemoattraction
(Henderson et al., 2006; Klyosov et al., 2012). The mentioned
polysaccharides showed good beneficial effects on regression of
fibrosis and reversal of cirrhosis in rats (Traber et al., 2013). With
one of these compounds, GR-MD-02, a large phase 2 trial for the
treatment of liver fibrosis and resultant portal hypertension in
patients with NASH cirrhosis is currently implemented.
MODULATORS OF CELLULAR
APOPTOSIS, AUTOPHAGY AND
SENESCENCE
Programmed cell death (apoptosis) and autophagy
(autophagocytosis) are physiological programs having
fundamental function during development and differentiation.
However, enhanced rates of apoptosis are also physiologically
important when aberrant cellular proliferation occurs or
unwanted cells should be removed. Similarly, exposure to
tremendous factors can induce a cellular senescence response
in which the growth of premalignant cells is haltered and
overshooting cell proliferation in tissue repair prevented.
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Since the pathogenesis of hepatic fibrosis and cirrhosis is
associated with a significant increase in ECM producing cells, it
is obvious that the targeted induction of apoptosis, autophagy,
or senescence in ECM-producing cells might be therapeutically
beneficial. The development of respective strategies targeting
profibrogenic cells in hepatic fibrosis is therefore a very
important therapeutic option.
Gliotoxin
Aspergillus fumigatus and many other fungi (Figure 7)
produce this highly potent mycotoxin. The toxicity if this
epidithiodioxopiperazine-type fungal toxin is majorly due to
the unusual intra-molecular disulfide bridge. Gliotoxin induced
apoptosis in rat and human HSC (Wright et al., 2001) potentially
through a specific thiol redox-dependent interaction with the
adenine nucleotide transporter in respective cells (Orr et al.,
2004). It further reduced the number of activated HSC in the
liver of rats treated with CCl4 or TAA (Wright et al., 2001; Dekel
et al., 2003). Although hepatocytes are rather robust against
this drug, all non-parenchymal cells showed a similar degree of
apoptosis when tested in normal and fibrotic precision-cut rat
liver slices (Hagens et al., 2006). Therefore, gliotoxin might be a
future good drug candidate when strict targeting strategies for
HSC become available. Although such targeting strategies are
under development and evaluation, this drug is presently only of
experimental interest.
Resveratrol
This compound (Figure 7) is a hydroxylated stilbene belonging
to the phytoalexins produced by many plants (e.g., grapes,
raspberries, mulberries, plums, peanuts). It acts as an antioxidant
and anti-mutagen, most likely by inhibition the activity of
FIGURE 7 | Gliotoxin and Resveratrol, two modulators of cellular apoptosis, autophagy and senescence. The potent sulfur-containing mycotoxin gliotoxin
(CAS 67-99-2) that can be isolated from many fungi and the stilbenoid resveratrol (trans-resveratrol: CAS 501-36-0, cis-resveratrol, CAS 61434-67-1) that acts as an
phytoalexin have been the subject of numerous experimental studies on hepatic fibrosis. Both substances have growth inhibitory activity and apoptotic capacity. In UV
light, resveratrol can be converted form its trans into its cis form. The images of Aspergillus fumigatus, Aspergillus terreus, Eurotium chevalieri were kindly provided by
the CABI/Royal Botanic Gardens, Kew, Richmond, UK and printed with kind permission of Dr. Paul F. Cannon.
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cyclooxygenase and hydroperoxidase (Jang et al., 1997). First
reports in 2000 investigated potential anti-fibrotic effects of
resveratrol and analogs in human MFB that were obtained by
outgrowths from non-tumoral liver explants (Godichaud et al.,
2000). This study revealed that resveratrol dose-dependently
inhibited proliferation of MFB and decreased expression of α-
SMA and collagen type I without affecting vimentin expression.
Moreover, the migration of MFB was inhibited and the secretion
of MMP2 increased by resveratrol. All these activities were
specific for resveratrol and not found in cells that were
stimulated with piceid or piceatonnol representing glucosylated
or hydroxylated analogs of resveratrol. Therapeutic effects were
found in the CCl4 model in mice in which resveratrol prevented
the toxin-induced glycogen decrease, expression of TGF-β and
further reduced the activity of the NF-κB pathway (Chávez
et al., 2008). Similar findings were obtained in the TAA model
in which the daily oral gavage of resveratrol for seven days
after a single intraperitoneal injection of TAA prevented body
and liver weight loss, liver inflammatory infiltrate, and hepatic
expression of fibrosis-related genes (Hong et al., 2010). In this
model, the authors also found that resveratrol decreased the level
of malondialdehyde, while the levels of glutathione peroxidase
and superoxide dismutase were increased. A therapeutic action
of resveratrol was also proven in murine models of chronic and
acute hepatic iron overload (Das et al., 2015). Mechanistically,
a very recent study demonstrated that resveratrol induces
autophagy, promotes cell death and concomitant apoptosis in
GRX cells (Meira Martins et al., 2015).
INTERFERING WITH PRO-FIBROGENIC
TARGET MOLECULES
Numerous profibrogenic proteins are known that drastically
affect the outcome of hepatic fibrosis. Prototypically for these
proteins are some matricellular proteins that are increased
expressed during progression of hepatic disease. They modulate
either the activity of profibrogenic cytokines or the process of
pathologic tissue remodeling. Some examples of this class of
proteins are briefly discussed in the following.
SPARC
The secreted protein acidic and rich in cysteine (SPARC) that
is also known as osteonectin is a 40-kDa calcium binding
protein that binds to collagen, increases the production and
activity of MMPs, modulates cell shape and disrupts cell-matrix
interactions. The major source of SPARC in fibrotic livers are
HSC, while other hepatic cell types produce only trace amounts
of this matricellular protein (Frizell et al., 1995). Adenoviral
overexpression of a SPARC antisense was suitable to attenuate
the development of hepatic fibrosis in rats in which fibrosis was
induced by TAA application (Camino et al., 2008). Subsequent
in vitro studies performed in immortalized human LX-2 and
rat CFSC-2G cell lines showed that the suppression of SPARC
prevents HSC adhesion to fibronectin, expression of TGF-β and
collagen as well as TGF-β- and PDGF-induced cell migration
(Atorrasagasti et al., 2011). In line with these anti-fibrotic
capacity of SPARC, mice that lacked SPARC had reduced hepatic
collagen deposits combined with elevated quantities of MMP-
2 and reduced expression of TGF-β1 when subjected to TAA
or BDL (Atorrasagasti et al., 2013). Therefore, it is temping
to speculate that SPARC is a potential drug candidate for
therapeutic intervention.
Osteopontin
This highly negative charged 33-kDa ECM protein is also known
as bone sialoprotein-1 (BSP-1) or secreted phosphoprotein 1
(SPP1), In HSC it is involved in the control of migration,
activation of MMP2, and production of collagen and TGF-β
type II receptor (Lee et al., 2004b). Based on these effects it was
proposed that osteopontin is a cytokine with key activities in the
extracellular protein network (Urtasun et al., 2012). This notion
was underpinned by the finding that osteopontin-deficient mice
were more susceptible to CCl4. It was therefore suggested
that the increase of this protein protects for fibrosis (Lorena
et al., 2006). In addition, it was demonstrated that osteopontin
deficiency is protective in ischemia-reperfusion hepatic injury in
mice, most likely by preventing hepatocyte death and sensitizing
macrophages to inflammatory signals (Patouraux et al., 2014).
Also the overall quantities of osteopontin impacts the resolution
of hepatic fibrosis, since osteopontin deficient mice that were
made fibrotic by TAA administration showed significant delays in
fibrosis resolution when compared to wild typemice (Leung et al.,
2013). However, in a murine model of alcoholic neutrophilic
hepatitis, the lack of osteopontin failed to prevent alcoholic
hepatitis, enhanced the expression of IL-17, and increased
the number of polymorphonuclear cells infiltrating the liver
potentially pointing to a more complex function of Osteopontin
in formation of liver insult (Lazaro et al., 2015).
CCN2/CTGF and CCN1/CYR61
The CCN (CYR61, CTGF, and NOV) protein family consists
of six conserved small secreted cysteine-rich proteins. These
matricellular proteins have a modular structure with up to
four individual modules including an insulin-like growth
factor binding domain, a von Willebrand Factor type C
motif, a thrombospondin type I module, and a carboxyl-
terminal cystine knot. The individual domains of the CCN
proteins confer different binding activities, intrinsic activities,
modulator activities, and antagonistic activities (Weiskirchen,
2011). Under normal conditions the different CCN proteins
take over important roles in embryonic development, cellular
commitment, tissue differentiation (angiogenesis, osteogenesis),
and matrix remodeling as well as wound healing. The most
intensively studied member of this family in experimental and
human liver disease is CCN2/CTGF. Its expression in liver tissue
correlates well with the extent of liver injury. The biological
inactivation of CCN2/CTGF by antisense nucleotides (Uchio
et al., 2004), small interfering RNA (Li et al., 2006, 2008a;
George and Tsutsumi, 2007; Georges et al., 2007), short hairpin
RNA (Yuhua et al., 2008) or hammerhead ribozymes (Gao
and Brigstock, 2009) abrogated the process of ongoing hepatic
fibrogenesis in vitro and in vivo. In this regard, it is noteworthy
that CCN2/CTGF binds to and increases the biological activity
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of TGF-β for the type II TGF-β receptor complex (Abreu
et al., 2002). Interestingly, the expression of CCN2/CTGF upon
stimulation with TGF-β1 was only marginally increased in
primary HSC but strongly increased in primary hepatocytes
suggesting that profibrogenic activities of CCN2/CTGF are
stimulated in a paracrine fashion (Gressner et al., 2007). In
contrast, the basal expression of CCN1/CYR61 in primary
hepatocytes is rather low compared to HSC and portal MFB
(Borkham-Kamphorst et al., 2014). In models of ongoing liver
fibrogenesis, elevated levels of CCN1/CYR61 were particularly
noticed during early periods of insult, while its expression
declined during prolonged phases of fibrogenesis (Borkham-
Kamphorst et al., 2014). Since the delivery of recombinant
protein in mice with established fibrosis accelerated fibrosis
regression, it was speculated that this CCN protein family might
have therapeutic potential by its capacity to induce cellular
senescence in hepatic MFB (Kim et al., 2013).
Tenascins, Syndecans, Aggrecan,
Lumican, and Fibromodulin
Another family of ECM proteins that is associated with hepatic
fibrogenesis are tenascins. This family contains four members
(TNC, TNR, TNX, and TNW) sharing multiple EGF-like repeats
and several fibronectin-III domains. It is assumed that tenascins
have affinity for fibronectin thereby blocking its interaction
with syndecans that are heparin sulfate and chondroitin sulfate
coupled single transmembrane proteins. TNC is upregulated
during chronic hepatic disease and mice that lacked TNC
were more prone to hepatic inflammation and fibrosis (El-
Karef et al., 2007). In addition, the expression of other keratin
sulfate proteoglycans such as syndecans, aggrecan, lumican, and
fibromodulin were linked to the pathogenesis of hepatic disease
and activation of HSC (Gressner et al., 1994). Although this class
of proteins were somewhat forgotten, it is obvious that they have
large potential as therapeutic targets in hepatic fibrosis.
Thrombospondins
The family of thrombospondins are implicated in multiple
biological processes. In particular, the finding that
thrombospondin-1 is involved in the conversion of latent
to activated forms of TGF-β family members has attracted much
interest (Schultz-Cherry andMurphy-Ullrich, 1993). Application
of a specific tetra-peptide (Leu-Ser-Lys-Leu) derived from the
latency-associated peptide of TGF-β prevented the progression
of hepatic fibrosis in a DMN model in rats through inhibition of
TGF-β1 activation and its downstream signaling (Kondou et al.,
2003).
WNT, Hedgehog and Notch Signaling
Compounds
The canonical Wnt/β-catenin signal pathway forms a close
signaling network with TGF-β thereby influencing liver fibrosis
by modulating HSC activation and survival. There are a variety
of Wnt pathway antagonists and inhibitors which provide a high
variability for targeting the respective pathways. They include
soluble receptors, siRNA, chemically synthesized transcription
factor competitors and transcription inhibitors (Guo et al., 2012).
However, there is presently a strong debate if the Wnt/β-catenin
pathway is beneficial or tremendous for the outcome of hepatic
fibrosis. While the blockade ofWnt/β-catenin signaling inhibited
HSC activation (Ge et al., 2014), the restoration ofWnt/β-catenin
signaling in alcohol liver diseased rats attenuated progression
of hepatic insult (Huang et al., 2015). However, certainly the
Wnt/β-catenin axis still provides potential targets attractive for
diagnosis, prognosis, and development of therapeutics (Monga,
2015).
The hedgehog pathway with its three homologs DHH, IHH,
and SHH and their receptors is involved in fate determination
of HSC and significantly participates in liver fibrosis (Yang et al.,
2014a). Several of its antagonists and agonists of the underlying
pathways are already in clinical use. Many different agents (e.g.,
IP-926, LDE-225, Gli-3, arsenic trioxide) can target the activity of
the receptor Smoothened.
Notch signaling is a crucial determinant of cell fate
decision that becomes visible during liver regeneration and
repairs. Alterations in Notch signaling are associated with liver
malignancies and it was therefore supposed that the underlying
pathways would provide novel drug targets to develop safe and
specific therapeutic agents for different hepatic lesions (Morell
and Strazzabosco, 2014).
MODULATORS OF CELL CYCLE OR
PROLIFERATION
Colchicine, Colchiceine
Both the toxic Cholchicum autumnale alkaloid colchicine and its
metabolite colchiceine (Figure 8) are inhibitors of microtubule
polymerization by binding to tubulin. Cholchicine is used
primarily in the treatment of gout and experimentally as a strong
inhibitor of mitosis in genetic karyotyping studies. The interest
in colchicine in hepatic fibrosis research arouse in 1975 when
Rojkind and Kershenobich found that the content of collagen
synthesis was blocked and liver function greatly improved in
cirrhotic rat livers (Rojkind and Kershenobich, 1975). A similar
protective activity of cholchicine was demonstrated in BDL rats
that received chronic oral administration of this drug (Poo et al.,
1993). A randomized, double-blind, placebo-controlled trial that
was performed in 100 cirrhotic patients arising form diverse
causes and followed for 14 years showed that the overall survival
rate in the cholchicine group was markedly better (Kershenobich
et al., 1988). However, this finding was not reproduced in another
trial that enrolled patients with alcohol-induced cirrhosis that
received colchicine (n = 274) or placebo (n = 275) for 2–6 years
(Morgan et al., 2005). The potential of this drug is not exhaustive
clarified and there are still appearing human studies showing
effective and safe anti-fibrotic benefits of this drug (Muntoni
et al., 2010). Possibly, the application of colchiceine that has
better anti-fibrotic properties than cholchicine in experimentally
induced CCl4-induced cirrhosis in rats (Nava-Ocampo et al.,
1997) and has overall lower toxic effects than cholchicine
(Dvorak et al., 2002) is worth to be tested in future clinical
studies.
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FIGURE 8 | Colchicine and cholchiceine. Both colchicine (CAS 64-86-8)
and its metabolite colchiceine (CAS 477-27-0) that are found in the autumn
crocus have been reported as antifibrotic agents in experimental models of
hepatic fibrosis.
MODULATORS OF ECM TURNOVER AND
COLLAGEN SYNTHESIS
It is obvious that alterations in ECM synthesis, breakdown, or
posttranslational modifications of ECM proteins are involved
in both initiation and progression of hepatic fibrosis (Karsdal
et al., 2015). The composition of the ECM is majorly regulated by
proteases and their inhibitors that control ECM remodeling (the
MMP/TIMP system) or by enzymes that are directly involved in
the synthesis, organization or crosslinking of ECM components
(Lysyloxidase and Lysyloxidase like 2). The understanding of
ECM remodeling during hepatic fibrogenesis has lead to the
uncovering of many novel therapeutic targets. Some of these are
briefly discussed in the following paragraphs.
MMPs and TIMPs
In general hepatic fibrosis is associated with an unbalanced
expression of matrix metalloproteinases (MMPs) and their
physiological inhibitors, the tissue inhibitors of MMPs (TIMPs).
The family of MMPs comprise 23 different members in
human and mouse (MMP-1 to MMP-28) that are not
numbered consecutively. These enzymes act as zinc-dependent
endopeptidases that have a role in a diverse range of physiological
and pathological processes (Visse andNagase, 2003; Jackson et al.,
2010). Under normal conditions, the different MMPs degrade
and remodel the ECM with different substrate specificities. They
are synthesized as inactive zymogens and become activated by
intracellular, extracellular, or cell surface-mediated proteolysis.
Once activated, the extracellular activity of MMPs is controlled
by TIMPs. These form a group of four members (TIMP-
1, TIMP-2, TIMP-3, and TIMP-4) with different affinity for
individual MMPs. The balance of MMP synthesis, activation
and inhibition by TIMPs is most critical for ECM homeostasis
and overactivity of TIMPs or suppressed expression of MMPs
favors fibrosis progression. In humans, there are only a few
MMPs (MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-13,
MMP-14) and TIMPs (TIMP-1, TIMP-2) expressed in liver
tissue or relevant for hepatic fibrogenesis and fibrolysis. A
detailed literature search that analyzed 243 Medline records
describing experimental models of liver fibrosis that evaluated
a defined anti-fibrotic intervention showed that all these genes
have a characteristic expression during degradation of normal
liver matrix, accumulation of fibrotic tissue and degradation
of fibrotic liver matrix (Hemmann et al., 2007). While for
example MMP-2 and MMP-14 are relevant during phases of
accumulation of fibrotic scar tissue, the activity of MMP-13 is
particular observed during degradation of normal tissue and
in the initiation process of degradation of fibrotic scar tissue
suggesting that the individual MMPs have pro- and anti-fibrotic
activities (Hemmann et al., 2007).
In line with this concept, the small interfering RNA targeting
TIMP-1 expression effectively suppressed MMP-2 expression
and activity in the CCl4 and BDL models in rats, while the
expression and activity of MMP-13 was elevated (Cong et al.,
2013). Likewise, the direct targeting of TIMP-2 by a synthetic
siRNA resulted in promotion of ECM degradation, decreased
MMP-2 expression, and increasedMMP-13 expression (Hu et al.,
2007). Other therapy strategies were based on the assignment
of inactivated MMP enzymes acting as profound scavengers for
TIMP-1. Mice that were treated with proteolytically inactive
MMP-9 mutants showed overall lower fibrosis scores and were
effective in preventing transdifferentiation of HSC in vitro and
in vivo (Roderfeld et al., 2006).
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Moreover, different cytokines are effective in modulating the
activity of the MMP/TIMP axis. Members of the PDGF family
(i.e., PDGF-B, PDGF-D) induce expression of TIMP-1 thereby
attenuating MMP-2 and MMP-9 activities in HSC and portal
MFB in vitro (Borkham-Kamphorst et al., 2015a,b). Likewise,
there are many other compounds or mixtures of substances
extracted from plants or fungi that directly or indirectly influence
expression or activity of different MMPs or their inhibitors.
A polysaccharide extracted from the entomopathogenic fungi
Cordyceps sinensis mycelia reduced activities of MMP-2 and
MMP-9 (Peng et al., 2013a), demonstrating that the modalities
to interfere with MMP activity are manifold.
Integrins, RGD Peptides, and RGD Analogs
Integrins are divalent cation-dependent heterodimeric,
membrane glycoproteins that are composed of non-covalently
associated α- and β-subunits. They regulate cell-cell contacts and
cellular interactions and attachment of immune cells with the
ECM. Most integrins recognize their respective ECM proteins
through short peptide stretches such as Arg-Gly-Asp (RGD),
Glu-Ile-Leu-Asp-Val (EILDV), or Arg-Glu-Asp-Val (REDV;
Supplementary Figure 6). For therapy of hepatic fibrosis,
the RGD peptide has attracted much interest because this
peptide is the predominant cell adhesive epitope to fibronectin
and well known to bind preferentially and with high affinity
to the integrin αvβ3.This integrin and other integrins play
essential role in angiogenesis and in fibroblasts where they are
central in differentiation, migration, and proliferation. They
have many ligands (e.g., vitronectin, fibronectin, fibrinogen,
osteopontin, and CCN1/CYR61) that are important in initiation
or progression of hepatic fibrosis. Although integrins have
no intrinsic enzymatic activity, they are capable to initiate
diverse signaling cascades after binding to its ECM partner.
They not only signal on their own but can also cooperate with
growth factor receptors or modify the activity of enzymes or
cytokines that are involved in ECM homeostasis. As good
ligands, the short RGD peptides are already able to induce
a conformational change from a closed to an open integrin
conformation (Hantgan et al., 1999). Therefore, these soluble
peptides can compete with insoluble ECM proteins for binding
to integrin receptors thereby preventing the initiation of signal
cascades or preventing cell adhesion. However, the RGD peptide
itself is not stable and rapidly degraded. Therefore, several
non-peptidic RGD mimetics such as the SF-6,5 that contains
guanidinium and carboxylic groups separated by an 11-carbon
atom backbone that mimic the distal configuration of functional
RGD sequence were developed (Greenspoon et al., 1993). This
compound is proteolytically more stable and serves as a useful
therapeutic agent in versatile pathological processes. In 1996,
it was shown that this RGD analog is therapeutically useful
and suitable to inhibit progression of TAA-induced fibrosis
in rats (Bruck et al., 1996). Similar findings were reported for
the RGD peptide GRGDS in the CCl4 model when injected
intraperitoneally three times a week for 1 month but were not
noticed when the control peptide GRGES were applied (Kotoh
et al., 2004). In vitro, the RGD peptide reduced accumulation
of type I collagen and increased the secretion of collagenases by
HSC (Iwamoto et al., 1999). A cyclic peptide (C*GRGDSPC*)
that has high affinity to the collagen type VI receptor binds
preferentially to activated HSC and when coupled to sterically
stable liposomes these particles accumulated in vivo 10-fold
higher to HSC than uncoupled liposomes in BDL rats (Du et al.,
2007). The concept that the RGD sequence is suitable to target
drugs specifically to activated HSC was also exploited in another
approach in which the quinolizidine alkaloid oxymatrine from
the root of the evergreen slow growing shrub (Sophora flavescens)
was specifically targeted by RGD peptide-labeled liposomes to
HSC in the CCl4 model in rats (Chai et al., 2012). Also the
encapsulation of oxymatrine into RGD-labeled biodegradable
polymersomes ignorantly reduced the expression of α-SMA and
collagen Iα1 in vitro and decreased hepatic connective tissue
deposition in BDL rats (Yang et al., 2014b).
Malotilate
This sulfur-containing drug (diisopropyl 1,3-dithiol-2-
ylidenemalonate; Supplementary Figure 7) was shown to
prevent paracetamol-induced liver damage in male mice when
given 1 h before application of paracetamol, most likely by
interacting with the bioactivation of paracetamol (Younes and
Siegers, 1985). Likewise, malotilate drastically reduced hepatic
inflammation, the increases in type I procollagen α2 mRNA
and activities of prolyl 4-hydroxylase and galactosylhydroxylysyl
glucosyltransferase that are key mediators in collagen fibril
formation in dimethylnitrosamine-treated rats (Ala-Kokko et al.,
1989). Malotilate was well tolerated in phase II study that enrolled
a small number of patients with cirrhosis of various aetiologies
and severity (Bührer et al., 1986) and shown to accelerate the
recovery of impaired protein metabolism in alcoholic liver
disease (Takase et al., 1989). However, this drug is nowadays
out of the focus, potentially because it is poorly water-soluble
and has low oral bioavailability. It will be interesting to follow if
novel spray-dried malotilate emulsions that can produce higher
plasma concentrations (Zhang et al., 2011a) will lead to a revival
in hepatic malotilate research.
Tranilast
This drug (Supplementary Figure 7) was originally approved
in Japan and South Korea and brought into the market in
1982 as an anti-allergic drug (Rizaben). Some years later, an
inhibitory effect on fibroblast proliferation and collagen synthesis
was found both in vitro and in vivo (Isaji et al., 1987; Yamada
et al., 1994). Thereafter, this drug was successfully tested in
different experimental models of liver injury. Tranilast dose-
dependently reduced mRNA expression of procollagen and TGF-
β1 in cultured rat HSC (Ikeda et al., 1996). In vivo it was recently
shown that tranilast has anti-inflammatory potential, antioxidant
activity, and immunomodulatory properties in TAA-induced
acute liver injury (Abdelaziz et al., 2015). However, human trials
with this drug were not initiated yet.
β-Aminopropionitrile
This small substance (BAPN) consists of an amine and nitrile
group that are linked via a C2 linker (Supplementary Figure 7).
It occurs in sweet pease and other Lathyrus plants and
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irreversibly inhibits the enzymatic activity of the Lysyl oxidase.
This enzyme is copper-dependent and cross-links collagen
or elastin by oxidative deamination of peptidyl lysine or
hydroxylysine and peptidyl lysine residues (Bondareva et al.,
2009). In a model in which rats were treated with CCl4 twice
weekly for 3–70 days, BAPN prevented early increase in liver
stiffness suggesting that it effectively prevented HSC activation,
collagen expression, crosslinking or deposition (Georges et al.,
2007). Although these findings are encouraging, more studies are
still required before clinical trials are performed in humans.
S 4682, S 0885, HOE 077, Safironil
S 4682 is a heterocyclic carbonyl-glycine inhibitor of the prolyl 4-
hydroxylase that catalyzes the crucial step in intracellular collagen
processing. This drug reduced hepatic collagen accumulation in
the CCl4 model in rats (Bickel et al., 1998). A similar effect was
found with S 0885 (Supplementary Figure 7) that is structurally
related to S 4682 (Bickel et al., 1991). The competitive prolyl 4-
hydroxylase inhibitors HOE 077 is a hydrophilic prodrug that
can be converted to active hydrophilic metabolites only within
hepatocytes. Like its congener safironil, HOE 077 prevented
stellate cell activation, expression of TIMP-1 mRNA, and
formation of collagen deposits in rat liver fibrosis (Bickel et al.,
1991; Wang et al., 1998; Sakaida et al., 1999).
Lysyl Oxidase-like-2
The enzyme LOXL2 catalyzes a rate limiting step that is
necessary in scaffolding and crosslinking of collagens and
elastins. Moreover, this enzyme is involved in the formation of
a microenvironment that is crucial for scar tissue formation in
hepatic fibrosis (Barry-Hamilton et al., 2010). Targeting LOXL2
with an inhibitory monoclonal antibody (AB0023) was highly
effective in targeting liver and lung fibrosis (Barry-Hamilton
et al., 2010). Studies with a humanized monoclonal antibody
against LOXL2, termed Simtuzumab (GS-6624), were recently
initiated and are currently being investigated in diverse ongoing
phase 2 trials involving HCV patients, primary sclerosing
cholangitis, NASH-related fibrosis and cirrhosis. Since the
expression of LOXL2 is also influenced by hypoxia, TGF-β, and
microRNAs (miR-26 and mIR-29), there are also other potential
strategies for targeting LOXL2 expression or activity (Wong et al.,
2014).
HISTONE DEACETYLASE AND
ACETYLTRANSFERASE BLOCKERS
Histone deacetylases (HDAC) are a family of enzymes that
remove acetyl groups from histones thereby suppressing general
gene transcription. Their activities are counterbalanced by
histone acetyl transferases (HAT) that acetylate lysine amino
acids on histones resulting in relaxed chromatin structures. The
ratio of acetylation and de-acylation adjudicate gene regulation.
Substances that prevent deacetylase or transferase activity are
suitable to modulate gene expression, replication, mitosis,
meiosis, and apoptosis. In addition, there are some non-histone
protein substrates of histone deacylases that are involved in
control of cell proliferation, cell migration, and cell death.
The 18 mammalian HDACs are grouped into four major
classes that are distinguished by their inhibitability by different
substances. They counteract oxidative stress and inflammation
and further influence MAP kinase driven pathways (Ferguson
and McKinsey, 2015). In experimental hepatology research,
several HDAC inhibitors have become in focus because they
can induce growth arrest, terminal differentiation, intrinsic
and extrinsic apoptotic pathways, autophagic cell death, and
senescence already at low concentrations (Dokmanovic et al.,
2007).
Curcumin
This natural phenol with a diarylhepanoid structure is the
yellow pigment associated with the curry spice that can be
isolated from Curcuma longa (turmeric) and to a lesser content
from ginger (Supplementary Figure 8). It is an inhibitor of
p300 histone deacetylases, cyclooxygenase, and arachidonate 5-
lipoxygenase and is further a compound that modulates NF-
κB, MAPKs, and pathways involved in apoptosis (Liu et al.,
2005a). There are a large wealth of experimental studies that have
unanimously shown that cucuminoids evolve strong antioxidant,
anti-inflammatory, and anti-fibrotic properties Chainani-Wu,
2003). It was shown that the dietary administration of whole
spice turmeric or ethanolic extracts thereof predict changes in
liver parenchymal cells in mice (Kandarkar et al., 1998). At
the molecular level, it was recently demonstrated that curcumin
modulates cell fate and metabolism by abrogating Hedgehog
signaling by downregulating essential key elements of this
pathway (i.e., Patched and Smoothened) in HSC (Lian et al.,
2015). Curcumin has also some other potential target sites inHSC
rendering that principal curcuminoid of turmeric as a potential
candidate to prevent or treat hepatic fibrosis in humans (Tang,
2015).
Trichostatin A
This antifungal and antibiotic drug (Supplementary Figure 8)
inhibits HDAC and cell cycle by interfering with the removal of
acetyl groups form histones and induction of apoptosis-related
genes. Work performed in telomerase-immortalized human
corneal fibroblasts has shown that this drug has antioxidant
activity preventing TGF-β-induced formation of ROS and
H202 and MFB differentiation by triggering the Nrf2-ARE
signaling pathway (Yang et al., 2013). In primary rat HSC,
trichostatin A induced hyperacetylation of histone H4 affecting
proliferation, transdifferentiation, and expression of fibrosis-
associated genes (Niki et al., 1999). Moreover, this compound
inhibited the occurrence of TGF-β1-induced epithelial-to-
mesenchymal transition in hepatocytes (Kaimori et al., 2010). In
the field of experimental hepatology, the therapeutic efficacy of
that drug on hepatic fibrosis was not tested in animals yet.
Valproic Acid
This substance (Supplementary Figure 8) is in use as an
anticonvulsant since several decades. Although the molecular
mechanism of its activity is not fully understood, it is believed
that this drug interferes with the gamma-aminobutyric acid
(GABA) metabolism and acts as a potent HDAC inhibitor.
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Although the treatment with valproic acid in long-term induced
impairment of mitochondrial function and strong hepatotoxicity
in humans (Pessayre et al., 1999), the chronic administration of
valproic acid inhibited HSC activation and hepatic fibrogenesis
in mice (Mannaerts et al., 2010). Beneficial effects of valproic
acid were also found in rats with TAA-induced hepatic fibrosis in
which the drug prevented the activation of HSC and decreased
collagen deposition, infiltration of inflammatory cells, and
further induced DNA damage and apoptosis in activated HSC
(Aher et al., 2015). Therefore, the view that the administration
of this drug for hepatic fibrosis still needs careful evaluation is
still valid (Ikura et al., 2010).
Epigallocatechin-3-Gallate
This gallic acid (EGCG) has a catechin structure that is one of the
major effective ingredients of green tea. It has antioxidant activity
and inhibits HATs, DNA methyltransferases, and tyrosinases.
EGCG is further effective in preventing NF-κB and TNF-α
activation (Choi et al., 2009) and induction of cell cycle arrest
and apoptosis (Du et al., 2012). EGCG was shown to prevent
hepatic inflammation, oxidative stress formation and ongoing
hepatic fibrosis in mice that were subjected to CCl4 (Tipoe et al.,
2010). Similar results were found in mice in which liver injury
was induced by BDL (Shen et al., 2015), and further in MCD
diet-induced hepatic steatosis in which EGCG inhibited IL-1β,
IL-6, TNF-α, and MCP-1 mRNA expression (Ding et al., 2015).
Furthermore, ECGC suppressed the phosphorylation of Smad2/3
and Akt/PKB and produced similar effects as LY294002 (that
is a highly selective inhibitor of phosphatidylinositol 3 kinase),
possibly suggesting that some of its activities are due to inhibition
of the PI3K/Akt/Smad pathway (Yu et al., 2015).
ANGIOTENSIN RECEPTOR ANTAGONISM
The peptide hormone angiotensin is part of the renin-
angiotensin system and acts through a class of G protein-coupled
receptors that in their activated forms activate phospholipase
C, cellular calcium increase, and protein kinase C. Based on
their binding specificities for ligands, the receptors can be
classified into four subtypes, i.e., AT1R, AT2R, AT3R, and AT4R
(Unger et al., 1996). The activity of angiotensin can be either
blocked by angiotensin-converting enzyme (ACE) inhibitors
that block the conversion of the decapeptide angiotensin I to
the biological active octapeptide angiotensin II, or alternatively
by antagonistic angiotensin II receptor blockers. Some ACE
inhibitors (e.g., perindopril) and several selective AT1 receptor
blockers (losartan, candesartan) have attracted the interest of
hepatic fibrosis research (Supplementary Figure 9). Historically,
these drugs become into the focus by the finding that perindopril
and candesartan were both effective in preventing pig serum-
induced liver fibrosis in rats (Yoshiji et al., 2001). Subsequently,
Bataller and co-workers have shown that the infusion of
angiotensin II during ongoing BDL-induced hepatic fibrosis
in rats significantly augmented hepatic fibrosis and promoted
inflammation, oxidative stress formation, and thrombogenic
events (Bataller et al., 2005). Countless subsequent proof-of-
concept studies confirmed that the renin-angiotensin system
significantly contributes to the pathogenesis of hepatic fibrosis
(Munshi et al., 2011). Recently, also some direct renin inhibitors
(e.g., aliskiren) that inhibit the formation of angiotensin
I from angiotensinogen were successfully tested in rodent
models of hepatic injury (Lee et al., 2013) suggesting that the
renin-angiotensin system offer many potential therapeutically
beneficial drug targets for interfering with hepatic fibrosis.
ENDOTHELIN RECEPTOR ANTAGONISM
Endothelins are a group of three (ET-1, ET-2, ET-3) potent
vasoconstrictive peptides that can bind with different affinity to
two G-protein coupled receptors, i.e., ETA and ETB (Maguire
and Davenport, 2015). These receptors are detectable on all
major hepatic cell types but are most abundant expressed
on HSC in which the expression of ET-1 is significantly
activated during cellular activation (Housset et al., 1993).
ET-1 (Supplementary Figure 10) and the 21-residue peptide
Sarafotoxin (S6C) that represent a potent ETB receptor agonist
are highly effective in stimulating HSC activation, while the
mixed ETA-ETB receptor antagonist bosentan blocked this
activity (Rockey and Chung, 1996). However, bosentan that
was applied in clinical studies for treatment of pulmonary
hypertension, turned out to evolve hepatotoxic effects hampering
the initiation of human trials testing the efficacy of ET blockers
in patients suffering from liver disease (Humbert et al., 2007).
Although the endothelin axis shifted out of the attention during
the last years, the complex physiology of the ET-1 system offers
many potential drug target that are particular suitable to interfere
with initiation of the fibrotic response (Rodríguez-Pascual et al.,
2014).
LEPTIN ANTAGONISM
Leptin is an adipokine that acts as a hormone and is majorly
involved in the regulation of energy balance. It binds to a cerebral
receptor that regulates appetite and body weight. Although
predominantly synthesized in adipose tissue, leptin is also
secreted from activated HSC (Ding et al., 2005). In addition,
leptin can induce expression of TGF-β and CTGF expression
in Kupffer cells thereby promoting the progression of hepatic
disease (Wang et al., 2009). In line with this assumption, the
application of leptin was associated with significant enhanced
TAA-induced liver disease, while the application of a competitive
leptin inhibitor attenuated chemically induced hepatic fibrosis
in mice and suppressed profibrogenic potential of HSC (Elinav
et al., 2009). Therefore, both the application of leptin inhibitors
and the application of adiponectin that opposes leptin functions
and signaling were proposed as effective means to interfere with
hepatic fibrogenesis (Handy et al., 2011).
THROMBIN ANTAGONISM AND
ANTICOAGULANTS
The serine protease thrombin is an essential converting factor
that is required in the coagulation cascade, and implicated in the
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physiology of blood clot formation. Beside this direct activity of
thrombin in control of haemostasis, thrombin can activate four
different protease-activated receptors (PAR-1, PAR-2, PAR-3, and
PAR-4) that belong to the seven transmembrane G-protein-
coupled receptor family. These stimulate upon proteolytic
activation cell proliferation and transdifferentiation in HSC,
while their expression increases in parallel with the severity and
duration of liver disease (Calvaruso et al., 2008). In experimental
fibrosis in rats induced by administration of CCl4, the synthetic
thrombin inhibitor SSR 182289was found to decrease the content
of α-SMA and expression of TIMP-1 (Duplantier et al., 2004).
Exposure of HSC to a PAR-1 antagonists resulted in inhibition
of primary rat HSC activation in vitro and protected against
fibrosis development in a rat model of cirrhosis induced by
BDL (Fiorucci et al., 2004). Conversely, PAR-1 and PAR-2
agonists induced stellate cell proliferation, again demonstrating
the importance of thrombin in the formation of liver fibrosis
(Gaça et al., 2002). Also the application of substances that
prevent the proteolytic activation of PAR receptors have anti-
fibrotic capacity. Such a drug is APC 366 that selectively blocks
the mast cell tryptase prevented hepatic fibrosis in rats (Lu
et al., 2014). Strategies counteracting PAR activity are therefore
still one attractive option for promotion of restoration of liver
health. Likewise, other compounds with anticoagulant activity,
such as warfarin (coumadin), might be successful to modulate
pre-existing fibrosis. However, evaluation of their anti-fibrotic
potential is still pending.
TYROSINE KINASE INHIBITORS
Tyrosine kinases are enzymes that catalyze the transfer of
the phosphate groups from nucleotide triphosphates (e.g.,
ATP, GTP) to tyrosine residues in a protein substrate. This
phosphorylation causes structural changes that induce altered
functions or enzymatic activities. Tyrosine kinases can be
classified into two groups, i.e., the transmembrane receptors
and the cytoplasmic non-receptor tyrosine kinases. Both
groups are linked to fundamental functions such as cell
differentiation, proliferation, growth factor signaling, apoptosis,
and malignant transformation. During the last decades, the
understanding in the biochemical activity of receptor tyrosine
kinases (RTKs) increased dramatically. Simultaneously, the
number of RTK inhibitor substances (Supplementary Figure 11)
that pharmaceutical companies developed for disease therapy
increased dramatically (Hunter, 2009).
Fibrotic disorders in many organs are influenced by RTKs and
non-receptor tyrosine kinases. Most prominently in fibrogenesis
are the transmembrane receptors for PDGF, TGF-β, VEGF, EGF,
FGFR, and JAK and the non-receptor tyrosine kinase c-Abl and
c-src (Beyer and Distler, 2013). Nowadays, highly selective or
pan-specific inhibitors targeting activity of multiple RTKs are on
the market. In hepatology research, many of them were tested
experimentally in ongoing and established fibrosis. Imatinib
(STI-571) that is specific for Abl and PDGF receptors attenuated
liver fibrosis and increased apoptosis, suppressed expression of
α-SMA and type I collagen, and further reduced proliferation
(Kuo et al., 2012). The same beneficial effects were reported
for the structurally related inhibitor nilotinib (AMN107) that
showed anti-fibrotic effects in CCl4- or to TAA-treated rats
(Shaker et al., 2011a,b; Shiha et al., 2014). The oral, multi-
targeted RTK inhibitor sunitinib (Su11248) blocked collagen
synthesis, attenuated contraction, reduced cell migration without
affecting cell viability, and inhibited PDGF-induced activation
of ERK1/2 MAPK and AKT/PKB phosphorylation in LX-2 cells
(Tugues et al., 2007; Majumder et al., 2013). Beneficial effects
of sunitinib were also shown in rats that were treated with
CCl4 (Tugues et al., 2007). The multikinase blocker sorafenib
attenuated liver injury and profibrogenic signaling in mice and
rats in a large variety of experimental models (Wang et al., 2010;
Hennenberg et al., 2011, p. 253; Thabut et al., 2011; Deng et al.,
2013; Hong et al., 2013; Su et al., 2015). Orantinib (TSU-68)
that has greatest potency against PDGFR auto-phosphorylation
was recently shown to block growth in HCC and fibroblast cell
lines (Hara et al., 2015). Worldwide, numerous other multi-
targeted RTK inhibitors (e.g., pazopanib) are currently tested in
experimental models.
METALS
Metals play pivotal roles in the liver. They are essential for
proper protein function, structure and stability. As part of
enzymes, they act as cofactors, or are indispensable direct
catalysts in biochemical reactions (Susnea and Weiskirchen,
2015). Consequently, the lack of an individual trace element leads
to shortcomings, failures, and illness. On the contrary, excess
metal supply resulting from genetic disorders, intoxication,
exorbitant dietary intake, organ failure, or during therapeutic
treatments such as blood transfusion and long-term parenteral
nutrition may result in elevated metal concentrations and
deposits. Mechanistically, hepatic overload with metals (i.e., iron,
copper) results in elevated ROS formation triggering cell stress,
apoptosis, and necrosis in hepatocytes. Therefore, cells have
developed sequestering mechanisms that protect against metal
toxicity. Best known is the family of metallothioneins that bind
a multitude of metals through thiol groups.
On the other side, some metals (particularly zinc) partly
functions as an antioxidant and zinc supplementation is
associated with decreased ROS formation (Kloubert and Rink,
2015). In BDL mice, zinc supplementation was effective in
suppressing progression of fibrosis through inhibition of collagen
production and by enhancing collagen degradation (Shi et al.,
2015). Mechanistically, inadequate supply with zinc results in
HSC activation that is associated with a reduction in intracellular
glutathione and increased quantities of intracellular H2O2
(Kojima-Yuasa et al., 2005). Although clinical trials in liver-
diseased patients are limited in size and quality, first results
from a double-blind, placebo-controlled human trial with a small
number of patients showed that zinc supplementation for 3
months significantly reduced blood ammonia levels in patients
with liver cirrhosis and hyperammonemia (Katayama et al.,
2014).
HERBAL SUPPLEMENTS
There is a bulk of reports describing the use of crude,
unclassified herbal preparations, purified mixtures, or single
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plant compounds for treatment of experimental hepatic disease.
Most of these medicinal formulations and remedies have
their origin in Traditional Chinese Medicine (TCM) that use
ingredients form plants, animals, humans, and mineral products
for healing. Although most the knowledge of TCM drugs was
developed over generations, it is thought that they have no real
rational mechanism of action (Nature, 2007). However, there is
no doubt that some of these “indigenous” drugs have produced
wonderful miracles in experimental research. Therefore, several
of these drugs became in the focus of global interest and
natural ingredients served as blueprints for the synthesis of novel
therapeutic drugs. Actually, there is a rapid growth in the field
of “Pharmacognosy” in which scientists bundle their knowledge
of bioactive products derived from natural sources. Particularly,
countless studies from Asia report the successful usage of
TCM (“folk medicines”) in animal studies. Also in Western
countries, TCM drugs are becoming increasingly important.
An interdisciplinary network in Germany, for example, has
set up a program in 1999 in which methods for sustainable
field production and post-harvest processing are developed for
selected plant species. The major the aim of this initiative
is to improve herbal drug quality and safety and to make
these drugs more reliable for all users (Heuberger et al.,
2010).
In the following, some herbs or mixtures including their most
important compounds are discussed.
Sho-Saiko-to
The mixture that is also known as TJ-7 or Xiao Chaihu Tang
is composed of seven herbals (Figure 9). It contains 17.5%
root of Bupleurum falcatum (Bupleurum, Chai Hu, Saiko),
5.0% root/stolon of Glycyrrhiza uralensis (Licorice, Gan Cao,
Kanzou), 7.5% root w/o rootlets of Panax ginseng (Asian ginseng,
Ren Shen, Ninjin), 12.5% tuber w/o cork layer of Pinelliae
ternatae (Pinellia, Ban Xia, Hange), 7.5% rot w/o periderm
of Scutellaria baicalensis (Baical skullcap, Huang Qin, Ougan),
2.5% root/rhizome of Zingiber officinale (Ginger, Sheng Jiang,
Shokyo), 7.5% fruit of Ziziphus jujube (Jujube, Da Zao, Daiso),
and 40% additives (Nishimura et al., 2001; Wen, 2007). Each
of these herbs contains several active biochemical constituents
that are considered to predict their pharmacological effects.
Bupleurum contains different Saikosaponins (e.g., A, B, C,
D) that represent a group of oleanane derivatives predicting
an anti-inflammatory action. Licorice is enriched with the
saponin Glycyrrihizin and the flavanone Liquiritin that are
both supposed to have anti-inflammatory and mineralocorticoid
activity. Ginseng contains ginsenosides (steroid glycosides) and
panaxic acid that strengthen the immune system and act as partial
agonists of steroid hormone receptors. Pinellia is enriched with
homogentisic acid, the sympathomimetic amine ephedrine, and
choline that is an essential compound necessary for structural
integrity and signaling of cell membranes. The anxiolytic and
sedative flavone baicalin, its aglycone baicalein, and wogonin that
have anti-oxidative, anti-inflammatory, and anti-viral activity
are considered to be therapeutic effective drugs of the Baical
skullcap. The relative of capsaicin gingerol and its dehydrated
product shogoal are the active compounds present in high
concentration in the rhizomes of ginger. Both compounds exhibit
a multitude of biological activities, ranging from anti-cancer,
anti-oxidant, anti-microbial, anti-inflammatory, and anti-allergic
to various central nervous system activities (Semwal et al.,
2015). The fruits of jujube are enriched in cyclic AMP, vitamins
(vitamin C, vitamin A, niacin, riboflavin, and thiamine) and
different glycosides that may have significant pharmacological
actions. Although it is hard to estimate and verify how the
individual ingredients exhibit their anti-fibrotic effects, studies
in rats that were subjected to a choline-deficient L-amino acid-
defined diet-induced liver fibrosis showed that the dietary intake
of 1% (w/w) Sho-saiko-to prevents fibrosis by inhibiting the
activation and proliferation of HSC (Sakaida et al., 1998).
Another beneficial effect of Sho-saiko-to is its potent anti-
fibrosuppressant activity that is in vivomediated by its inhibitory
effect on lipid peroxidation both in hepatocytes and HSC
(Shimizu et al., 1999). In line, these beneficial effects on hepatic
fibrosis were also achieved by other herbal mixtures (TJ-
135, Inchin-ko-to; TJ-48, Juzen-taiho-to; TJ-25, Keishi-bukuryo-
gan) in the db/db mouse model of NASH (Takahashi et al.,
2014).
Salvia Miltiorrhiza
This plant is also known as red sage and the dried roots
are known in TCM as Dan Shen. This herb contains a great
wealth of flavonoids, terpens, chinons, lignans, steroids, and
tannins (Figure 10). However, in regard to their beneficial
effects on liver fibrogenesis, specific ingredients with antioxidant
properties (e.g., salvianolic acid B, tanshinone IIA), cytotoxic
attributes (dihydrotanshinone), or substances that interfere with
cell migration, cell invasion and MMP activity (tanshinone
I) are presently discussed as the major bioactive compounds
in Salvia miltiorrhiza. In addition, magnesium lithospermate
B and the monomer IH764-3 are further in the focus of
experimental studies. When Salvia was given from the onset
of CCl4 treatment it effectively reduced expression of TGF-β,
collagen types I and III, TIMP-1, and further increased expression
of MMP-13 in rats (Wasser et al., 1998). Likewise, water-soluble
extracts of Salvia miltiorrhiza suppressed decreased activity
of caspase-1 and expression of Bax, Bcl-2, and cytochrome
c thereby preventing hepatic apoptosis in rats (Lee et al.,
2006). Similar results were reported for a standardized fraction
of Salvia miltiorrhiza (PF2401-SF) in rats in which hepatic
fibrosis was induced by TAA (Parajuli et al., 2015). Also
the in vitro or in vivo beneficial effects of individual salvia
miltiorrhiza ingredients such as salvianolic acid B (Wang et al.,
2012), salvianolic acid A (Lin et al., 2006), tanshinone IIA
(Pan and Wang, 2012), dihydrotanshinone I (Liu et al., 2010),
tanshinone I (Kim et al., 2003), magnesium lithospermate B
(Paik et al., 2011), and monomer IH764-3 (Liu et al., 2012)
was proven experimentally. The combined administration of
lithospermate B and the caspase-inhibitor nivocasan effectively
reversed hepatic fibrosis in rats demonstrating that the addition
of other pharmacological active constituents might enhance
the beneficial effects of this herbal drug (Kim do et al.,
2013).
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FIGURE 9 | Sho-shaiko-to a herbal mixture and its main ingredients. Sho-saiko-to contains root of Bupleurum, root/stolon of Glycyrrhiza, root w/o rootlets of
Panax ginseng, tuber w/o cork layer of Pinelliae, rot w/o periderm of Scutellaria, root/rhizome of Zingiber, and fruit of Ziziphus jujube. Each herb contribute some key
ingredients that together are made responsible for the antifibrotic activity of Sho-saiko-to. Bupleurum contains different Saikosaponins (e.g., Saikosaponin A, CAS
20736-09-8; Saikosaponin D, CAS 20874-52-6), while licorice is enriched with the glycyrrihizin (CAS 1405-86-3) and liquiritin (CAS 551-15-5). Ginseng contains
different ginsenosides and panaxic acid. Pinellia is enriched with homogentisic acid (CAS 451-13-8), ephedrine (CAS 299-42-3), and choline (CAS 67-48-1). Baical
skullcap contains baicalin (CAS 21967-41-9), baicalein (CAS 491-67-8), and wogonin (CAS 632-85-9). The active components of ginger are gingerol and shogoal.
Jujube is enriched in cyclic AMP (CAS 60-92-4), vitamin C (CAS 50-81-7), vitamin A (CAS 68-26-8), niacin (CAS 59-67-6), riboflavin (CAS 83-88-5), and thiamine
(CAS 59-43-8). The plant images were provided by Dr. Heidi Heuberger (LfL, Bayerische Landesanstalt für Landwirtschaft, Freising, Germany, www.lfl.bayern.de/).
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FIGURE 10 | Salvia miltiorrhiza and its active compounds. In the roots of saliva miltiorrhiza are many ingredients with antifibrotic activity including salvianolic acid
B (CAS 121521-90-2), magnesium lithospermate B (CAS 122021-74-3), tanshinone I (CAS 568-73-0), dihydrotanshinone (CAS 20958-18-3), and tanshinone IIA (CAS
568-72-9). The plant images of Salvia miltiorrhiza were provided by Dr. Heidi Heuberger (LfL, Bayerische Landesanstalt für Landwirtschaft, Freising, Germany).
FIGURE 11 | Astragaloside IV. This compound (CAS 84687-43-4) is a lanolin alcohol-shaped tetracyclic triterpenoid saponin with broad pharmacological activities
affecting collagen metabolism and modulating pathogenesis of inflammation and viral infections. The images of Astragalus mongholicus were provided by Dr. Heidi
Heuberger (LfL, Bayerische Landesanstalt für Landwirtschaft, Freising, Germany).
Astragaloside IV
This saponin is found in highest concentrations in the
roots of Astragalus plants such as Astragalus propinquus and
Astragalus mongholicus (milk-vetch root, Huang Qi; Figure 11).
Astragaloside IV effectively inhibited NF-κB activation and
prevented inflammatory gene expression in LPS-treated mice
(Zhang and Frei, 2015). It further suppressed collagen production
in activated HSC by inhibition of oxidative stress-related
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pathways (Li et al., 2013). In vivo data obtained in porcine-serum-
induced hepatic fibrosis in rats further showed that Astragaloside
IV is therapeutically beneficial and efficiently decreasing liver
damage and expression of pro-fibrogenic genes (Liu et al., 2009b).
Compound 861
This herbal compound is an extract of 10 mixed herbs including
Salvia miltiorrhiza, Astragalus mongholicus, and Spatholobus
suberectus (Millettia root; Ji Xue Teng) as its main components.
There are several studies that show that this herbal mixture
evolves anti-fibrotic effects in vitro, most likely by counteracting
activities of individual TGF-β signal components (Wang et al.,
2004, 2008; Li et al., 2008b). This mixture has been shown
experimentally to be effective in suppressing fibrogenesis,
degradation of collagen matrix, and attenuation of TIMP-1
expression and HSC proliferation. Moreover, a clinical open trial
performed with 2000 patients showed significant improvement of
hepatic damage (Wang, 2000; Wang et al., 2004). In addition, the
anti-fibrotic capacity of this drug was proven in a double blind,
placebo-controlled clinical trial with 136 patients with HBV-
related fibrosis that were treated for 24 weeks with that drug
(Yin et al., 2004). In China, compound 861 is approved by the
State food and Drug Administration and broadly marketed as an
anti-fibrotic agent (Zhang and Schuppan, 2014).
Fuzheng Huayu (FZHY)
The FZHY formula is a preparation that consists of six
TCM herbs, namely Salvia miltiorrhizae, Cordyceps (Chong
Cao), Semen Persicae (Tan Ren), Gynostemma Pentaphyllum
(Jiaogulan), Pollen Pini (Song Hua Fen), Fructus Schisandrae
Chinensis (Wu Wei Zi) (Liu et al., 2009a). This herbal mixture
display a large variety of biological actions in hepatic fibrosis. In
vitro it inhibited cellular activation, proliferation, and collagen
secretion in HSC and protects hepatocytes from oxidative
stress and apoptosis, and further reduced MMP-2/9 activities
in fibrotic liver tissue (Liu et al., 2009a). It was suggested
that each of the individual ingredients of FZHY evolve their
specific hepatoprotective activity that in sum prevent hepatic
fibrosis. Semen Persicae decreased hepatic hydroxyproline, Radix
Salvia Miltiorrhizae improved liver function, while Cordyceps
and Gynostemma Pentaphyllum helped to decrease serum
aminotransferase activity (Liu et al., 2009a). This herbal mixture
was already studied in several clinical trials. In particular, a large
well-designed Chinese multicenter study in which the efficacy
and safety of FZHY capsules were tested showed that FZHY has
good therapeutic effects on alleviating liver fibrosis in patients
suffering from chronic HBV infection without any adverse effects
(Liu et al., 2005b). This drug is approved in China and is currently
tested in a FDA-approved trial in patients with chronic HCV
(Zhang and Schuppan, 2014).
Biejiaruangan Compound (CBJRGC)
This decoction contains Carapax trionycis (turtle shell) and 10
herbs (e.g., panax, read peony root, cordyceps sinensis, forsythia).
Serum collected from rats that were perfused with CBJRGC
decreased the proliferation and expression of desmin, synapsin,
and PDGF in a HSC line (Guo et al., 2004). This drug is approved
in China and was the first TCM composition that has been
officially used for treating hepatic fibrosis in China (Guo et al.,
2004). Together with FZHY, CBJRGC reached sales of over $30
million in China (Zhang and Schuppan, 2014).
Other TCM Medicines
There are several other TCM available that are supposed to
have hepatoprotective effects. Such a formulation is Yi Guan
Jian (YGJ) that is composed out of Radix Rehmanniae (Shen Di
Huang), Fructus Lycii (Gou Qi Zi), Radix Glehnaia (Sha Shen),
Radix Ophopogonis (Mai Men Dong), Radix Angelicae Sinensis
(Dang Gui), and Fructus Meliae Toosendan (Chuan Lian Zi).
In DMN-treated rats, the oral administration of this traditional
TCM prevented body weight loss, collagen accumulation, and
expression of TIMP-1 and α-SMA (Lin et al., 2011a). A modified
YGJ (mYGJ) in which three more herbs (Astragalus mongholicus,
Trionyx sinensis, and Eupolyphaga sinensis) were added to YGJ
was shown to effectively induce HSC apoptosis through ROS
accumulation and induction of intrinsic apoptotic pathways (Lin
et al., 2011b).
LIV.52, LIV-42, Livol, Liver cure, Livomyn,
Livfit, Livactine, Hepatomed, Jigrine,
Tefroli, Stimuliv, Livfit, Silybon, Liverubin
A number of other polyherbal formulations are available that
were not rigorously tested in animal experimentation for their
therapeutic efficacy. Although their pharmacological action is
not really understood, they are offered by various companies
for the treatment of viral hepatitis, drug-induced liver disease,
alcohol-induced hepatotoxicity, and cholestatic jaundice. Most of
these drugs originated from India where actually more than 87
medical plants are used in the preparation of 33 patented herbal
formulations (Ramadoss et al., 2012). First reports however,
show that these compositions might be beneficial. Livactine
reduced the hepatotoxic effect of paracetamol-induced liver
injury in rats (Mayuren et al., 2010). Liv.52 also known also
LiverCare is composed of ingredients from Capparis spinosa
(Capers), Cichorium intybus (Wild chicory), Mandur bhasma
(Ferric Oxide Calx), Solanum nigrum (Black Nightshade),
Terminalia arjuna (Arjuna), Cassia occidentalis (Negro coffee),
Achillea millefolium (Yarrow), and Tamarix gallica (Tamarisk).
Livol (IHF-100) is a purely herbal product containing different
plant ingredients. Livomyn contains 18 herbals in different
quantities. Both, Livol and Livomyn showed hepatoprotective
effects in rats treated with CCl4 (Sapakal et al., 2008).
Livfit and Stimuliv each contain extracts from a number of
different potent hepatoprotective herbs and are produced on
the basis of Ayurveda. Hepatomed contains extracts from
eight herbals and offered with indications against jaundice,
infective hepatitis, liver cirrhosis, and hepatospleenomegaly.
The polyherbal Jirgine contains aqueous extracts of 14 plants
that evolve hepatoprotective effects during TAA-induced hepatic
damage (Ahmad et al., 2002). Tefroli and Liverubin are each
composed of six herbal and should be effective in drug-
induced hepatitis, viral and alcoholic hepatitis as well as
hepatic damage. Silybon and Liverubin are made out of an
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extract of the seeds from Silybum marianum (milk thistle). Its
active ingredient is silymarin that has been tested already in
several experimental models of hepatic fibrosis and recently
turned out to be particular suitable to block progression of
fibrosis in the early stages of liver injury (Clichici et al.,
2015). Other drugs such as rographolide, neoandrographolide,
picroside, kutkoside, phyllanthin, and hypophyllanthin that are
ingredient of Phylannthus and other plants have been suggested
as hepatoprotective drugs.
Silymarin
Silymarin is a standardized herbal extract of the milk thistle
(Silybum marianum) that is native throughout the world. It
contains four main components (silibinin, silidianin, silicristin,
and isosilibinin). Curative, intragastric delivery of high doses
of silymarin in rats is sufficient to increase the resolution
of CCl4-induced fibrosis (Tsai et al., 2008) and to protect
for decreased expression of fibrotic parameters such as CTGF
in CCl4-induced hepatic fibrogenesis (Tzeng et al., 2013).
Recently, gene expression profiling performed in HepG2 cells
showed that silymarin (like glycyrrhizin and ursodeoxycholic
acid) affect the expression of genes that are relevant for
neurotransmission, and glucose- and lipid metabolisms (Hsiang
et al., 2015). Silybin (also known as Silibinin; Figure 12)
representing the most pharmacologically active substance of
silymarin. It alone has hepatoprotective properties and is
effective in preventing mitochondrial failure and inflammation
(Serviddio et al., 2014).
Xanthohumol
This prenylated flavonoid (Figure 13) is the principal chalcone
of the hop plant (Humulus lupulus). It is able to scavenge
ROS and modulate the activity of a broad range of enzymes
and pathways that are involved in pro-inflammatory signaling
(Weiskirchen et al., 2015). It inhibits cyclooxygenases, expression
of prostaglandin E2, and the NF-κB signaling pathway.
Xanthohumol (XN) at 5µM inhibits the activation of primary
human HSC in vitro, reduces expression of pro-inflammatory
genes, and induces apoptosis (Dorn et al., 2010). In vivo,
it was shown that XN inhibited pro-inflammatory and pro-
fibrogenic hepatic gene expression and suppressed hepatic NF-
κB activity in mice that were subjected to CCl4 (Dorn et al.,
2012). Several in vitro cell culture models, precision cut liver
slices, in vivo experiments in rats and mice have consistently
shown that XN reduces ROS formation and DNA damage
in hepatocytes, has beneficial effects on fat metabolisms and
protects against hepatocyte apoptosis and is considered as a
cancer chemopreventive agent (Weiskirchen et al., 2015). It was
therefore suggested already one decade ago that engineering
of XN biosynthesis and other related prenylflavonoids from
FIGURE 12 | Silymarin extract. The extract of silybum marianum is a standardized herbal extract containing the four main components silibinin (CAS 22888-70-6),
silidianin (CAS 29782-68-1), silicristin (CAS 33889-69-9), and isosilibinin (CAS 72581-71-6).
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hops might be good targets for breeding or biotechnological
modification with the aim to increase XN and levels for beer
brewing (Stevens and Page, 2004).
OTHER COMPOUNDS WITH
HEPATOPROTECTIVE,
ANTI-INFLAMMATORY OR ANTI-FIBROTIC
EFFECTS
Minoxidil
This drug (Supplementary Figure 12) is a FDA-approved
medication for hair loss in men and women with
antihypertensive activities. It is a piperidinopyrimidine derivative
that was shown to inhibit fibroblast proliferation without causing
cytotoxicity and confer a loss of lysyl hydroxylase activity (Murad
and Pinnell, 1987). Later it was demonstrated that minoxidil is
unlikely to serve as an anti-fibroticum in vitro (Zuurmond et al.,
2005). Instead, it was noticed that minoxidil acts as a K(ATP)
channel opener that accelerates DNA synthesis after partial
hepatectomy without affecting the liver function (Yamasaki et al.,
2005).
Tetrandrine
This compound is the major pharmacologically active compound
of Stephania tetrandra and its roots termed Han Fang Ji are
widely used in TCM. It is a calcium channel blocker and potent
smooth muscle relaxant and further has anti-inflammatory
activity because it inhibits the degranulation of mast cells. Studies
performed in mice showed that this drug inhibited NF-κB
activity in Concanavalin A-induced hepatitis and prevented T-
cell mediated liver injury (Feng et al., 2008). In vitro it inhibited
proliferation of HCC cell lines by suppression of cell cycle
progression at the G2/M phase (Yu and Ho, 2013) and promotes
apoptosis of activated HSC (Yin et al., 2007).
Caffeine
This water- and lipid-soluble methylxanthine alkaloid
(Supplementary Figure 12) compound is a competitive
receptor antagonist at all four adenosine receptors that are
generally slowing down the metabolic activity of the body. A
human association study conducted with 177 chronic hepatitis
virus infected patients has suggested that caffeine consumption
in form of regular coffee intake is associated with less severe
hepatic fibrosis (Modi et al., 2010). At the cellular level, caffeine is
able to increase HSC apoptosis, intracellular F-actin expression,
cyclic AMP production, while inhibiting procollagen type Ic
and α-SMA expression (Shim et al., 2013). In the same study,
the expression of TGF-β and α-SMA in rats treated with TAA
was significant lowered. These beneficial effects of coffee and
caffeine were also determined in rats treated with CCl4 or TAA
(Moreno et al., 2011; Arauz et al., 2013). Mechanistically, it is
assumed that caffeine directly evolves its antifibrotic properties
at a point in which either HSC activation is diminished or
in which inflammatory and fibrotic processes are attenuated.
However, there is another report showing that decaffeinated
coffee is also fibroprotective in TAA-treated rats (Arauz et al.,
2013). Moreover, some coffee (e.g., Turkish coffee) conversely
impressed and potentiated liver hepatoxicity, inflammation and
fibrosis in the CCl4 model (Poyrazoglu et al., 2008).
Pirfenidone
This compound (Supplementary Figure 12) is approved in
several countries for the treatment of idopathic pulmonary
fibrosis. In this disease it prevents accumulation of inflammatory
cell, proliferation of fibroblasts, expression of cytokines and
ECM formation. It has however, a more general anti-fibrotic
activity in lung, heart, kidney, and liver (Schaefer et al., 2011).
In experimental cirrhosis that was either induced by chronic
administration of CCl4 application, BDL surgery, or DMN in rats,
pirfenidone evolved strong antioxidant properties and reduced
expression of pro-fibrogenic genes and collagen, while genes
associated with hepatic regeneration were increased (Tada et al.,
2001; Salazar-Montes et al., 2008). Moreover, also when applied
in a fully curative manner, the drug showed similar beneficial
effects (García et al., 2002). In humans, this drug improved
inflammation, fibrosis and steatosis in patients with chronic
hepatitis C when applied for 2 years (Flores-Contreras et al.,
2014). Mechanistically, an early study that applied this drug
to cultured HSC demonstrated that was able to inhibit PDGF-
induced activation of the Na+/H+ exchanger (Di Sario et al.,
2002).
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
(AcSDKP)
The tetrapeptide AcSDKP is normally present as an endogenous
peptide in human plasma and circulating mononuclear cells.
It is proteolytically released from its precursor thymosin-β4 by
prolyl oligopeptidase (Suzuki et al., 2014). AcSDKP evolved anti-
fibrotic effects in rats that were either subjected to BDL or treated
with CCl4, most likely by direct exerting anti-fibrogenic effects
on HSC (Chen et al., 2010; Zhang et al., 2012a). In addition,
this substance inhibited fibroblast proliferation and collagen
synthesis in vitro (Peng et al., 2001).
Prostaglandins
Prostaglandins are a group of biological mediators produced
by a cascade that requires cyclooxygenases and prostaglandin
synthases. Individual prostaglandins have attractedmuch interest
in many research fields because they are majorly responsible
for pain and inflammation. Prostaglandin E2 and derivatives
significantly delayed the deposition of hepatic collagen in
nutritional injury in rats (Ruwart et al., 1988). Moreover,
Prostaglandin E suppressed PDGF activity in cultured HSC
(Beno and Davis, 1995) and was effective in preventing activation
of HSC in Schistosoma japonicum infected rabbits (Zou et al.,
2007).
Fluorofenidone
This pyridone agent (Supplementary Figure 12) is also known as
AKF-PDwas initially introduced as a drug that exerts strong anti-
fibrotic effect in kidney. Preliminary reports performed in DMN-
treated rats and in different immortalized HSC cell lines (LX-2,
CFSC) showed that it attenuates hepatic fibrosis by suppressing
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FIGURE 13 | Xanthohumol. This principal prenylated chalcone (CAS 6754-58-1) of the hop plant (upper left panel) and its prenylated flavanone (i.e., isoxanthohumol,
CAS 70872-29-6) have anti-inflammatory, antioxidant, hypoglycemic activities, and anticancer effects. Xanthohumol is included in high concentration in the hop oil
that is produced from lupulin glands (lower left panel). Hop images were kindly provided by Dr. Claus Hellerbrand (Department of Internal Medicine I, University
Hospital Regensburg. Regensburg, Germany).
HSC proliferation and activation by blocking MAPK signaling
(Peng et al., 2013b). In primary rat HSC fluorofenidone caused
G0/G1 cell cycle arrest by reducing expression of cyclin D1 and
cyclin E (Peng et al., 2014).
Vitamin D
Vitamin D receptor ligands such as calcipotriol
(Supplementary Figure 12) inhibit HSC activation and
counteract progression of CCl4-induced hepatic fibrosis in
mice (Ding et al., 2013). It antagonized TGF-β signaling via
VDR/Smad3 genomic crosstalk by blocking Smad residency
on chromatin and compromising acetylation of histone H3
thereby suppressing pro-fibrogenic gene expression (Ding et al.,
2013). Although this anti-fibrotic activity was reproduced in the
TAA model in mice, Vitamin D failed to ameliorate established
fibrosis and further induced a high mortality rate in BDL rats
(Abramovitch et al., 2015).
BILE ACIDS AND FXR ANTAGONISTS
Bear bile known as “Tang Ban Cao” that is highly enriched
in ursodeoxycholic acid (UDCA) was applied in TCM already
long before introduction of modern medicine. There it is
used as an anti-inflammatory formulation reducing the effects
of alcohol over-consumption and restoring liver homeostasis.
Bile acids act as physiological emulgators and signal via
a large bunch of specialized bile acid receptors such as
Farnesoid X receptors (FXR), transmembrane G-protein-coupled
receptors, pregnane X receptor, vitamin D receptor, and
constitutive androstane receptor (Schaap et al., 2014). In
hepatology, bile acid receptors are versatile drug targets. In
particular, endogenous (CDCA, doxycholic acid, cholic acid,
lithocholic acid) and (semi-)synthetic FXR agonists (obeticholic
acid) are applied to cure various types of liver diseases
(Supplementary Figure 13). In general, these substances have
beneficial effects on glucose metabolisms, enhance insulin
sensitivity, reduce hepatic lipogenesis, and increase β-oxidation.
Moreover, FXR receptors control the synthesis of bile acid
synthesis and are therefore key regulators of gut microbiota.
Therefore, these receptors, their pathway and the microbiota
itself provide endless therapeutic drug targets to treat hepatic
inflammation and fibrosis (Sayin et al., 2013). Recently, a
multicentre trial with obeticholic acid was performed showing
that this drug is suitable to improve histology in patients with
non-cirrhotic, non-alcoholic steatohepatitis (Neuschwander-
Tetri et al., 2015).
FISH OIL AND OMEGA-3 FATTY ACIDS
Fish oil-based lipid emulsions that contain high concentrations
of the omega-3 (ω-3) polyunsaturated fatty acids such as
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
have an inflammation dampering effect on hepatic inflammation
by interfering with the arachinodonic acid pathway and
inhibition of pro-inflammatory cytokines (Schmöcker et al.,
2007). Cold-water fishes are the most widely available dietary
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FIGURE 14 | Fish as a dietary source of ω-3 fatty acids. Cold-water fishes such as salmon, herring, mackerel, and others are dietary sources of ω-3 fatty acids.
They are characterized by a double bond at the third carbon atom from the end of the carbon chain. The depicted fishes contain high concentrations of
eicosapentaenoic acid (EPA, CAS 10417-94-4) and docosahexyenoic acid (DHA, CAS 6217-54-5). The grams of ω-3 fatty acids per 100 gr fish is given in
parentheses. The different fish images were published with the kind permission of Mr. Claude Nozères, Government of Canada, Department of Fisheries and Oceans
(www.marinespecies.org/carms/photogallery.php).
source of EPA and DHA that contain up to 2.35% ω-3 fatty acids
(Figure 14). In mice, ω-3 fatty acid supplementation prevented
the pathogenesis of hepatic steatosis and CCl4-induced hepatic
fibrosis (Alwayn et al., 2005; Shaaban et al., 2014). Likewise,
the Menhaden diet enriched in ω-3 fatty acids reduced hepatic
necrosis and inflammation in mice that underwent BDL (Lee
et al., 2008). In contrast, the dietary supplementation of fish ω-
3 fatty acids in rats that underwent BDL significantly impaired
liver functions suggesting that ω-3 might be of potential hazard
during biliary atresia (Chen et al., 2013). In a very recent
report, it was demonstrated that DHA but not EPA attenuates
Western diet-induced hepatic fibrosis in mice lacking the low-
density lipoprotein receptor (Lytle et al., 2015). This study further
revealed that the pre-treatment of human LX-2 cells with DHA,
but not other unsaturated fatty acids, blocked TGF-β-mediated
induction of collagen expression. This data suggests that the
different ω-3 fatty acids might have diverse biological effects on
the pathogenesis of hepatic fibrosis and thatmore defined fish oils
enriched with a specific ω-3 fatty might be therapeutically more
useful.
MARINE BIOACTIVE COMPOUNDS
There are an increasing number of potent drugs originating
from the marine environment (Figure 15). The marine-
derived bioactive compounds are structurally and biologically
intriguing, and more than 30,000 compounds with unique
structures and diverse pharmacological activities have been
isolated so far. In hepatology research, several marine-derived
compounds with antioxidant or antifibrotic potential were
already tested. Some of these drugs targeting the activity
of COX-1, COX-2, or phospholipase A2 thereby inhibiting
eicosanoid production (e.g., pacifenol, epitacondiol, stypotriol).
Others inhibit NF-κB activity (hymenialdisine), prevent TGF-
β-induced Smad phosphorylation (hyrtiosal), or are direct
antioxidants (fucoxanthin, astaxanthin, β-chitosan, diverse
polysaccharides), or affect receptor tyrosine kinases (philinopside
A). In addition, beneficial effects of diverse fish oil supplements
(e.g., menhaden oil) were reported. For more details about
marine hepatoprotective compounds and their beneficial effects
in hepatic fibrosis were recently summarized (Nair et al.,
2015).
CONCLUSIONS AND PERSPECTIVES
Preclinical work from many laboratories has identified and
evaluated hundreds of substances or mixtures of components
showing highly beneficial effects in therapy of experimental
hepatic fibrosis. They counteract intracellular ROS formation,
prevent hepatic infiltration with circulating blood cells, or
target pro-inflammatory and pro-fibrotic signaling pathways or
mediators involved in ECM generation or turnover. Scientists
and clinicians agree that it is now the time to estimate if these
encouraging findings can be translated to the clinic. In particular,
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FIGURE 15 | Bioactive compounds derived from marine organisms. (A) There is a large variety of organisms that may serve as a biological source for
anti-fibrotic compounds. (B) Scytonemin (CAS 152075-98-4), pyrogallol (CAS 87-66-1), chlorogenic acid (CAS 327-97-9), catechin, (CAS 154-23-4), α-coumaric acid
(CAS 614-60-8), and rutin (CAS 153-18-4) are substances with different structures, that however have similar anti-inflammatory and anti-fibrotic activities. The
individual figures in (A) were published with the kind permission of Mr. Claude Nozères, Government of Canada, Department of Fisheries and Oceans
(www.marinespecies.org/carms/photogallery.php).
a first screen for safety and efficacy would provide urgently
needed data on pharmacodynamics and pharmacokinetics of
these “pipeline drugs.” Moreover, it will be necessary to test
in volunteers if the beneficial effects of these drugs can be
reproduced in humans. Of course, the transfer to human is
somewhat hampered because most of these drugs were only
tested in models of ongoing fibrogenesis and information about
the curative effects are still missing. Therefore, in future it would
be more sensible if drug candidates are tested in models of
established fibrosis than to confirm their hepatoprotective or
anti-fibrotic effects in other disease models. This would not only
expand the knowledge of the usability of a specific drug but
further helps to make science in fibrosis research more cost-
effective and minimize the number of animals used in preclinical
experiments requested by the 3R guiding principles proposed by
Russell and Burch.
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
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Supplementary Figure 1 | Sulfur-containing antioxidants with therapeutic
potential in hepatic fibrosis. Glutathione (CAS 70-18-8), N-acetyl-L-cysteine
(CAS 616-91-1), S-nitroso-N-acetylcysteine (CAS 56577-02-7),
S-adenosyl-L-methionine (CAS 29908-03-0), S-allylcysteine (CAS 21593-77-1),
bucillamine (CAS 65002-17-7), lipoic acid (CAS 1200-22-2), and taurine (CAS
107-35-7) were shown to evolve beneficial effects in experimental hepatic fibrosis.
Supplementary Figure 2 | The Nicotinamide adenine dinucleotide
phosphate oxidases (NOXs) and their inhibition. Nicotinamide (CAS 98-92-0)
and nicotinic acid (CAS 59-67-6) serve as nicotinamide adenine dinucleotide
precursors. NADPH oxidases (NOXs) catalyzes the transfer of electrons form
NADPH to molecular oxygen thereby producing superoxide and other ROS.
GKT137831 is a dual inhibitor showing high affinity for NOX1 and NOX4 but not
for other isoforms, while decursin (CAS:5928-25-6) was found experimentally to
suppress NOX1, NOX2 and NOX4.
Supplementary Figure 3 | HMG-CoA reductase inhibitors. Atorvastatin (CAS
134523-00-5), fluvastatin (CAS 93957-54-1), rosuvastatin (CAS 287714-41-4),
pitavastatin (CAS 147511-69-1), pravastatin (CAS 81093-37-0), lovastatin (CAS
75330-75-5), and simvastatin (CAS 79902-63-9) are presentative statins that
interfere with hepatic fibrogenesis by inhibiting HMG-CoA reductase thereby
preventing formation of mevalonate from HMG-CoA.
Supplementary Figure 4 | Thiazolidinediones in liver healthy. All members of
this class (e.g., pioglitazone, CAS 111025-46-8; rosiglitazone, CAS 122320-73-4)
are derivatives of the parent compound 2,4-thiazolidinedione (CAS 2295-31-0).
These compounds that are also known as glitazones activate nuclear receptors
(PPARs) that lead to modulation of target gene transcription.
Supplementary Figure 5 | Therapeutic polysaccharides targeting
galectins. The carbohydrate-based compounds GR-MD-02 and GM-CT-01
(DAVANAT) bind to galectin-1 and galectin-3 thereby preventing its inflammation-
and fibrosis-associated chemoattraction. The backbone of GM-CT-01 is a
proprietary galactomannan polysaccharide composed of (1→4)-linked
β-D-mannopyranosyl units, to which single α-D-galactopyranosyl is attached by
(1→6)-linkage. The mannose to galactose ratio is approximately 1.7 with mean
molecular weight of approximately 50 kDa. Likewise, GR-MD-02 is a proprietary
galactoarabino-rhamnogalacturonate polymer that is comprised predominantly of
1,4-linked galacturonic acid, with β-galactose and arabinose side chains of
approximately 50 kDa (not shown). Both polysaccharides bind with high affinity to
galectins, thereby preventing their pro-inflammatory function in recruting
inflammatory cells to the diseased liver tissue. The depicted human galectin
structures were generated with the Ribbons software (ver 3.0) using the structure
coordinates that are deposited in the RCSB Protein Data Bank under accession
nos. and 1GZW (galectin-1) and 1A3K (galectin-3), respectively.
Supplementary Figure 6 | RGD-peptide and integrins. Integrin function can
be blocked by the tripeptide RGD or substances that have a similar structural
arrangement such as the non-peptidic RGD mimetic SF-6,5. Both substances
bind with high affinity to regions within integrins.
Supplementary Figure 7 | Inhibitors of collagen synthesis and fibroblast
proliferation. Malotilate (CAS 59937-28-9), transilast (CAS 53902-12-8),
HOE 077 (CAS 128075-79-6), S 0885 (CAS 117517-22-3)
β-aminopropionitrile (CAS 151-18-8), and safironil (CAS 134377-69-8) are
drugs that interfere with fibroblastic proliferation and expression or synthesis
of collagen.
Supplementary Figure 8 | Histone deacetylase and acetyltransferase
blockers. The curcuma longa ingredient curcumin (CAS 458-37-7), trichostatin A
(TSA, CAS 58880-19-6), and valproic acid (CAS 99-66-1) marked under a
multitude of brand names are potent histone deacetylase blocker, while the green
tea ingredient epigallocatechin-3-gallate (EGCG, CAS 989-51-5) interferes with
the activity of acetyltransferases.
Supplementary Figure 9 | Angiotensin receptor antagonism. The
Angiotensin axis can be blocked by ACE inhibitors (e.g., perindopril, CAS
107133-36-8), selective receptor blockers (losartan, CAS 114798-26-4;
candesartan, CAS 139481-59-7), or direct renin inhibitors (e.g., aliskiren; CAS
173334-57-1).
Supplementary Figure 10 | Endothelin-1. ET-1 (CAS 117399-94-7) is a potent
vasoconstrictor involved in the formation of portal hypertension. The major
biological active peptide consists of 21 residues. It is stepwise processed from a
212 aa precursor form. The mature peptide contains two disulfide bonds (disulfide
bridges: 1-15 and 3-11). The X-ray structure of mature human ET-1 that is
deposited in the RCSB Protein Data Base under accession no. 1EDN shows that
the entire carboxy terminal tail (residues 16-21) that is crucial for receptor binding
and vasoactivity foms a helix.
Supplementary Figure 11 | RTK inhibitor substances. Numerous studies
demonstrated that Imatinib (CAS 152459-95-5), nilotinib (CAS 641571-10-0),
sunitinib (CAS 557795-19-4), sorafenib (CAS 284461-73-0), and orantinib (CAS
252916-29-3) have beneficial activities in hepatic fibrosis by targeting diverse
receptor kinases (for details see text).
Supplementary Figure 12 | Miscellaneous compounds with
hepatoprotective, anti-inflammatory or anti-fibrotic effects. Vitamin D (CAS
67-97-0), tetrandrine (CAS 518-34-3), caffeine (CAS 58-08-2), pirfenidone (CAS
53179-13-8), and minoxidil (CAS 38304-91-5) are compounds that showed
anti-inflammatory and anti-fibrotic activities in various fibrosis models.
Supplementary Figure 13 | Bile acids and FXR antagonists. Obeticholic acid
(OCA, CAS 459789-99-2) is a semi-synthetic bile acid derivate related to
Ursodeoxycholate (UDCA, CAS 128-13-2) used to treat cholestatic liver disease.
In contrast to UDCA, OCA and other bile acids (cholic acid, lithocholic acid, and
deoxycholic acid) are FXR ligands.
REFERENCES
Abdelazim, S. A., Darwish, H. A., Ali, S. A., Rizk, M. Z., and Kadry, M. O. (2015).
Potential antifibrotic and angiostatic impact of idebenone, carnosine and
vitamin E in nano-sized titanium dioxide-induced liver injury. Cell. Physiol.
Biochem. 35, 2402–2411. doi: 10.1159/000374041
Abdelaziz, R. R., Elkashef, W. F., and Said, E. (2015). Tranilast reduces serum
IL-6 and IL-13 and protects against thioacetamide-induced acute liver injury
and hepatic encephalopathy. Environ. Toxicol. Pharmacol. 40, 259–267. doi:
10.1016/j.etap.2015.06.019
Abramovitch, S., Sharvit, E., Weisman, Y., Bentov, A., Brazowski, E., Cohen,
G., et al. (2015). Vitamin D inhibits development of liver fibrosis in
an animal model but cannot ameliorate established cirrhosis. Am. J.
Physiol. Gastrointest. Liver Physiol. 308, G112–G120. doi: 10.1152/ajpgi.001
32.2013
Abreu, J. G., Ketpura, N. I., Reversade, B., and De Robertis, E. M. (2002).
Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and
TGF-β. Nat. Cell Biol. 4, 599–604. doi: 10.1038/ncb826
Adikwu, E., and Deo, O. (2013). Hepatoprotective effect of vitamin C (ascorbic
acid). Pharmacol. Pharm. 4, 84–92. doi: 10.4236/pp.2013.41012
Frontiers in Pharmacology | www.frontiersin.org 30 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Aher, J. S., Khan, S., Jain, S., Tikoo, K., and Jena, G. (2015). Valproate ameliorates
thioacetamide-induced fibrosis by hepatic stellate cell inactivation. Hum. Exp.
Toxicol. 34, 44–55. doi: 10.1177/0960327114531992
Ahmad, A., Pillai, K. K., Najmi, A. K., Ahmad, S. J., Pal, S. N., and Balani, D.
K. (2002). Evaluation of hepatoprotective potential of jigrine post-treatment
against thioacetamide induced hepatic damage. J. Ethnopharmacol. 79, 35–41.
doi: 10.1016/S0378-8741(01)00349-X
Ala-Kokko, L., Stenbäck, F., and Ryhänen, L. (1989). Preventive effect of malotilate
on dimethylnitrosamine-induced liver fibrosis in the rat. J. Lab. Clin. Med. 113,
177–183.
Al-Attar, A. M. (2011). Hepatoprotective influence of vitamin C on thioacetamide-
induced liver cirrhosis inWistar male rats. Pharmacol. Toxicol. 6, 218–233. doi:
10.3923/jpt.2011.218.233
Alwayn, I. P., Gura, K., Nosé, V., Zausche, B., Javid, P., Garza, J., et al. (2005).
Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine
model of nonalcoholic fatty liver disease. Pediatr. Res. 57, 445–452. doi:
10.1203/01.PDR.0000153672.43030.75
Amália, P. M., Possa, M. N., Augusto, M. C., and Francisca, L. S. (2007). Quercetin
prevents oxidative stress in cirrhotic rats. Dig. Dis. Sci. 52, 2616–2621. doi:
10.1007/s10620-007-9748-x
Arauz, J., Moreno, M. G., Cortés-Reynosa, P., Salazar, E. P., and Muriel, P.
(2013). Coffee attenuates fibrosis by decreasing the expression of TGF-β and
CTGF in a murine model of liver damage. J. Appl. Toxicol. 33, 970–979. doi:
10.1002/jat.2788
Arauz, J., Rivera-Espinoza, Y., Shibayama, M., Favari, L., Flores-Beltrán, R. E.,
and Muriel, P. (2015). Nicotinic acid prevents experimental liver fibrosis by
attenuating the prooxidant process. Int. Immunopharmacol. 28, 244–251. doi:
10.1016/j.intimp.2015.05.045
Argo, C. K., Loria, P., Caldwell, S. H., and Lonardo, A. (2008). Statins in
liver disease: a molehill, an iceberg, or neither? Hepatology 48, 662–669. doi:
10.1002/hep.22402
Arias, M., Sauer-Lehnen, S., Treptau, J., Janoschek, N., Theuerkauf, I., Buettner,
R., et al. (2003). Adenoviral expression of a transforming growth factor-β1
antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats.
BMC Gastroenterol. 3, 29. doi: 10.1186/1471-230X-3-29
Atorrasagasti, C., Aquino, J. B., Hofman, L., Alaniz, L., Malvicini, M., Garcia, M.,
et al. (2011). SPARC downregulation attenuates the profibrogenic response of
hepatic stellate cells induced by TGF-β1 and PDGF.Am. J. Physiol. Gastrointest.
Liver Physiol. 300, G739–G748. doi: 10.1152/ajpgi.00316.2010
Atorrasagasti, C., Peixoto, E., Aquino, J. B., Kippes, N., Malvicini, M., Alaniz, L.,
et al. (2013). Lack of the matricellular protein SPARC (secreted protein, acidic
and rich in cysteine) attenuates liver fibrogenesis in mice. PLoS ONE 8:e54962.
doi: 10.1371/journal.pone.0054962
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M.,
Oyasu, M., et al. (2010). Allosteric inhibition of lysyl oxidase-like-2 impedes
the development of a pathologic microenvironment. Nat. Med. 16, 1009–1017.
doi: 10.1038/nm.2208
Bataller, R., Gäbele, E., Parsons, C. J., Morris, T., Yang, L., Schoonhoven, R., et al.
(2005). Systemic infusion of angiotensin II exacerbates liver fibrosis in bile
duct-ligated rats. Hepatology 41, 1046–1055. doi: 10.1002/hep.20665
Bataller, R., Schwabe, R. F., Choi, Y. H., Yang, L., Paik, Y. H., Lindquist, J., et al.
(2003). Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. NADPH
oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in
hepatic fibrosis. J. Clin. Invest. 112, 1383–1394. doi: 10.1172/JCI18212
Baumgardner, J. N., Shankar, K., Hennings, L., Albano, E., Badger, T. M., and
Ronis, M. J. (2008). N-acetylcysteine attenuates progression of liver pathology
in a rat model of nonalcoholic steatohepatitis. J. Nutr. 138, 1872–1879.
Beno, D. W., and Davis, B. H. (1995). Prostaglandin E suppresses hepatic fibrosis:
section I. The in vivo approach; Section II. The in vitro approach. Am. J. Ther.
2, 687–705. doi: 10.1097/00045391-199509000-00018
Beyer, C., and Distler, J. H. (2013). Tyrosine kinase signaling in fibrotic disorders:
translation of basic research to human disease. Biochim. Biophys. Acta 1832,
897–904. doi: 10.1016/j.bbadis.2012.06.008
Bickel, M., Baader, E., Brocks, D. G., Engelbart, K., Günzler, V., Schmidts, H. L.,
et al. (1991). Beneficial effects of inhibitors of prolyl 4-hydroxylase in CCl4-
induced fibrosis of the liver in rats. J. Hepatol. 13, S26–S33. doi: 10.1016/0168-
8278(91)90005-v
Bickel, M., Baringhaus, K. H., Gerl, M., Günzler, V., Kanta, J., Schmidts, L., et al.
(1998). Selective inhibition of hepatic collagen accumulation in experimental
liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. Hepatology 28,
404–411. doi: 10.1002/hep.510280217
Boettcher, E., Csako, G., Pucino, F., Wesley, R., and Loomba, R. (2012).
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients
with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 35, 66–75. doi:
10.1111/j.1365-2036.2011.04912.x
Bondareva, A., Downey, C. M., Ayres, F., Liu, W., Boyd, S. K., Hallgrimsson, B.,
et al. (2009). The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes
the metastatic colonization potential of circulating breast cancer cells. PLoS
ONE 4:e5620. doi: 10.1371/journal.pone.0005620
Bonefeld, K., and Møller, S. (2011). Insulin-like growth factor-I and the liver. Liver
Int. 31, 911–919. doi: 10.1111/j.1478-3231.2010.02428.x
Borkham-Kamphorst, E., Alexi, P., Tihaa, L., Haas, U., and Weiskirchen, R.
(2015b). Platelet-derived growth factor-D modulates extracellular matrix
homeostasis and remodeling through TIMP-1 induction and attenuation of
MMP-2 and MMP-9 gelatinase activities. Biochem Biophys Res Commun. 457,
307–313. doi: 10.1016/j.bbrc.2014.12.106
Borkham-Kamphorst, E., Herrmann, J., Stoll, D., Treptau, J., Gressner, A. M.,
and Weiskirchen, R. (2004). Dominant-negative soluble PDGF-beta receptor
inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab. Invest.
84, 766–777. doi: 10.1038/labinvest.3700094
Borkham-Kamphorst, E., Kovalenko, E., van Roeyen, C. R., Gassler, N., Bomble,
M., Ostendorf, T., et al. (2008). Platelet-derived growth factor isoform
expression in carbon tetrachloride-induced chronic liver injury. Lab. Invest. 88,
1090–1100. doi: 10.1038/labinvest.2008.71
Borkham-Kamphorst, E., Meurer, S. K., van de Leur, E., Haas, U., Tihaa, L.,
and Weiskirchen, R. (2015a). PDGF-D signaling in portal myofibroblasts and
hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α
and β. Cell Signal. 27, 1305–1314. doi: 10.1016/j.cellsig.2015.03.012
Borkham-Kamphorst, E., Schaffrath, C., van de Leur, E., Haas, U., Tihaa,
L., Meurer, S. K., et al. (2014). The anti-fibrotic effects of CCN1/CYR61
in primary portal myofibroblasts are mediated through induction of
reactive oxygen species resulting in cellular senescence, apoptosis and
attenuated TGF-β signaling. Biochim Biophys Acta 1843, 902–914. doi:
10.1016/j.bbamcr.2014.01.023
Borrás, C., Gambini, J., López-Grueso, R., Pallardó, F. V., and Viña, J. (2010).
Direct antioxidant and protective effect of estradiol on isolated mitochondria.
Biochim. Biophys. Acta. 1802, 205–211. doi: 10.1016/j.bbadis.2009.
09.007
Bors, W., Michel, C., Stettmaier, K., Lu, Y., and Foo, L. Y. (2004).
Antioxidant mechanisms of polyphenolic caffeic acid oligomers, constituents
of Salvia officinalis. Biol. Res. 37, 301–311. doi: 10.4067/S0716-97602004000
200017
Bruck, R., Hershkoviz, R., Lider, O., Aeed, H., Zaidel, L., Matas, Z., et al. (1996).
Inhibition of experimentally-induced liver cirrhosis in rats by a nonpeptidic
mimetic of the extracellular matrix-associated Arg-Gly-Asp epitope. J. Hepatol.
24, 731–738. doi: 10.1016/S0168-8278(96)80270-4
Bührer, M., Le Cotonnec, J. Y., Wermeille, M., and Bircher, J. (1986). Treatment
of liver disease with malotilate. A pharmacokinetic and pharmacodynamic
phase II study in cirrhosis. Eur. J. Clin. Pharmacol. 30, 407–416. doi:
10.1007/BF00607952
Calvaruso, V.,Maimone, S., Gatt, A., Tuddenham, E., Thursz,M., Pinzani, M., et al.
(2008). Coagulation and fibrosis in chronic liver disease. Gut 57, 1722–1727.
doi: 10.1136/gut.2008.150748
Camino, A. M., Atorrasagasti, C., Maccio, D., Prada, F., Salvatierra, E., Rizzo, M.,
et al. (2008). Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis
in rats. J. Gene Med. 10, 993–1004. doi: 10.1002/jgm.1228
Campbell, J. S., Hughes, S. D., Gilbertson, D. G., Palmer, T. E., Holdren, M.
S., Haran, A. C., et al. (2005). Platelet-derived growth factor C induces liver
fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A.
102, 3389–3394. doi: 10.1073/pnas.0409722102
Cao, Q., Mak, K. M., and Lieber, C. S. (2002). Dilinoleoylphosphatidylcholine
prevents transforming growth factor-beta1-mediated collagen accumulation
in cultured rat hepatic stellate cells. J. Lab. Clin. Med. 139, 202–210. doi:
10.1067/mlc.2002.121853
Frontiers in Pharmacology | www.frontiersin.org 31 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Chai, N. L., Fu, Q., Shi, H., Cai, C. H., Wan, J., Xu, S. P., et al. (2012). Oxymatrine
liposome attenuates hepatic fibrosis via targeting hepatic stellate cells.World J.
Gastroenterol. 18, 4199–4206. doi: 10.3748/wjg.v18.i31.4199
Chainani-Wu, N. (2003). Safety and anti-inflammatory activity of curcumin:
a component of tumeric (Curcuma longa). J. Altern. Complement Med. 9,
161–168. doi: 10.1089/107555303321223035
Chang, B., Nishikawa, M., Nishiguchi, S., and Inoue, M. (2005). L-carnitine
inhibits hepatocarcinogenesis via protection of mitochondria. Int. J. Cancer
113, 719–729. doi: 10.1002/ijc.20636
Chávez, E., Reyes-Gordillo, K., Segovia, J., Shibayama, M., Tsutsumi, V., Vergara,
P., et al. (2008). Resveratrol prevents fibrosis, NF-kappaB activation and TGF-β
increases induced by chronic CCl4 treatment in rats. J. Appl. Toxicol. 28, 35–43.
doi: 10.1002/jat.1249
Chen, C. C., Ho, C. Y., Chaung, H. C., Tain, Y. L., Hsieh, C. S., Kuo, F. Y.,
et al. (2013). Fish omega-3 fatty acids induce liver fibrosis in the treatment
of bile duct-ligated rats. Dig. Dis. Sci. 58, 440–447. doi: 10.1007/s10620-012-
2489-5
Chen, Y. W., Liu, B. W., Zhang, Y. J., Chen, Y. W., Dong, G. F., Ding, X. D., et al.
(2010). Preservation of basal AcSDKP attenuates carbon tetrachloride-induced
fibrosis in the rat liver. J. Hepatol. 53, 528–536. doi: 10.1016/j.jhep.2010.03.027
Cheng, A. L., Shen, Y. C., and Zhu, A. X. (2011). Targeting fibroblast growth
factor receptor signaling in hepatocellular carcinoma. Oncology 81, 372–380.
doi: 10.1159/000335472
Chiang, D. J., Pritchard, M. T., and Nagy, L. E. (2011). Obesity, diabetes mellitus,
and liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G697–G702.
doi: 10.1152/ajpgi.00426.2010
Choi, H. S., Kang, J. W., and Lee, S. M. (2015). Melatonin attenuates carbon
tetrachloride-induced liver fibrosis via inhibition of necroptosis. Transl. Res.
166, 292–303. doi: 10.1016/j.trsl.2015.04.002
Choi, K. C., Jung, M. G., Lee, Y. H., Yoon, J. C., Kwon, S. H., Kang,
H. B., et al. (2009). Epigallocatechin-3-gallate, a histone acetyltransferase
inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression
of RelA acetylation. Cancer Res. 69, 583–592. doi: 10.1158/0008-5472.CAN-
08-2442
Choi, Y. J., Kim da, H., Kim, S. J., Kim, J., Jeong, S. I., Chung, C. H., et al. (2014).
Decursin attenuates hepatic fibrogenesis through interrupting TGF-β-mediated
NAD(P)H oxidase activation and Smad signaling in vivo and in vitro. Life Sci.
108, 94–103. doi: 10.1016/j.lfs.2014.05.012
Chtourou, Y., Fetoui, H., Jemai, R., Ben Slima, A., Makni, M., and Gdoura,
R. (2015). Naringenin reduces cholesterol-induced hepatic inflammation in
rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear
factor κB pathway. Eur. J. Pharmacol. 746, 96–105. doi: 10.1016/j.ejphar.2014.
10.027
Clichici, S., Olteanu, D., Nagy, A. L., Oros, A., Filip, A., and Mircea, P. A. (2015).
Silymarin inhibits the progression of fibrosis in the early stages of liver injury
in CCl4-treated rats. J. Med. Food 18, 290–298. doi: 10.1089/jmf.2013.0179
Cong, M., Liu, T., Wang, P., Fan, X., Yang, A., Bai, Y., et al. (2013). Antifibrotic
effects of a recombinant adeno-associated virus carrying small interfering RNA
targeting TIMP-1 in rat liver fibrosis. Am. J. Pathol. 182, 1607–1616. doi:
10.1016/j.ajpath.2013.01.036
Corpechot, C., Barbu, V., Wendum, D., Kinnman, N., Rey, C., Poupon, R., et al.
(2002). Hypoxia-induced VEGF and collagen I expressions are associated
with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35,
1010–1021. doi: 10.1053/jhep.2002.32524
Crespo, I., San-Miguel, B., Fernández, A., Ortiz de Urbina, J., González-Gallego,
J., and Tuñón, M. J. (2015). Melatonin limits the expression of profibrogenic
genes and ameliorates the progression of hepatic fibrosis in mice. Transl. Res.
165, 346–357. doi: 10.1016/j.trsl.2014.10.003
Crosas-Molist, E., and Fabregat, I. (2015). Role of NADPH oxidases
in the redox biology of liver fibrosis. Redox Biol. 6, 106–111. doi:
10.1016/j.redox.2015.07.005
Czochra, P., Klopcic, B., Meyer, E., Herkel, J., Garcia-Lazaro, J. F., Thieringer, F.,
et al. (2006). Liver fibrosis induced by hepatic overexpression of PDGF-B in
transgenic mice. J. Hepatol. 45, 419–428. doi: 10.1016/j.jhep.2006.04.010
Dang, Z. C., Audinot, V., Papapoulos, S. E., Boutin, J. A., and Löwik, C. W.
(2003). Peroxisome proliferator-activated receptor gamma (PPARgamma) as
a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 278,
962–967. doi: 10.1074/jbc.M209483200
Das, S. K., DesAulniers, J., Dyck, J. R., Kassiri, Z., and Oudit, G. Y. (2015).
Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine
models of iron-overload. Liver Int. doi: 10.1111/liv.12893. [Epub ahead of
print].
De Bleser, P. J., Xu, G., Rombouts, K., Rogiers, V., and Geerts, A. (1999).
Glutathione levels discriminate between oxidative stress and transforming
growth factor-beta signaling in activated rat hepatic stellate cells. J. Biol. Chem.
274, 33881–33887. doi: 10.1074/jbc.274.48.33881
de Gouville, A. C., Boullay, V., Krysa, G., Pilot, J., Brusq, J. M., Loriolle, F.,
et al. (2005). Inhibition of TGF-beta signaling by an ALK5 inhibitor protects
rats from dimethylnitrosamine-induced liver fibrosis. Br. J. Pharmacol. 145,
166–177. doi: 10.1038/sj.bjp.0706172
Dekel, R., Zvibel, I., Brill, S., Brazovsky, E., Halpern, Z., and Oren, R. (2003).
Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide
rat model. Dig. Dis. Sci. 48, 1642–1647. doi: 10.1023/A:1024792529601
De Minicis, S., Seki, E., Paik, Y. H., Osterreicher, C. H., Kodama, Y.,
Kluwe, J., et al. (2010). Role and cellular source of nicotinamide adenine
dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology 52, 1420–1430.
doi: 10.1002/hep.23804
Demiroren, K., Dogan, Y., Kocamaz, H., Ozercan, I. H., Ilhan, S., Ustundag, B.,
et al. (2014). Protective effects of L-carnitine, N-acetylcysteine and genistein in
an experimental model of liver fibrosis. Clin. Res. Hepatol. Gastroenterol. 38,
63–72. doi: 10.1016/j.clinre.2013.08.014
Deng, Y. R., Ma, H. D., Tsuneyama, K., Yang, W., Wang, Y. H., Lu, F. T., et al.
(2013). STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis
by the protein kinase inhibitor sorafenib. J. Autoimmun. 46, 25–34. doi:
10.1016/j.jaut.2013.07.008
Devi, S. L., and Anuradha, C. V. (2010). Oxidative and nitrosative stress in
experimental rat liver fibrosis: protective effect of taurine. Environ. Toxicol.
Pharmacol. 29, 104–110. doi: 10.1016/j.etap.2009.11.005
Devi, S. L., Viswanathan, P., and Anuradha, C. V. (2010). Regression of liver
fibrosis by taurine in rats fed alcohol: effects on collagen accumulation, selected
cytokines and stellate cell activation. Eur. J. Pharmacol. 647, 161–170. doi:
10.1016/j.ejphar.2010.08.011
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., et al.
(2013). A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic
response. Cell 153, 601–613. doi: 10.1016/j.cell.2013.03.028
Ding, X., Saxena, N. K., Lin, S., Xu, A., Srinivasan, S., and Anania, F. A. (2005). The
roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation
of liver fibrosis and stellate cell biology. Am. J. Pathol. 166, 1655–1669. doi:
10.1016/S0002-9440(10)62476-5
Ding, Y., Sun, X., Chen, Y., Deng, Y., and Qian, K. (2015). Epigallocatechin
gallate attenuated non-alcoholic steatohepatitis induced by methionine-
and choline-deficient diet. Eur. J. Pharmacol. 761, 405–412. doi:
10.1016/j.ejphar.2015.05.005
Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Casini, A., Ceni, E.,
et al. (2002). Effect of pirfenidone on rat hepatic stellate cell proliferation
and collagen production. J. Hepatol. 37, 584–591. doi: 10.1016/S0168-
8278(02)00245-3
Dokmanovic, M., Clarke, C., and Marks, P. A. (2007). Histone deacetylase
inhibitors: overview and perspectives. Mol. Cancer Res. 5, 981–989. doi:
10.1158/1541-7786.MCR-07-0324
Domitrovic´, R., Jakovac, H., Tomac, J., and Sain, I. (2009). Liver fibrosis in mice
induced by carbon tetrachloride and its reversion by luteolin. Toxicol. Appl.
Pharmacol. 241, 311–321. doi: 10.1016/j.taap.2009.09.001
Dorn, C., Heilmann, J., and Hellerbrand, C. (2012). Protective effect of
xanthohumol on toxin-induced liver inflammation and fibrosis. Int. J. Clin.
Exp. Pathol. 5, 29–36. doi: 10.1055/s-0031-1295738
Dorn, C., Kraus, B., Motyl, M., Weiss, T. S., Gehrig, M., Schölmerich, J.,
et al. (2010). Xanthohumol, a chalcon derived from hops, inhibits hepatic
inflammation and fibrosis. Mol. Nutr. Food Res. 54, S205–S213. doi:
10.1002/mnfr.200900314
Du, G. J., Zhang, Z., Wen, X. D., Yu, C., Calway, T., Yuan, C. S., et al. (2012).
Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive
polyphenol in green tea. Nutrients 4, 1679–1691. doi: 10.3390/nu41
11679
Du, S. L., Pan, H., Lu, W. Y., Wang, J., Wu, J., and Wang, J. Y. (2007).
Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy
Frontiers in Pharmacology | www.frontiersin.org 32 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
of hepatic fibrosis in rats. J. Pharmacol. Exp. Ther. 322, 560–568. doi:
10.1124/jpet.107.122481
Duplantier, J. G., Dubuisson, L., Senant, N., Freyburger, G., Laurendeau, I.,
Herbert, J. M., et al. (2004). A role for thrombin in liver fibrosis. Gut 53,
1682–1687. doi: 10.1136/gut.2003.032136
Dvorak, Z., Ulrichova, J., Pichard-Garcia, L., Modriansky, M., and
Maurel, P. (2002). Comparative effect of colchicine and colchiceine
on cytotoxicity and CYP gene expression in primary human
hepatocytes. Toxicol In Vitro 16, 219–227. doi: 10.1016/S.0887-2333(02)
00004-8
EASL. European Association for Study of Liver (2015). EASL Recommendations
on Treatment of Hepatitis C. J. Hepatol. 63, 199–236. doi:
10.1016/j.jhep.2015.03.025
Efe, C. (2013). Drug induced autoimmune hepatitis and TNF-α blocking
agents: is there a real relationship? Autoimmun. Rev. 12, 337–339. doi:
10.1016/j.autrev.2012.03.010
Elinav, E., Ali, M., Bruck, R., Brazowski, E., Phillips, A., Shapira, Y., et al. (2009).
Competitive inhibition of leptin signaling results in amelioration of liver
fibrosis through modulation of stellate cell function. Hepatology 49, 278–286.
doi: 10.1002/hep.22584
El-Karef, A., Yoshida, T., Gabazza, E. C., Nishioka, T., Inada, H., Sakakura, T.,
et al. (2007). Deficiency of tenascin-C attenuates liver fibrosis in immune-
mediated chronic hepatitis in mice. J. Pathol. 211, 86–94. doi: 10.1002/path.
2099
El Taghdouini, A., Najimi, M., Sancho-Bru, P., Sokal, E., and van Grunsven,
L. A. (2015). In vitro reversion of activated primary human hepatic
stellate cells. Fibrogenesis Tissue Repair 8:14. doi: 10.1186/s13069-015-
0031-z
EU Parliament (2010). Directive 2010/63/EU of the European Parliament and
of the Council on the Protection of Animals Used for Scientific Purposes.
Official Journal of the European Union 2010. L276/33–L276/79 (22 September
2010). Available online at: http://eur-lex.europa.eu/legal-content/EN/TXT/?
uri=CELEX%3A32010L0063
EU Parliament (2013). Seventh Report from the Commission to the Council and
the European Parliament on the Statistics on the Number of Animals Used for
Experimental andOther Scientific Purposes in theMember States of the European
Union in the Year 2011 {WD(2013) 497} (5 December 2013). Available online at:
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013DC0859
Feng, D., Mei, Y., Wang, Y., Zhang, B., Wang, C., and Xu, L. (2008).
Tetrandrine protects mice from concanavalin A-induced hepatitis through
inhibiting NF-kappaB activation. Immunol Lett. 121, 127–133. doi:
10.1016/j.imlet.2008.10.001
Ferguson, B. S., and McKinsey, T. A. (2015). Non-sirtuin histone deacetylases
in the control of cardiac aging. J. Mol. Cell Cardiol. 83, 14–20. doi:
10.1016/j.yjmcc.2015.03.010
Fiorucci, S., Antonelli, E., Distrutti, E., Severino, B., Fiorentina, R., Baldoni, M.,
et al. (2004). PAR1 antagonism protects against experimental liver fibrosis. Role
of proteinase receptors in stellate cell activation. Hepatology 39, 365–375. doi:
10.1002/hep.20054
Flores-Contreras, L., Sandoval-Rodríguez, A. S., Mena-Enriquez, M. G., Lucano-
Landeros, S., Arellano-Olivera, I., Alvarez-Álvarez, A., et al. (2014). Treatment
with pirfenidone for two years decreases fibrosis, cytokine levels and enhances
CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol.
14:131. doi: 10.1186/1471-230X-14-131
Foo, N. P., Lin, S. H., Lee, Y. H., Wu, M. J., and Wang, Y. J. (2011). α-Lipoic
acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling
in hepatic stellate cells activated by PDGF and TGF-β. Toxicology. 282, 39–46.
doi: 10.1016/j.tox.2011.01.009
Friedman, S. L. (2008). Hepatic stellate cells: protean, multifunctional,
and enigmatic cells of the liver. Physiol. Rev. 88, 125–172. doi:
10.1152/physrev.00013.2007
Frizell, E., Liu, S. L., Abraham, A., Ozaki, I., Eghbali, M., Sage, E. H., et al. (1995).
Expression of SPARC in normal and fibrotic livers.Hepatology 21, 847–854. doi:
10.1016/0270-9139(95)90540-5
Fuchs, B. C., Hoshida, Y., Fujii, T., Wei, L., Yamada, S., Lauwers, G. Y., et al.
(2014). Epidermal growth factor receptor inhibition attenuates liver fibrosis
and development of hepatocellular carcinoma. Hepatology 59, 1577–1590. doi:
10.1002/hep.26898
Gaça, M. D., Zhou, X., and Benyon, R. C. (2002). Regulation of hepatic stellate
cell proliferation and collagen synthesis by proteinase-activated receptors.
J. Hepatol. 36, 362–369. doi: 10.1016/S0168-8278(01)00285-9
Galicia-Moreno, M., Rodríguez-Rivera, A., Reyes-Gordillo, K., Segovia, J.,
Shibayama, M., Tsutsumi, V., et al. (2009). N-acetylcysteine prevents carbon
tetrachloride-induced liver cirrhosis: role of liver transforming growth factor-
beta and oxidative stress. Eur. J. Gastroenterol. Hepatol. 21, 908–914. doi:
10.1097/MEG.0b013e32831f1f3a
Gao, R. P., and Brigstock, D. R. (2009). Connective tissue growth factor
hammerhead ribozyme attenuates human hepatic stellate cell function. World
J. Gastroenterol. 15, 3807–3813. doi: 10.3748/wjg.15.3807
García, L., Hernández, I., Sandoval, A., Salazar, A., Garcia, J., Vera, J., et al.
(2002). Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol.
37, 797–805. doi: 10.1016/S0168-8278(02)00272-6
García-Trevijano, E. R., Iraburu, M. J., Fontana, L., Domínguez-Rosales, J.
A., Auster, A., Covarrubias-Pinedo, A., et al. (1999). Transforming growth
factor beta1 induces the expression of alpha1(I) procollagen mRNA by a
hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate
cells. Hepatology 29, 960–970. doi: 10.1002/hep.510290346
Ge, W. S., Wang, Y. J., Wu, J. X., Fan, J. G., Chen, Y. W., and Zhu, L. (2014).
β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin
signaling inhibits hepatic stellate cell activation. Mol. Med. Rep. 9, 2145–2151.
doi: 10.3892/mmr.2014.2099
Gellibert, F., de Gouville, A. C., Woolven, J., Mathews, N., Nguyen, V. L., Bertho-
Ruault, C., et al. (2006). Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-
4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): a
potent, selective, and orally active transforming growth factor-beta type I
receptor inhibitor. J. Med. Chem. 49, 2210–2221. doi: 10.1021/jm0509905
George, J., and Tsutsumi, M. (2007). siRNA-mediated knockdown of connective
tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis
in rats. Gene Ther. 14, 790–803. doi: 10.1038/sj.gt.3302929
Georges, P. C., Hui, J. J., Gombos, Z., McCormick, M. E., Wang, A. Y., Uemura,
M., et al. (2007). Increased stiffness of the rat liver precedes matrix deposition:
implications for fibrosis.Am. J. Physiol. Gastrointest. Liver. Physiol. 293, G1147–
G1154. doi: 10.1152/ajpgi.00032.2007
Godichaud, S., Krisa, S., Couronné, B., Dubuisson, L., Mérillon, J. M., Desmoulière,
A., et al. (2000). Deactivation of cultured human liver myofibroblasts by
trans-resveratrol, a grapevine-derived polyphenol.Hepatology 31, 922–931. doi:
10.1053/he.2000.5848
Greenspoon, N., Hershkoviz, R., Alon, R., Varon, D., Shenkman, B., Marx, G.,
et al. (1993). Structural analysis of integrin recognition and the inhibition
of integrin-mediated cell functions by novel nonpeptidic surrogates of the
Arg-Gly-Asp sequence. Biochemistry 32, 1001–1008. doi: 10.1021/bi0005
5a002
Gressner, A. M., Krull, N., and Bachem, M. G. (1994). Regulation of proteoglycan
expression in fibrotic liver and cultured fat-storing cells. Pathol. Res. Pract. 190,
864–882. doi: 10.1016/S0344-0338(11)80990-8
Gressner, A. M., Weiskirchen, R., Breitkopf, K., and Dooley, S. (2002). Roles of
TGF-β in hepatic fibrosis. Front. Biosci. 7, d793–d807. doi: 10.2741/gressner
Gressner, A. M., and Weiskirchen, R. (2006). Modern pathogenetic concepts
of liver fibrosis suggest stellate cells and TGF-beta as major players and
therapeutic targets. J. Cell. Mol. Med. 10, 76–99. doi: 10.1111/j.1582-
4934.2006.tb00292.x
Gressner, O. A., Lahme, B., Demirci, I., Gressner, A. M., and Weiskirchen, R.
(2007). Differential effects of TGF-beta on connective tissue growth factor
(CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J. Hepatol.
47, 699–710. doi: 10.1016/j.jhep.2007.05.015
Guo, S. G., Zhang, W., Jiang, T., Dai, M., Zhang, L. F., Meng, Y. C., et al. (2004).
Influence of serum collected from rat perfused with compound Biejiaruangan
drug on hepatic stellate cells.World J. Gastroenterol. 10, 1487–1494.
Guo, Y., Xiao, L., Sun, L., and Liu, F. (2012). Wnt/beta-catenin signaling: a
promising new target for fibrosis diseases. Physiol. Res. 61, 337–346.
Hagens, W. I., Olinga, P., Meijer, D. K., Groothuis, G. M., Beljaars, L., and Poelstra,
K. (2006). Gliotoxin non-selectively induces apoptosis in fibrotic and normal
livers. Liver Int. 26, 232–239. doi: 10.1111/j.1478-3231.2005.01212.x
Hammerich, L., and Tacke, F. (2014). Interleukins in chronic liver disease: lessons
learned from experimental mouse models. Clin. Exp. Gastroenterol. 7, 297–306.
doi: 10.2147/CEG.S43737
Frontiers in Pharmacology | www.frontiersin.org 33 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Handy, J. A., Fu, P. P., Kumar, P., Mells, J. E., Sharma, S., Saxena, N. K., et al.
(2011). Adiponectin inhibits leptin signalling via multiple mechanisms to
exert protective effects against hepatic fibrosis. Biochem. J. 440, 385–395. doi:
10.1042/BJ20102148
Hantgan, R. R., Paumi, C., Rocco, M., and Weisel, J. W. (1999). Effects of
ligand-mimetic peptides Arg-Gly-Asp-X (X = Phe, Trp, Ser) on alphaIIbbeta3
integrin conformation and oligomerization. Biochemistry 38, 14461–14474. doi:
10.1021/bi9907680
Hara, Y., Yamashita, T., Oishi, N., Nio, K., Hayashi, T., Nomura, Y., et al.
(2015). TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting
microenvironmental platelet-derived growth factor signaling. Anticancer Res.
35, 1423–1431.
Harrison, S. A., Torgerson, S., Hayashi, P., Ward, J., and Schenker, S.
(2003). Vitamin E and vitamin C treatment improves fibrosis in patients
with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98, 2485–2490. doi:
10.1111/j.1572-0241.2003.08699.x
Hemmann, S., Graf, J., Roderfeld, M., and Roeb, E. (2007). Expression of
MMPs and TIMPs in liver fibrosis—a systematic review with special emphasis
on anti-fibrotic strategies. J. Hepatol. 46, 955–975. doi: 10.1016/j.jhep.2007.
02.003
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Poirier, F., Russo, F.
P., Iredale, J. P., et al. (2006). Galectin-3 regulates myofibroblast activation
and hepatic fibrosis. Proc. Natl. Acad. Sci. U.S.A. 103, 5060–5065. doi:
10.1073/pnas.0511167103
Hennenberg, M., Trebicka, J., Kohistani, Z., Stark, C., Nischalke, H. D.,
Krämer, B., et al. (2011). Hepatic and HSC-specific sorafenib effects in rats
with established secondary biliary cirrhosis. Lab. Invest. 91, 241–251. doi:
10.1038/labinvest.2010.148
Heuberger, H., Bauer, R., Friedl, F., Heubl, G., Hummelsberger, J., Nögel, R., et al.
(2010). Cultivation and breeding of Chinese medicinal plants in Germany.
Planta Med. 76, 1956–1962. doi: 10.1055/s-0030-1250528
Heymann, F., Hamesch, K., Weiskirchen, R., and Tacke, F. (2015). The
concanavalin A model of acute hepatitis in mice. Lab. Anim. 49, 12–20. doi:
10.1177/0023677215572841
Hong, F., Chou, H., Fiel, M. I., and Friedman, S. L. (2013). Antifibrotic activity
of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets,
dosing, and window of efficacy in vivo. Dig. Dis. Sci. 58, 257–264. doi:
10.1007/s10620-012-2325-y
Hong, S. W., Jung, K. H., Zheng, H. M., Lee, H. S., Suh, J. K., Park, I. S., et al.
(2010). The protective effect of resveratrol on dimethylnitrosamine-induced
liver fibrosis in rats. Arch. Pharm. Res. 33, 601–609. doi: 10.1007/s12272-010-
0415-y
Horwitz, L. D. (2003). Bucillamine: a potent thiol donor with multiple
clinical applications. Cardiovasc. Drug. Rev. 21, 77–90. doi: 10.1111/j.1527-
3466.2003.tb00107.x
Housset, C., Rockey, D. C., and Bissell, D. M. (1993). Endothelin receptors in rat
liver: lipocytes as a contractile target for endothelin 1. Proc. Natl. Acad. Sci.
U.S.A. 90, 9266–9270. doi: 10.1073/pnas.90.20.9266
Hsiang, C. Y., Lin, L. J., Kao, S. T., Lo, H. Y., Chou, S. T., and Ho, T. Y.
(2015). Glycyrrhizin, silymarin, and ursodeoxycholic acid regulate a common
hepatoprotective pathway in HepG2 cells. Phytomedicine 22, 768–777. doi:
10.1016/j.phymed.2015.05.053
Hu, Y. B., Li, D. G., and Lu, H.M. (2007).Modified synthetic siRNA targeting tissue
inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene
Med. 9, 217–229. doi: 10.1002/jgm.1009
Huang, C. K., Yu, T., de la Monte, S. M., Wands, J. R., Derdak, Z., and
Kim, M. (2015). Restoration of Wnt/β-catenin signaling attenuates alcoholic
liver disease progression in a rat model. J. Hepatol. 63, 191–198. doi:
10.1016/j.jhep.2015.02.030
Huang, Q., Huang, R., Zhang, S., Lin, J., Wei, L., He, M., et al.
(2013). Protective effect of genistein isolated from Hydrocotyle
sibthorpioides on hepatic injury and fibrosis induced by chronic
alcohol in rats. Toxicol. Lett. 217, 102–110. doi: 10.1016/j.toxlet.2012.
12.014
Humbert, M., Segal, E. S., Kiely, D. G., Carlsen, J., Schwierin, B., and
Hoeper, M. M. (2007). Results of European post-marketing surveillance
of bosentan in pulmonary hypertension. Eur. Respir. J. 30, 338–344. doi:
10.1183/09031936.00138706
Hunter, T. (2009). Tyrosine phosphorylation: thirty years and counting. Curr.
Opin. Cell Biol. 21, 140–146. doi: 10.1016/j.ceb.2009.01.028
Ikeda, H., Inao, M., and Fujiwara, K. (1996). Inhibitory effect of tranilast on
activation and transforming growth factor beta 1 expression in cultured
rat stellate cells. Biochem. Biophys. Res. Commun. 227, 322–327. doi:
10.1006/bbrc.1996.1508
Ikura, Y., Iwasa, Y., and Ueda, M. (2010). Valproic acid administration for hepatic
fibrosis: a balance between antifibrotic efficacy and hepatotoxicity. Hepatology
51, 2227–2228. doi: 10.1002/hep.23688
Inagaki, Y., Higashi, K., Kushida, M., Hong, Y. Y., Nakao, S., Higashiyama, R., et al.
(2008). Hepatocyte growth factor suppresses profibrogenic signal transduction
via nuclear export of Smad3 with galectin-7. Gastroenterology 134, 1180–1190.
doi: 10.1053/j.gastro.2008.01.014
Isaji, M., Nakajoh, M., and Naito, J. (1987). Selective inhibition of collagen
accumulation by N-(3,4-dimethoxycinnamoyl)anthranilic acid (N-5′) in
granulation tissue. Biochem. Pharmacol. 36, 469–474. doi: 10.1016/0006-
2952(87)90353-4
Ishikawa, H., Takaki, A., Tsuzaki, R., Yasunaka, T., Koike, K., Shimomura, Y.,
et al. (2014). L-carnitine prevents progression of non-alcoholic steatohepatitis
in a mouse model with upregulation of mitochondrial pathway. PLoS ONE
9:e100627. doi: 10.1371/journal.pone.0100627
Iwamoto, H., Sakai, H., Kotoh, K., Nakamuta, M., and Nawata, H. (1999). Soluble
Arg-Gly-Asp peptides reduce collagen accumulation in cultured rat hepatic
stellate cells. Dig. Dis. Sci. 44, 1038–1045. doi: 10.1023/A:1026633302985
Jackson, B. C., Nebert, D.W., and Vasiliou, V. (2010). Update of human andmouse
matrix metalloproteinase families. Hum. Genomics 4, 194–201.
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W.,
et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product
derived from grapes. Science 275, 218–220. doi: 10.1126/science.275.5297.218
Jong, C. J., Azuma, J., and Schaffer, S. (2012). Mechanism underlying
the antioxidant activity of taurine: prevention of mitochondrial oxidant
production. Amino. Acids 42, 2223–2232. doi: 10.1007/s00726-011-0962-7
Junnarkar, S. P., Tapuria, N., Mani, A., Dijk, S., Fuller, B., Seifalian, A.
M., et al. (2010). Attenuation of warm ischemia-reperfusion injury in the
liver by bucillamine through decreased neutrophil activation and Bax/Bcl-
2 modulation. J. Gastroenterol. Hepatol. 25, 1891–1899. doi: 10.1111/j.1440-
1746.2010.06312.x
Kaimori, A., Potter, J. J., Choti, M., Ding, Z., Mezey, E., and Koteish, A. A. (2010).
Histone deacetylase inhibition suppresses the transforming growth factor
beta1-induced epithelial-to-mesenchymal transition in hepatocytes.Hepatology
52, 1033–1045. doi: 10.1002/hep.23765
Kandarkar, S. V., Sawant, S. S., Ingle, A. D., Deshpande, S. S., and Maru, G. B.
(1998). Subchronic oral hepatotoxicity of turmeric in mice–histopathological
and ultrastructural studies. Indian J. Exp. Biol. 36, 675–679.
Karsdal, M. A., Manon-Jensen, T., Genovese, F., Kristensen, J. H., Nielsen, M. J.,
Sand, J. M., et al. (2015). Novel insights into the function and dynamics of
extracellular matrix in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol.
308, G807–G830. doi: 10.1152/ajpgi.00447.2014
Katayama, K., Saito, M., Kawaguchi, T., Endo, R., Sawara, K., Nishiguchi, S., et al.
(2014). Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary
randomized, placebo-controlled double-blind trial. Nutrition 30, 1409–1414.
doi: 10.1016/j.nut.2014.04.018
Kawaguchi, K., Sakaida, I., Tsuchiya, M., Omori, K., Takami, T., and Okita,
K. (2004). Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-
altered lesions in rat liver cirrhosis induced by a choline-deficient L-
amino acid-defined diet. Biochem. Biophys. Res. Commun. 315, 187–195. doi:
10.1016/j.bbrc.2004.01.038
Kaya-Dagistanli, F., Tanriverdi, G., Altinok, A., Ozyazgan, S., and Ozturk, M.
(2013). The effects of alpha lipoic acid on liver cells damages and apoptosis
induced by polyunsaturated fatty acids. Food Chem. Toxicol. 53, 84–93. doi:
10.1016/j.fct.2012.11.026
Kendall, T. J., Hennedige, S., Aucott, R. L., Hartland, S. N., Vernon, M. A., Benyon,
R. C., et al. (2009). p75 Neurotrophin receptor signaling regulates hepatic
myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis.
Hepatology 49, 901–910. doi: 10.1016/j.fct.2012.11.026
Kershenobich, D., Vargas, F., Garcia-Tsao, G., Perez Tamayo, R., Gent, M., and
Rojkind, M. (1988). Colchicine in the treatment of cirrhosis of the liver.N. Engl.
J. Med. 318, 1709–1713. doi: 10.1056/NEJM198806303182602
Frontiers in Pharmacology | www.frontiersin.org 34 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Kim, J. Y., Kim, K. M., Nan, J. X., Zhao, Y. Z., Park, P. H., Lee, S. J., et al. (2003).
Induction of apoptosis by tanshinone I via cytochrome c release in activated
hepatic stellate cells. Pharmacol. Toxicol. 92, 195–200. doi: 10.1034/j.1600-
0773.2003.920410.x
Kim, K. H., Chen, C. C., Monzon, R. I., and Lau, L. F. (2013). Matricellular
protein CCN1 promotes regression of liver fibrosis through induction of
cellular senescence in hepatic myofibroblasts.Mol. Cell Biol. 33, 2078–2090. doi:
10.1128/MCB.00049-13
Kim do, Y., Chung, S. I., Ro, S. W., Paik, Y. H., Lee, J. I., Jung, M. K., et al.
(2013). Combined effects of an antioxidant and caspase inhibitor on the reversal
of hepatic fibrosis in rats. Apoptosis 18, 1481–1491. doi: 10.1007/s10495-013-
0896-5
Kinoshita, K., Limuro, Y., Otogawa, K., Saika, S., Inagaki, Y., Nakajima,
Y., et al. (2007). Adenovirus-mediated expression of BMP-7 suppresses
the development of liver fibrosis in rats. Gut 56, 706–714. doi:
10.1136/gut.2006.092460
Klein, S., Klösel, J., Schierwagen, R., Körner, C., Granzow,M., Huss, S., et al. (2012).
Atorvastatin inhibits proliferation and apoptosis, but induces senescence in
hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab.
Invest. 92, 1440–1450. doi: 10.1038/labinvest.2012.106
Kloubert, V., and Rink, L. (2015). Zinc as a micronutrient and its preventive role
of oxidative damage in cells. Food Funct. 6, 3195–3204. doi: 10.1039/C5FO
00630A
Klyosov, A., Zomer, E., and Platt, D. (2012). DAVANAT R© (GM-CT-01) and colon
cancer: preclinical and clinical (phase I and II) studies. Glycobiol. Drug Design
89–130. doi: 10.1021/bk-2012-1102.ch004
Kojima-Yuasa, A., Umeda, K., Ohkita, T., Opare Kennedy, D., Nishiguchi, S., and
Matsui-Yuasa, I. (2005). Role of reactive oxygen species in zinc deficiency-
induced hepatic stellate cell activation. Free Radic. Biol. Med. 39, 631–640. doi:
10.1016/j.freeradbiomed.2005.04.015
Kondou, H., Mushiake, S., Etani, Y., Miyoshi, Y., Michigami, T., and Ozono,
K. (2003). A blocking peptide for transforming growth factor-β1 activation
prevents hepatic fibrosis in vivo. J. Hepatol. 39, 742–748. doi: 10.1016/S0168-
8278(03)00377-5
Kotoh, K., Nakamuta, M., Kohjima, M., Fukushima, M., Morizono, S.,
Kobayashi, N., et al. (2004). Arg-Gly-Asp (RGD) peptide ameliorates carbon
tetrachloride-induced liver fibrosis via inhibition of collagen production and
acceleration of collagenase activity. Int. J. Mol. Med. 14, 1049–1053. doi:
10.3892/ijmm.14.6.1049
Kuo, W. L., Yu, M. C., Lee, J. F., Tsai, C. N., Chen, T. C., and Chen, M. F.
(2012). Imatinib mesylate improves liver regeneration and attenuates liver
fibrogenesis in CCL4-treated mice. J. Gastrointest. Surg. 16, 361–369. doi:
10.1007/s11605-011-1764-7
Lan, T., Kisseleva, T., and Brenner, D. A. (2015). Deficiency of NOX1
or NOX4 prevents liver inflammation and fibrosis in mice through
inhibition of hepatic stellate cell activation. PLoS ONE 10:e0129743. doi:
10.1371/journal.pone.0129743
Lazaro, R., Wu, R., Lee, S., Zhu, N. L., Chen, C. L., French, S. W., et al.
(2015). Osteopontin deficiency does not prevent but promotes alcoholic
neutrophilic hepatitis in mice. Hepatology 61, 129–140. doi: 10.1002/hep.
27383
Leclercq, I. A., Sempoux, C., Stärkel, P., and Horsmans, Y. (2006). Limited
therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats.
Gut. 55, 1020–1029. doi: 10.1136/gut.2005.079194
Lee, K. C., Chan, C. C., Yang, Y. Y., Hsieh, Y. C., Huang, Y. H., and Lin, H. C.
(2013). Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat
in mice fed with a methionine and choline deficient diet. PLoS ONE 8:e77817.
doi: 10.1371/journal.pone.0077817
Lee, M. H., Yoon, S., and Moon, J. O. (2004a). The flavonoid naringenin inhibits
dimethylnitrosamine-induced liver damage in rats. Biol. Pharm. Bull. 27, 72–76.
doi: 10.1248/bpb.27.72
Lee, S., Kim, S., Le, H. D., Meisel, J., Strijbosch, R. A., Nose, V., et al.
(2008). Reduction of hepatocellular injury after common bile duct
ligation using omega-3 fatty acids. J. Pediatr. Surg. 43, 2010–2015. doi:
10.1016/j.jpedsurg.2008.05.030
Lee, S. H., Seo, G. S., Park, Y. N., Yoo, T. M., and Sohn, D. H. (2004b). Effects and
regulation of osteopontin in rat hepatic stellate cells. Biochem. Pharmacol. 68,
2367–2378. doi: 10.1016/j.bcp.2004.08.022
Lee, T. Y., Chang, H. H., Wang, G. J., Chiu, J. H., Yang, Y. Y., and Lin, H. C. (2006).
Water-soluble extract of Salvia miltiorrhiza ameliorates carbon tetrachloride-
mediated hepatic apoptosis in rats. J. Pharm Pharmacol. 58, 659–665. doi:
10.1211/jpp.58.5.0011
Lemoine, M., Serfaty, L., Cervera, P., Capeau, J., and Ratziu, V. (2014). Hepatic
molecular effects of rosiglitazone in human non-alcoholic steatohepatitis
suggest long-term pro-inflammatory damage.Hepatol. Res. 44, 1241–1247. doi:
10.1111/hepr.12244
Leung, T. M., Wang, X., Kitamura, N., Fiel, M. I., and Nieto, N. (2013).
Osteopontin delays resolution of liver fibrosis. Lab Invest. 93, 1082–1089. doi:
10.1038/labinvest.2013.104
Li, G., Li, D., Xie, Q., Shi, Y., Jiang, S., and Jin, Y. (2008a). RNA interfering
connective tissue growth factor prevents rat hepatic stellate cell activation
and extracellular matrix production. J. Gene Med. 10, 1039–1047. doi:
10.1002/jgm.1223
Li, G., Xie, Q., Shi, Y., Li, D., Zhang, M., Jiang, S., et al. (2006). Inhibition of
connective tissue growth factor by siRNA prevents liver fibrosis in rats. J. Gene
Med. 8, 889–900. doi: 10.1002/jgm.894
Li, J., Li, X., Xu, W., Wang, S., Hu, Z., Zhang, Q., et al. (2015a). Antifibrotic
effects of luteolin on hepatic stellate cells and liver fibrosis by targeting
AKT/mTOR/p70S6K and TGFβ/Smad signalling pathways. Liver Int. 35,
1222–1233. doi: 10.1111/liv.12638
Li, L., Zhao, X. Y., and Wang, B. E. (2008b). Down-regulation of transforming
growth factor beta 1/activin receptor-like kinase 1 pathway gene expression
by herbal compound 861 is related to deactivation of LX-2 cells. World J.
Gastroenterol. 14, 2894–2899. doi: 10.3748/wjg.14.2894
Li, M., Wang, X. F., Shi, J. J., Li, Y. P., Yang, N., Zhai, S., et al. (2015b). Caffeic
acid phenethyl ester inhibits liver fibrosis in rats. World J. Gastroenterol. 21,
3893–3903. doi: 10.3748/wjg.v21.i13.3893
Li, X., Wang, X., Han, C., Wang, X., Xing, G., Zhou, L., et al. (2013). Astragaloside
IV suppresses collagen production of activated hepatic stellate cells via
oxidative stress-mediated p38 MAPK pathway. Free Radic. Biol. Med. 60,
168–176. doi: 10.1016/j.freeradbiomed.2013.02.027
Lian, N., Jiang, Y., Zhang, F., Jin, H., Lu, C., Wu, X., et al. (2015).
Curcumin regulates cell fate and metabolism by inhibiting hedgehog signaling
in hepatic stellate cells. Lab. Invest. 95, 790–803. doi: 10.1038/labinvest.
2015.59
Lin, H. J., Chen, J. Y., Lin, C. F., Kao, S. T., Cheng, J. C., Chen, H. L., et al. (2011a).
Hepatoprotective effects of Yi Guan Jian, an herbal medicine, in rats with
dimethylnitrosamine-induced liver fibrosis. J. Ethnopharmacol. 134, 953–960.
doi: 10.1016/j.jep.2011.02.013
Lin, H. J., Tseng, C. P., Lin, C. F., Liao, M. H., Chen, C. M., Kao,
S. T., et al. (2011b). A Chinese herbal decoction, modified Yi Guan
Jian, induces apoptosis in hepatic stellate cells through an ROS-mediated
mitochondrial/caspase pathway. Evid. Based Complement Alternat Med.
2011:459531. doi: 10.1155/2011/459531
Lin, Y. L., Lee, T. F., Huang, Y. J., and Huang, Y. T. (2006). Antiproliferative
effect of salvianolic acid A on rat hepatic stellate cells. J. Pharm. Pharmacol.
58, 933–939. doi: 10.1211/jpp.58.7.0008
Liu, C., Hu, Y., Xu, L., Liu, C., and Liu, P. (2009a). Effect of FuzhengHuayu formula
and its actions against liver fibrosis. Chin. Med. 4:12. doi: 10.1186/1749-8546-
4-12
Liu, H., Wei, W., Sun, W. Y., and Li, X. (2009b). Protective effects of
astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and
in vitro effects on hepatic stellate cells. J. Ethnopharmacol. 122, 502–508. doi:
10.1016/j.jep.2009.01.035
Liu, H. L., Chen, Y., Cui, G. H., and Zhou, J. F. (2005a). Curcumin, a potent anti-
tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell
line Raji proliferation. Acta Pharmacol. Sin. 26, 603–609. doi: 10.1111/j.1745-
7254.2005.00081.x
Liu, L., Wei, J., Huo, X., Fang, S., Yao, D., Gao, J., et al. (2012). The Salvia
miltiorrhizamonomer IH764-3 induces apoptosis of hepatic stellate cells in vivo
in a bile duct ligation-induced model of liver fibrosis. Mol. Med. Rep. 6,
1231–1238. doi: 10.3892/mmr.2012.1076
Liu, P., Hu, Y. Y., Liu, C., Xu, L. M., Liu, C. H., Sun, K. W., et al. (2005b).
Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis
due to chronic hepatitis B. World J. Gastroenterol. 11, 2892–2899. doi:
10.3748/wjg.v11.i19.2892
Frontiers in Pharmacology | www.frontiersin.org 35 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Liu, Q., Zhang, Y., Lin, Z., Shen, H., Chen, L., Hu, L., et al. (2010). Danshen
extract 15,16-dihydrotanshinone I functions as a potential modulator against
metabolic syndrome through multi-target pathways. J. Steroid Biochem. Mol.
Biol. 120, 155–163. doi: 10.1016/j.jsbmb.2010.03.090
Liu, X., Wang, W., Hu, H., Tang, N., Zhang, C., Liang, W., et al. (2006). Smad3
specific inhibitor, naringenin, decreases the expression of extracellular matrix
induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm. Res. 23,
82–89. doi: 10.1007/s11095-005-9043-5
Lorena, D., Darby, I. A., Gadeau, A. P., Leen, L. L., Rittling, S., Porto, L. C.,
et al. (2006). Osteopontin expression in normal and fibrotic liver. altered
liver healing in osteopontin-deficient mice. J. Hepatol. 44, 383–390. doi:
10.1016/j.jhep.2005.07.024
Lu, J., Chen, B., Li, S., and Sun, Q. (2014). Tryptase inhibitor APC
366 prevents hepatic fibrosis by inhibiting collagen synthesis induced by
tryptase/protease-activated receptor 2 interactions in hepatic stellate cells. Int.
Immunopharmacol. 20, 352–357. doi: 10.1016/j.intimp.2014.04.001
Lytle, K. A., Depner, C. M., Wong, C. P., and Jump, D. B. (2015). Docosahexaenoic
acid attenuates Western diet induced hepatic fibrosis in Ldlr−/− mice
by targeting the TGFβ-Smad3 pathway. J. Lipid Res. 56, 1936–1946. doi:
10.1194/jlr.M061275
Maguire, J. J., and Davenport, A. P. (2015). Endothelin receptors and their
antagonists. Semin. Nephrol. 35, 125–136. doi: 10.1016/j.semnephrol.2015.
02.002
Majumder, S., Piguet, A. C., Dufour, J. F., and Chatterjee, S. (2013). Study of
the cellular mechanism of Sunitinib mediated inactivation of activated hepatic
stellate cells and its implications in angiogenesis. Eur. J. Pharmacol. 705, 86–95.
doi: 10.1016/j.ejphar.2013.02.026
Manea, S. A., Constantin, A., Manda, G., Sasson, S., and Manea, A. (2015).
Regulation of Nox enzymes expression in vascular pathophysiology: focusing
on transcription factors and epigenetic mechanisms. Redox Biol. 5, 358–366.
doi: 10.1016/j.redox.2015.06.012
Mannaerts, I., Nuytten, N. R., Rogiers, V., Vanderkerken, K., van Grunsven, L.
A., and Geerts, A. (2010). Chronic administration of valproic acid inhibits
activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 51,
603–614. doi: 10.1002/hep.23334
Marcolin, E., San-Miguel, B., Vallejo, D., Tieppo, J., Marroni, N., González-
Gallego, J., et al. (2012). Quercetin treatment ameliorates inflammation and
fibrosis in mice with nonalcoholic steatohepatitis. J. Nutr. 142, 1821–1828. doi:
10.3945/jn.112.165274
Marra, F., and Tacke, F. (2014). Roles for chemokines in liver disease.
Gastroenterology 147, 577–594.e1. doi: 10.1053/j.gastro.2014.06.043
Martin, I. V., Borkham-Kamphorst, E., Zok, S., van Roeyen, C. R., Eriksson, U.,
Boor, P., et al. (2013). Platelet-derived growth factor (PDGF)-C neutralization
reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am. J.
Pathol. 18, 2107–2117. doi: 10.1016/j.ajpath.2012.09.006
Mayuren, C., Reddy, V. V., Priya, S. V., and Devi, V. A. (2010). Protective
effect of Livactine against CCl(4) and paracetamol induced hepatotoxicity in
adult Wistar rats. N. Am. J. Med. Sci. 2, 491–495. doi: 10.4297/najms.201
0.2491
Mazo, D. F., de Oliveira, M. G., Pereira, I. V., Cogliati, B., Stefano, J. T., de
Souza, G. F., et al. (2013). S-nitroso-N-acetylcysteine attenuates liver fibrosis in
experimental nonalcoholic steatohepatitis. Drug. Des. Devel. Ther. 7, 553–563.
doi: 10.3892/mmr.2014.2995
Mazor, D., Greenberg, L., Shamir, D., Meyerstein, D., and Meyerstein, N.
(2006). Antioxidant properties of bucillamine: possible mode of action.
Biochem. Biophys. Res. Commun. 349, 1171–1175. doi: 10.1016/j.bbrc.2006.
08.155
Meira Martins, L. A., Vieira, M. Q., Ilha, M., de Vasconcelos, M., Biehl, H.
B., Lima, D. B., et al. (2015). The interplay between apoptosis, mitophagy
and mitochondrial biogenesis induced by resveratrol can determine activated
hepatic stellate cells death or survival. Cell Biochem. Biophys. 71, 657–672. doi:
10.1007/s12013-014-0245-5
Meurer, S. K., Lahme, B., Tihaa, L., Weiskirchen, R., and Gressner, A. M. (2005).
N-acetyl-L-cysteine suppresses TGF-beta signaling at distinct molecular steps:
the biochemical and biological efficacy of a multifunctional, antifibrotic drug.
Biochem. Pharmacol. 70, 1026–1034. doi: 10.1016/j.bcp.2005.07.001
Min, A. K., Kim, M. K., Seo, H. Y., Kim, H. S., Jang, B. K., Hwang, J. S., et al. (2010).
α-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the
TGF-β signaling pathway. Biochem. Biophys. Res. Commun. 393, 536–541. doi:
10.1016/j.bbrc.2010.02.050
Modi, A. A., Feld, J. J., Park, Y., Kleiner, D. E., Everhart, J. E., Liang, T. J.,
et al. (2010). Increased caffeine consumption is associated with reduced hepatic
fibrosis. Hepatology 51, 201–209. doi: 10.1002/hep.23279
Monga, S. P. (2015). β-Catenin signaling and roles in liver homeostasis,
injury, and tumorigenesis. Gastroenterology 148, 1294–1310. doi:
10.1053/j.gastro.2015.02.056
Morell, C. M., and Strazzabosco, M. (2014). Notch signaling and new therapeutic
options in liver disease. J. Hepatol. 60, 885–890. doi: 10.1016/j.jhep.2013.11.028
Moreno, M. G., Chávez, E., Aldaba-Muruato, L. R., Segovia, J., Vergara, P.,
Tsutsumi, V., et al. (2011). Coffee prevents CCl(4)-induced liver cirrhosis in
the rat. Hepatol. Int. 5, 857–863. doi: 10.1007/s12072-010-9247-6
Morgan, T. R., Weiss, D. G., Nemchausky, B., Schiff, E. R., Anand, B., Simon,
F., et al. (2005). Colchicine treatment of alcoholic cirrhosis: a randomized,
placebo-controlled clinical trial of patient survival. Gastroenterology 128,
882–890. doi: 10.1053/j.gastro.2005.01.057
Munshi, M. K., Uddin, M. N., and Glaser, S. S. (2011). The role of the renin-
angiotensin system in liver fibrosis. Exp. Biol. Med. (Maywood) 236, 557–566.
doi: 10.1258/ebm.2011.010375
Muntoni, S., Rojkind, M., and Muntoni, S. (2010). Colchicine reduces procollagen
III and increases pseudocholinesterase in chronic liver disease. World J.
Gastroenterol. 16, 2889–2894. doi: 10.3748/wjg.v16.i23.2889
Murad, S., and Pinnell, S. R. (1987). Suppression of fibroblast proliferation and
lysyl hydroxylase activity by minoxidil. J. Biol. Chem. 262, 11973–11978.
Nair, D. G., Weiskirchen, R., and Al-Musharafi, S. K. (2015). The use of
marine-derived bioactive compounds as potential hepatoprotective agents.
Acta Pharmacol. Sin. 36, 158–170. doi: 10.1038/aps.2014.114
Nakamura, M., Bhatnagar, A., and Sadoshima, J. (2012). Overview of
pyridine nucleotides review series. Circ. Res. 111, 604–610. doi:
10.1161/CIRCRESAHA.111.247924
Nan, Y. M., Fu, N., Wu, W. J., Liang, B. L., Wang, R. Q., Zhao, S. X., et al. (2009).
Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand. J.
Gastroenterol. 44, 358–365. doi: 10.1080/00365520802530861
Nature (2007). Hard to swallow. Nature 448, 105–106.
Nava-Ocampo, A. A., Suster, S., and Muriel, P. (1997). Effect of colchiceine and
ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver
histology in experimentally induced carbon tetrachloride cirrhosis in rats. Eur.
J. Clin. Invest. 27, 77–84. doi: 10.1046/j.1365-2362.1997.910615.x
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., van Natta, M. L.,
Abdelmalek, M. F., et al. (2015). NASH Clinical Research Network. Farnesoid
X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic
steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Lancet 385, 956–965. doi: 10.1016/S0140-6736(14)61933-4
Niki, T., Rombouts, K., De Bleser, P., De Smet, K., Rogiers, V., Schuppan,
D., et al. (1999). A histone deacetylase inhibitor, trichostatin A, suppresses
myofibroblastic differentiation of rat hepatic stellate cells in primary culture.
Hepatology 29, 858–867. doi: 10.1002/hep.510290328
Nishimura, N., Naora, K., Hirano, H., and Iwamoto, K. (2001). Changes in the
dissolution of tolbutamide by a traditional Chinese medicine, Sho-saiko-to
(Xiao Chaihu Tang). Biol. Pharm. Bull. 24, 409–413. doi: 10.1248/bpb.24.409
Oakley, F., Trim, N., Constandinou, C. M., Ye, W., Gray, A. M., Frantz, G., et al.
(2003). Hepatocytes express nerve growth factor during liver injury: evidence
for paracrine regulation of hepatic stellate cell apoptosis. Am. J. Pathol. 163,
1849–1858. doi: 10.1016/S0002-9440(10)63544-4
Okada, Y., Yamaguchi, K., Nakajima, T., Nishikawa, T., Jo, M., Mitsumoto, Y.,
et al. (2013). Rosuvastatin ameliorates high-fat and high-cholesterol diet-
induced nonalcoholic steatohepatitis in rats. Liver Int. 33, 301–311. doi:
10.1111/liv.12033
Okuyama, H., Nakamura, H., Shimahara, Y., Uyama, N., Kwon, Y.W., Kawada, N.,
et al. (2005). Overexpression of thioredoxin prevents thioacetamide-induced
hepatic fibrosis in mice. J. Hepatol. 42, 117–123. doi: 10.1016/j.jhep.2004.09.020
Olteanu, D., Nagy, A., Dudea, M., Filip, A., Muresan, A., Catoi, C., et al. (2012).
Hepatic and systemic effects of rosuvastatin on an experimental model of bile
duct ligation in rats. J. Physiol. Pharmacol. 63, 483–496.
Orr, J. G., Leel, V., Cameron, G. A., Marek, C. J., Haughton, E. L., Elrick, L. J., et al.
(2004). Mechanism of action of the antifibrogenic compound gliotoxin in rat
liver cells. Hepatology 40, 232–242. doi: 10.1002/hep.20254
Frontiers in Pharmacology | www.frontiersin.org 36 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Oseini, A. M., and Roberts, L. R. (2009). PDGFRalpha: a new therapeutic target
in the treatment of hepatocellular carcinoma? Expert. Opin. Ther. Targets 13,
443–454. doi: 10.1517/14728220902719233
Padayatty, S. J., Katz, A., Wang, Y., Eck, P., Kwon, O., Lee, J. H., et al. (2003).
Vitamin C as an antioxidant: evaluation of its role in disease prevention. J. Am.
Coll. Nutr. 22, 18–35. doi: 10.1080/07315724.2003.10719272
Paik, Y. H., Yoon, Y. J., Lee, H. C., Jung, M. K., Kang, S. H., Chung, S. I., et al.
(2011). Antifibrotic effects of magnesium lithospermate B on hepatic stellate
cells and thioacetamide-induced cirrhotic rats. Exp.Mol. Med. 43, 341–349. doi:
10.3858/emm.2011.43.6.037
Pan, T. L., andWang, P.W. (2012). Explore the molecular mechanism of apoptosis
induced by tanshinone IIA on activated rat hepatic stellate cells. Evid. Based
Complement Alternat. Med. 2012:734987. doi: 10.1155/2012/734987
Parajuli, D. R., Zhao, Y. Z., Jin, H., Chi, J. H., Li, S. Y., Kim, Y. C., et al. (2015).
Anti-fibrotic effect of PF2401-SF, a standardized fraction of Salvia miltiorrhiza,
in thioacetamide-induced experimental rats liver fibrosis. Arch. Pharm. Res. 38,
549–555. doi: 10.1007/s12272-014-0425-2
Park, J. H., Ryu, S. H., Choi, E. K., Ahn, S. D., Park, E., Choi, K. C.,
et al. (2015a). SKI2162, an inhibitor of the TGF-β type I receptor (ALK5),
inhibits radiation-induced fibrosis in mice. Oncotarget 6, 4171–4179. doi:
10.18632/oncotarget.2878
Park, J. K., Ki, M. R., Lee, H. R., Hong, I. H., Ji, A. R., Ishigami, A., et al.
(2010). Vitamin C deficiency attenuates liver fibrosis by way of up-regulated
peroxisome proliferator-activated receptor-γ expression in senescence marker
protein 30 knockout mice. Hepatology 51, 1766–1777. doi: 10.1002/hep.
23499
Park, S. A., Kim, M. J., Park, S. Y., Kim, J. S., Lee, S. J., Woo, H. A., et al.
(2015b). EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking
TGF-β/Smad and ROS signaling. Cell. Mol. Life Sci. 72, 2023–2039. doi:
10.1007/s00018-014-1798-6
Patouraux, S., Rousseau, D., Rubio, A., Bonnafous, S., Lavallard, V. J.,
Lauron, J., et al. (2014). Osteopontin deficiency aggravates hepatic injury
induced by ischemia-reperfusion in mice. Cell Death Dis. 5:e1208. doi:
10.1038/cddis.2014.174
Peng, H., Carretero, O. A., Raij, L., Yang, F., Kapke, A., and Rhaleb, N. E. (2001).
Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and
kidney in aldosterone-salt hypertensive rats. Hypertension 37, 794–800. doi:
10.1161/01.HYP.37.2.794
Peng, J., Li, X., Feng, Q., Chen, L., Xu, L., and Hu, Y. (2013a). Anti-fibrotic effect
of Cordyceps sinensis polysaccharide: Inhibiting HSC activation, TGF-β1/Smad
signalling, MMPs and TIMPs. Exp. Biol. Med. (Maywood) 238, 668–677. doi:
10.1177/1535370213480741
Peng, Y., Yang, H., Wang, N., Ouyang, Y., Yi, Y., Liao, L., et al. (2014).
Fluorofenidone attenuates hepatic fibrosis by suppressing the proliferation and
activation of hepatic stellate cells.Am. J. Physiol. Gastrointest. Liver Physiol. 306,
G253–G263. doi: 10.1152/ajpgi.00471.2012
Peng, Y., Yang, H., Zhu, T., Zhao, M., Deng, Y., Liu, B., et al. (2013b). The
antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways.
Eur. J. Clin. Invest. 43, 358–368. doi: 10.1111/eci.12053
Pessayre, D., Mansouri, A., Haouzi, D., and Fromenty, B. (1999). Hepatotoxicity
due to mitochondrial dysfunction. Cell Biol. Toxicol. 15, 367–373. doi:
10.1023/A:1007649815992
Pfalzer, A. C., Choi, S. W., Tammen, S. A., Park, L. K., Bottiglieri, T., Parnell, L.
D., et al. (2014). S-adenosylmethionine mediates inhibition of inflammatory
response and changes in DNA methylation in human macrophages. Physiol.
Genomics 46, 617–623. doi: 10.1152/physiolgenomics.00056.2014
Poo, J. L., Feldmann, G., Moreau, A., Gaudin, C., and Lebrec, D. (1993). Early
colchicine administration reduces hepatic fibrosis and portal hypertension
in rats with bile duct ligation. J. Hepatol. 19, 90–94. doi: 10.1016/S0168-
8278(05)80181-3
Poyrazoglu, O. K., Bahcecioglu, I. H., Ataseven, H., Metin, K., Dagli, A. F., Yalniz,
M., et al. (2008). Effect of unfiltered coffee on carbon tetrachloride-induced liver
injury in rats. Inflammation 31, 408–413. doi: 10.1007/s10753-008-9092-0
Rafacho, B. P., Stice, C. P., Liu, C., Greenberg, A. S., Ausman, L. M., and Wang, X.
D. (2015). Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic
inflammation and precancerous lesions by flavonoid luteolin is associated with
increased sirtuin 1 activity in mice. Hepatobiliary Surg. Nutr. 4, 124–134. doi:
10.3978/j.issn.2304-3881.2014.08.06
Ramadoss, S., Kannan, K., Balamurugan, K., Jeganathan, N. S., and Manavalan, R.
(2012). Evaluation of hepato-protective activity in the ethanolic extract of Sida
rhombifolia Linn. against paracetamol-induced hepatic injury in albino rats.
RJPBCS 3, 497–501.
Rockey, D. C., and Chung, J. J. (1996). Endothelin antagonism in experimental
hepatic fibrosis.Implications for endothelin in the pathogenesis of wound
healing. J. Clin. Invest. 98, 1381–1388. doi: 10.1172/JCI118925
Roderfeld, M., Weiskirchen, R., Wagner, S., Berres, M. L., Henkel, C., Grötzinger,
J., et al. (2006). Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9
mutants in mice. FASEB J. 20, 444–454. doi: 10.1096/fj.05-4828com
Rodríguez-Pascual, F., Busnadiego, O., and González-Santamaría, J. (2014). The
profibrotic role of endothelin-1: is the door still open for the treatment of
fibrotic diseases? Life Sci. 118, 156–164. doi: 10.1016/j.lfs.2013.12.024
Rojkind, M., and Kershenobich, D. (1975). Effect of colchicine on collagen,
albumin and transferrin synthesis by cirrhotic rat liver slices. Biochim. Biophys.
Acta 378, 415–423. doi: 10.1016/0005-2787(75)90186-0
Rombouts, K., Kisanga, E., Hellemans, K., Wielant, A., Schuppan, D., and Geerts,
A. (2003). Effect of HMG-CoA reductase inhibitors on proliferation and
protein synthesis by rat hepatic stellate cells. J. Hepatol. 38, 564–572. doi:
10.1016/S0168-8278(03)00051-5
Russell, W. M. S., and Burch, R. L. (1959). The Principles of Humane Experimental
Technique. London: Methuen & Co Ltd, 1959. Reprinted by UFAW, Potters Bar,
Herts, 1992. Available online at: http://altweb.jhsph.edu/pubs/books/humane_
exp/het-toc
Ruwart, M. J., Rush, B. D., Snyder, K. F., Peters, K. M., Appelman, H. D.,
and Henley, K. S. (1988). 16,16-Dimethyl prostaglandin E2 delays collagen
formation in nutritional injury in rat liver. Hepatology 8, 61–64. doi:
10.1002/hep.1840080112
Sakaida, I., Matsumura, Y., Akiyama, S., Hayashi, K., Ishige, A., and Okita,
K. (1998). Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and
enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient
L-amino acid-defined diet. J. Hepatol. 28, 298–306. doi: 10.1016/0168-
8278(88)80017-5
Sakaida, I., Uchida, K., Hironaka, K., and Okita, K. (1999). Prolyl 4-hydroxylase
inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis.
J. Gastroenterol. 34, 376–377. doi: 10.1007/s005350050277
Salazar-Montes, A., Ruiz-Corro, L., López-Reyes, A., Castrejón-Gómez,
E., and Armendáriz-Borunda, J. (2008). Potent antioxidant role of
pirfenidone in experimental cirrhosis. Eur. J. Pharmacol. 595, 69–77. doi:
10.1016/j.ejphar.2008.06.110
Sánchez-Valle, V., Chávez-Tapia, N. C., Uribe,M., andMéndez-Sánchez, N. (2012).
Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr.
Med. Chem. 19, 4850–4860. doi: 10.2174/092986712803341520
Sanderson, N., Factor, V., Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., et al.
(1995). Hepatic expression of mature transforming growth factor beta 1 in
transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. U.S.A.
92, 2572–2576. doi: 10.1073/pnas.92.7.2572
San-Miguel, B., Crespo, I., Sánchez, D. I., González-Fernández, B., Ortiz de Urbina,
J. J., Tuñón, M. J., et al. (2015). Melatonin inhibits autophagy and endoplasmic
reticulum stress in mice with carbon tetrachloride-induced fibrosis. J. Pineal.
Res. 59, 151–162. doi: 10.1111/jpi.12247
Sapakal, V. D., Ghadge, R. V., Adnaik, R. S., Naikwade, N. S., and Magdum, C. S.
(2008). Comparative hepatoprotective activity of Liv-52 and livomyn against
carbon tetrachloride-induced hepatic injury in rats. Int. J. Green Pharm. 2,
79–82. doi: 10.4103/0973-8258.41175
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H. U., Bamberg, K., et al.
(2013). Gut microbiota regulates bile acid metabolism by reducing the levels of
tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab.
17, 225–235. doi: 10.1016/j.cmet.2013.01.003
Schaap, F. G., Trauner, M., and Jansen, P. L. (2014). Bile acid receptors as
targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 11, 55–67. doi:
10.1038/nrgastro.2013.151
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., and Kossen, K. (2011).
Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 20,
85–97. doi: 10.1183/09059180.00001111
Schmöcker, C., Weylandt, K. H., Kahlke, L., Wang, J., Lobeck, H., Tiegs, G., et al.
(2007). Omega-3 fatty acids alleviate chemically induced acute hepatitis by
suppression of cytokines. Hepatology 45, 864–869. doi: 10.1002/hep.21626
Frontiers in Pharmacology | www.frontiersin.org 37 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Schultz-Cherry, S., and Murphy-Ullrich, J. E. (1993). Thrombospondin causes
activation of latent transforming growth factor-beta secreted by endothelial
cells by a novel mechanism. J. Cell Biol. 122, 923–932. doi: 10.1083/jcb.122.
4.923
Semwal, R. B., Semwal, D. K., Combrinck, S., and Viljoen, A. M. (2015). Gingerols
and shogaols: important nutraceutical principles from ginger. Phytochemistry
117, 554–568. doi: 10.1016/j.phytochem.2015.07.012
Serviddio, G., Bellanti, F., Stanca, E., Lunetti, P., Blonda, M., Tamborra, R., et al.
(2014). Silybin exerts antioxidant effects and induces mitochondrial biogenesis
in liver of rat with secondary biliary cirrhosis. Free Radic. Biol. Med. 73,
117–126. doi: 10.1016/j.freeradbiomed.2014.05.002
Shaaban, A. A., Shaker, M. E., Zalata, K. R., El-kashef, H. A., and Ibrahim, T. M.
(2014). Modulation of carbon tetrachloride-induced hepatic oxidative stress,
injury and fibrosis by olmesartan and omega-3.Chem. Biol. Interact. 207, 81–91.
doi: 10.1016/j.cbi.2013.10.008
Shaker, M. E., Salem, H. A., Shiha, G. E., and Ibrahim, T. M. (2011a).
Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and
attenuates liver fibrosis progression. Fundam. Clin. Pharmacol. 25, 248–257.
doi: 10.1111/j.1472-8206.2010.00824.x
Shaker, M. E., Zalata, K. R., Mehal, W. Z., Shiha, G. E., and Ibrahim, T. M.
(2011b). Comparison of imatinib, nilotinib and silymarin in the treatment
of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.
Toxicol. Appl. Pharmacol. 252, 165–175. doi: 10.1016/j.taap.2011.02.004
Shen, K., Feng, X., Su, R., Xie, H., Zhou, L., and Zheng, S. (2015). Epigallocatechin
3-gallate ameliorates bile duct ligation induced liver injury in mice by
modulation of mitochondrial oxidative stress and inflammation. PLoS ONE
10:e0126278. doi: 10.1371/journal.pone.0126278
Shi, F., Sheng, Q., Xu, X., Huang, W., and Kang, Y. J. (2015). Zinc supplementation
suppresses the progression of bile duct ligation-induced liver fibrosis in mice.
Exp. Biol. Med. (Maywood) 240, 1197–1204. doi: 10.1177/1535370214558026
Shiha, G. E., Abu-Elsaad, N. M., Zalata, K. R., and Ibrahim, T. M. (2014). Tracking
anti-fibrotic pathways of nilotinib and imatinib in experimentally induced
liver fibrosis: an insight. Clin. Exp. Pharmacol. Physiol. 41, 788–797. doi:
10.1111/1440-1681.12286
Shim, S. G., Jun, D. W., Kim, E. K., Saeed, W. K., Lee, K. N., Lee, H. L., et al.
(2013). Caffeine attenuates liver fibrosis via defective adhesion of hepatic
stellate cells in cirrhotic model. J. Gastroenterol. Hepatol. 28, 1877–1884. doi:
10.1111/jgh.12317
Shimizu, I., Ma, Y. R., Mizobuchi, Y., Liu, F., Miura, T., Nakai, Y., et al. (1999).
Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats.
Hepatology 29, 149–160. doi: 10.1002/hep.510290108
Shinkawa, H., Takemura, S., Minamiyama, Y., Kodai, S., Tsukioka, T., Osada-
Oka, M., et al. (2009). S-allylcysteine is effective as a chemopreventive agent
against porcine serum-induced hepatic fibrosis in rats. Osaka City Med. J. 55,
61–69.
Shirin, H., Sharvit, E., Aeed, H., Gavish, D., and Bruck, R. (2013). Atorvastatin and
rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.World
J. Gastroenterol. 19, 241–248. doi: 10.3748/wjg.v19.i2.241
Stefano, J. T., Cogliati, B., Santos, F., Lima, V. M., Mazo, D. C., Matte, U.,
et al. (2011). S-Nitroso-N-acetylcysteine induces de-differentiation of activated
hepatic stellate cells and promotes antifibrotic effects in vitro. Nitric Oxide 25,
360–365. doi: 10.1016/j.niox.2011.07.001
Stevens, J. F., and Page, J. E. (2004). Xanthohumol and related prenylflavonoids
from hops and beer: to your good health! Phytochemistry 65, 1317–1330. doi:
10.1016/j.phytochem.2004.04.025
Su, T. H., Shiau, C. W., Jao, P., Liu, C. H., Liu, C. J., Tai, W. T., et al. (2015).
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal
transducer and activator of transcription 3 inhibition. Proc. Natl. Acad. Sci.
U.S.A. 112, 7243–7248. doi: 10.1073/pnas.1507499112
Surapaneni, K. M., and Jainu, M. (2014). Pioglitazone, quercetin and hydroxy
citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis.
Pharmacognosy Res. 6, 153–162. doi: 10.4103/0974-8490.129037
Susnea, I., and Weiskirchen, R. (2015). Trace metal imaging in diagnostic of
hepatic metal disease. Mass Spectrom. Rev. doi: 10.1002/mas.21454. [Epub
ahead of print].
Suzuki, Y., Katagiri, F., Sato, F., Fujioka, K., Sato, Y., Fujioka, T., et al. (2014).
Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in
patients with end stage renal disease after kidney transplantation. Biol. Pharm.
Bull. 37, 1075–1079. doi: 10.1248/bpb.b13-00992
Tada, S., Nakamuta, M., Enjoji, M., Sugimoto, R., Iwamoto, H., Kato, M.,
et al. (2001). Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis
in rats. Clin. Exp. Pharmacol. Physiol. 28, 522–527. doi: 10.1046/j.1440-
1681.2001.03481.x
Thabut, D., Routray, C., Lomberk, G., Shergill, U., Glaser, K., Huebert, R., et al.
(2011). Complementary vascular and matrix regulatory pathways underlie the
beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54,
573–585. doi: 10.1002/hep.24427
Tahan, V., Ozaras, R., Canbakan, B., Uzun, H., Aydin, S., Yildirim, B., et al. (2004).
Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J. Pineal.
Res. 37, 78–84. doi: 10.1111/j.1600-079X.2004.00137.x
Takahashi, Y., Soejima, Y., Kumagai, A., Watanabe, M., Uozaki, H., and Fukusato,
T. (2014). Inhibitory effects of Japanese herbal medicines sho-saiko-to and
juzen-taiho-to on nonalcoholic steatohepatitis in mice. PLoS ONE 9:e87279.
doi: 10.1371/journal.pone.0087279
Takase, S., Matsuda, Y., Yasuhara, M., and Takada, A. (1989). Effects of malotilate
treatment on alcoholic liver disease. Alcohol 6, 219–222. doi: 10.1016/0741-
8329(89)90021-9
Tang, Y. (2015). Curcumin targets multiple pathways to halt hepatic stellate
cell activation: updated mechanisms in vitro and in vivo. Dig. Dis. Sci. 60,
1554–1564. doi: 10.1007/s10620-014-3487-6
Tipoe, G. L., Leung, T. M., Liong, E. C., Lau, T. Y., Fung, M. L.,
and Nanji, A. A. (2010). Epigallocatechin-3-gallate (EGCG) reduces liver
inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-
induced liver injury in mice. Toxicology 273, 45–52. doi: 10.1016/j.tox.2010.
04.014
Traber, P. G., Chou, H., Zomer, E., Hong, F., Klyosov, A., Fiel, M. I., et al.
(2013). Regression of fibrosis and reversal of cirrhosis in rats by galectin
inhibitors in thioacetamide-induced liver disease. PLoS ONE 8:e75361. doi:
10.1371/journal.pone.0075361
Trebicka, J., Hennenberg, M., Odenthal, M., Shir, K., Klein, S., Granzow, M., et al.
(2010). Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation
via decreased turnover of hepatic stellate cells. J. Hepatol. 53, 702–712. doi:
10.1016/j.jhep.2010.04.025
Tsai, J. H., Liu, J. Y., Wu, T. T., Ho, P. C., Huang, C. Y., Shyu, J. C., et al.
(2008). Effects of silymarin on the resolution of liver fibrosis induced by
carbon tetrachloride in rats. J. Viral Hepat. 15, 508–514. doi: 10.1111/j.1365-
2893.2008.00971.x
Tsalkidou, E. G., Tsaroucha, A. K., Chatzaki, E., Lambropoulou, M.,
Papachristou, F., Trypsianis, G., et al. (2014). The effects of apigenin on
the expression of Fas/FasL apoptotic pathway in warm liver ischemia-
reperfusion injury in rats. Biomed. Res. Int. 2014:157216. doi: 10.1155/2014/
157216
Tugues, S., Fernandez-Varo, G., Muñoz-Luque, J., Ros, J., Arroyo, V., Rodés,
J., et al. (2007). Antiangiogenic treatment with sunitinib ameliorates
inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.
Hepatology 46, 1919–1926. doi: 10.1002/hep.21921
Tzeng, J. I., Chen, M. F., Chung, H. H., and Cheng, J. T. (2013). Silymarin decreases
connective tissue growth factor to improve liver fibrosis in rats treated
with carbon tetrachloride. Phytother Res. 27, 1023–1028. doi: 10.1002/ptr.
4829
Uchio, K., Graham, M., Dean, N. M., Rosenbaum, J., and Desmoulière, A.
(2004). Down-regulation of connective tissue growth factor and type I collagen
mRNA expression by connective tissue growth factor antisense oligonucleotide
during experimental liver fibrosis. Wound Repair Regen. 12, 60–66. doi:
10.1111/j.1067-1927.2004.012112.x-1
Unger, T., Chung, O., Csikos, T., Culman, J., Gallinat, S., Gohlke, P., et al. (1996).
Angiotensin receptors. J. Hypertens. Suppl. 14, S95–S103.
Urtasun, R., Lopategi, A., George, J., Leung, T. M., Lu, Y., Wang, X., et al. (2012).
Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via
integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 55,
594–608. doi: 10.1002/hep.24701
Visse, R., and Nagase, H. (2003). Matrix metalloproteinases and tissue inhibitors
of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92,
827–839. doi: 10.1161/01.RES.0000070112.80711.3D
Frontiers in Pharmacology | www.frontiersin.org 38 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
Wang, B. E. (2000). Treatment of chronic liver diseases with traditional
Chinese medicine. J. Gastroenterol. Hepatol. 15, E67–E70. doi: 10.1046/j.1440-
1746.2000.02100.x
Wang, E., Chen, F., Hu, X., and Yuan, Y. (2014). Protective effects of apigenin
against furan-induced toxicity in mice. Food Funct. 5, 1804–1812. doi:
10.1039/C4FO00038B
Wang, J., Leclercq, I., Brymora, J. M., Xu, N., Ramezani-Moghadam, M., London,
R. M., et al. (2009). Kupffer cells mediate leptin-induced liver fibrosis.
Gastroenterology 137, 713–723. doi: 10.1053/j.gastro.2009.04.011
Wang, L., Wang, B. E., Wang, J., Xiao, P. G., and Tan, X. H. (2008).
Herbal compound 861 regulates mRNA expression of collagen synthesis-
and degradation-related genes in human hepatic stellate cells. World J.
Gastroenterol. 14, 1790–1794. doi: 10.3748/wjg.14.1790
Wang, L., Wang, J., Wang, B. E., Xiao, P. G., Qiao, Y. J., and Tan, X. H.
(2004). Effects of herbal compound 861 on human hepatic stellate cell
proliferation and activation. World J. Gastroenterol. 10, 2831–2835. doi:
10.3748/wjg.v10.i19.2831
Wang, R., Yu, X. Y., Guo, Z. Y., Wang, Y. J., Wu, Y., and Yuan, Y. F. (2012).
Inhibitory effects of salvianolic acid B on CCl(4)-induced hepatic fibrosis
through regulating NF-κB/IκBα signaling. J. Ethnopharmacol. 144, 592–598.
doi: 10.1016/j.jep.2012.09.048
Wang, W., Zhao, C., Zhou, J., Zhen, Z., Wang, Y., and Shen, C. (2013). Simvastatin
ameliorates liver fibrosis via mediating nitric oxide synthase in rats with
non-alcoholic steatohepatitis-related liver fibrosis. PLoS ONE 8:e76538. doi:
10.1371/journal.pone.0076538
Wang, Y., Gao, J., Zhang, D., Zhang, J., Ma, J., and Jiang, H. (2010). New insights
into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
J. Hepatol. 53, 132–144. doi: 10.1016/j.jhep.2010.02.027
Wang, Y. J., Wang, S. S., Bickel, M., Guenzler, V., Gerl, M., and Bissell, D. M.
(1998). Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell
activation in rat liver injury: differential effects in males and females. Am. J.
Pathol. 152, 279–287.
Wasser, S., Ho, J. M., Ang, H. K., and Tan, C. E. (1998). Salvia miltiorrhiza reduces
experimentally-induced hepatic fibrosis in rats. J. Hepatol. 29, 760–771. doi:
10.1016/S0168-8278(98)80257-2
Weiskirchen, R. (2011). CCN proteins in normal and injured liver. Front. Biosci.
(Landmark Ed). 16, 1939–1961. doi: 10.2741/3832
Weiskirchen, R., Mahli, A., Weiskirchen, S., and Hellerbrand, C. (2015). The
hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the
activation of hepatic stellate cells at different levels. Front. Physiol. 6:140. doi:
10.3389/fphys.2015.00140
Wen, J. (2007). Sho-saiko-to, a clinically documented herbal preparation for
treating chronic liver disease. HerbalGram 73, 34–43.
Wong, C. C., Tse, A. P., Huang, Y. P., Zhu, Y. T., Chiu, D. K., Lai, R. K., et al. (2014).
Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic
niche formation in hepatocellular carcinoma. Hepatology 60, 1645–1658. doi:
10.1002/hep.27320
Wright, M. C., Issa, R., Smart, D. E., Trim, N., Murray, G. I., Primrose, J. N., et al.
(2001). Gliotoxin stimulates the apoptosis of human and rat hepatic stellate
cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121,
685–698. doi: 10.1053/gast.2001.27188
Xia, J. L., Dai, C., Michalopoulos, G. K., and Liu, Y. (2006). Hepatocyte growth
factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 168,
1500–1512. doi: 10.2353/ajpath.2006.050747
Yamada, H., Tajima, S., Nishikawa, T., Murad, S., and Pinnell, S. R. (1994).
Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts.
J. Biochem. 116, 892–897.
Yamasaki, K., Takemura, S., Minamiyama, Y., Hai, S., Yamamoto, S., Kodai,
S., et al. (2005). Minoxidil, a K(ATP) channel opener, accelerates DNA
synthesis following partial hepatectomy in rats. Biofactors 23, 15–23. doi:
10.1002/biof.5520230103
Yang, J. J., Tao, H., and Li, J. (2014a). Hedgehog signaling pathway as key player
in liver fibrosis: new insights and perspectives. Expert Opin. Ther. Targets 18,
1011–1021. doi: 10.1517/14728222.2014.927443
Yang, J., Hou, Y., Ji, G., Song, Z., Liu, Y., Dai, G., et al. (2014b). Targeted delivery
of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic
drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats. Eur.
J. Pharm. Sci. 52, 180–190. doi: 10.1016/j.ejps.2013.11.017
Yang, L., Kwon, J., Popov, Y., Gajdos, G. B., Ordog, T., Brekken, R. A., et al. (2014c).
Vascular endothelial growth factor promotes fibrosis resolution and repair in
mice. Gastroenterology 146, 1339–1350.e1. doi: 10.1053/j.gastro.2014.01.061
Yang, L., Qu, M., Wang, Y., Duan, H., Chen, P., Wang, Y., et al. (2013).
Trichostatin A inhibits transforming growth factor-β-induced reactive oxygen
species accumulation and myofibroblast differentiation via enhanced NF-E2-
related factor 2-antioxidant response element signaling. Mol. Pharmacol. 83,
671–680. doi: 10.1124/mol.112.081059
Yin, M. F., Lian, L. H., Piao, D. M., and Nan, J. X. (2007). Tetrandrine stimulates
the apoptosis of hepatic stellate cells and ameliorates development of fibrosis
in a thioacetamide rat model. World J. Gastroenterol. 13, 1214–1220. doi:
10.3748/wjg.v13.i8.1214
Yin, S. S., Wang, B. E., Wang, T. L., Jia, J. D., and Qian, L. X. (2004). [The
effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis:
a randomized, double blind, placebo controlled clinical trial]. Zhonghua Gan
Zang Bing Za Zhi. 12, 467–470.
Yoo, N. Y., Jeon, S., Nam, Y., Park, Y. J., Won, S. B., and Kwon, Y. H. (2015).
Dietary supplementation of genistein alleviates liver inflammation and fibrosis
mediated by a methionine-choline-deficient diet in db/db mice. J. Agric. Food
Chem. 63, 4305–4311. doi: 10.1021/acs.jafc.5b00398
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani,
T., et al. (2001). Angiotensin-II type 1 receptor interaction is a major
regulator for liver fibrosis development in rats. Hepatology 34, 745–750. doi:
10.1053/jhep.2001.28231
Younes, M., and Siegers, C. P. (1985). Effect of malotilate on paracetamol-induced
hepatotoxicity. Toxicol. Lett. 25, 143–146. doi: 10.1016/0378-4274(85)90074-8
Yu, C., Wang, F., Jin, C., Huang, X., Miller, D. L., Basilico, C., et al. (2003). Role of
fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic
injury and fibrogenesis. Am. J. Pathol. 163, 1653–1662. doi: 10.1016/S0002-
9440(10)63522-5
Yu, C., Wang, F., Jin, C., Wu, X., Chan, W. K., and McKeehan, W. L.
(2002). Increased carbon tetrachloride-induced liver injury and fibrosis in
FGFR4-deficient mice. Am. J. Pathol. 161, 2003–2010. doi: 10.1016/S0002-
9440(10)64478-1
Yu, D. K., Zhang, C. X., Zhao, S. S., Zhang, S. H., Zhang, H., Cai, S. Y.,
et al. (2015). The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-
ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated
by the PI3K/Akt/Smad pathway. Acta Pharmacol. Sin. 36, 473–482. doi:
10.1038/aps.2014.155
Yu, V. W., and Ho, W. S. (2013). Tetrandrine inhibits hepatocellular carcinoma
cell growth through the caspase pathway and G2/M phase. Oncol Rep. 29,
2205–2210. doi: 10.3892/or.2013.2352
Yuhua, Z., Wanhua, R., Chenggang, S., Jun, S., Yanjun, W., and Chunqing, Z.
(2008). Disruption of connective tissue growth factor by short hairpin RNA
inhibits collagen synthesis and extracellular matrix secretion in hepatic stellate
cells. Liver Int. 28, 632–639. doi: 10.1111/j.1478-3231.2008.01730.x
Zhang, F., Zhuge, Y. Z., Li, Y. J., and Gu, J. X. (2014). S-adenosylmethionine
inhibits the activated phenotype of human hepatic stellate cells via Rac1
and matrix metalloproteinases. Int. Immunopharmacol. 19, 193–200. doi:
10.1016/j.intimp.2014.01.021
Zhang, J., Gao, Y., Qian, S., Liu, X., and Zu, H. (2011a). Physicochemical and
pharmacokinetic characterization of a spray-dried malotilate emulsion. Int. J.
Pharm. 414, 186–192. doi: 10.1016/j.ijpharm.2011.05.032
Zhang, J., Liu, X., Lei, X., Wang, L., Guo, L., Zhao, G., et al. (2010). Discovery and
synthesis of novel luteolin derivatives as DAT agonists. Bioorg. Med. Chem. 18,
7842–7848. doi: 10.1016/j.bmc.2010.09.049
Zhang, J. J., Wang, Y. L., Feng, X. B., Song, X. D., and Liu, W. B. (2011b).
Rosmarinic acid inhibits proliferation and induces apoptosis of hepatic stellate
cells. Biol. Pharm. Bull. 34, 343–348. doi: 10.1248/bpb.34.343
Zhang, L., and Schuppan, D. (2014). Traditional Chinese Medicine (TCM)
for fibrotic liver disease: hope and hype. J. Hepatol. 61, 166–168. doi:
10.1016/j.jhep.2014.03.009
Zhang, L., Xu, L. M., Chen, Y. W., Ni, Q. W., Zhou, M., Qu, C. Y., et al.
(2012a). Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct
ligation induced liver fibrosis in rats. World J. Gastroenterol. 18, 5283–5288.
doi: 10.3748/wjg.v18.i37.5283
Zhang, M., Song, G., and Minuk, G. Y. (1996). Effects of hepatic
stimulator substance, herbal medicine, selenium/vitamin E, and
Frontiers in Pharmacology | www.frontiersin.org 39 January 2016 | Volume 6 | Article 303
Weiskirchen Hepatoprotective and Anti-fibrotic Agents
ciprofloxacin on cirrhosis in the rat. Gastroenterology 110, 1150–1155.
doi: 10.1053/gast.1996.v110.pm8613004
Zhang, W., Wu, R., Zhang, F., Xu, Y., Liu, B., Yang, Y., et al. (2012b).
Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic
steatohepatitis by activating the adenosine monophosphate-activated protein
kinase signalling pathway. Clin. Exp. Pharmacol. Physiol. 39, 1026–1033. doi:
10.1111/1440-1681.12020
Zhang, W. J., and Frei, B. (2015). Astragaloside IV inhibits NF- κ B activation
and inflammatory gene expression in LPS-treated mice. Mediators Inflamm.
2015:274314. doi: 10.1155/2015/274314
Zou, W. L., Yang, Z., Zang, Y. J., Li, D. J., Liang, Z. P., and Shen, Z. Y. (2007).
Inhibitory effects of prostaglandin E1 on activation of hepatic stellate cells in
rabbits with schistosomiasis. Hepatobiliary Pancreat. Dis. Int. 6, 176–181.
Zuurmond, A. M., van der Slot-Verhoeven, A. J., van Dura, E. A., De Groot,
J., and Bank, R. A. (2005). Minoxidil exerts different inhibitoryeffects on
gene expression of lysyl hydroxylase 1, 2, and 3: implications for collagen
cross-linking and treatment of fibrosis. Matrix Biol. 24, 261–270. doi:
10.1016/j.matbio.2005.04.002
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Weiskirchen. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 40 January 2016 | Volume 6 | Article 303
